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“Everybody is a genius. But if you judge a fish by its ability to climb a tree, it will live 
its whole life believing that it is stupid”.
Attributed to Albert Einstein
(Excerpt from The Rhythm of Life: Living Every day with Passion and Purpose by 
Matthew Kelly, 2004)
        Voor Mama
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Clinical background. Cardiovascular disease (CVD), including coronary heart disease 
(CHD), accounts for over 17 million deaths each year worldwide (1). Although the 
mortality rate of CHD steadily declined over the last decade due to improved treatment 
options, CVD and more specifically CHD, remain the leading cause of death in Europe (2) 
and the US (3). Also, during this timeframe, the incidence of heart failure has remained 
unaltered (3). In addition, the aging population and the increased incidence of cardiac 
risk factors, e.g. smoking, obesity, hypertension, hypercholesterolemia and diabetes 
mellitus, contributed to increased CHD-related morbidity. Therefore, the expectation is 
that both the incidence of CVD and the economic costs of CVD will keep rising in the 
future above the expenditure of $320.1 billion in 2011 in the US and €196 billion in the 
EU each year (2, 3). 
Ischemic heart disease: atherosclerosis. The principle underlying cause of CVD is 
atherosclerosis, an inflammatory disease associated with increased blood levels of 
apolipoprotein B-containing lipoproteins such as low-density lipoprotein (LDL) (4, 
5). This LDL increase, combined with other cardiac risk factors, may ultimately lead 
to activation of the inflammatory response through the release of phospholipids by 
modification of LDL. Platelets are recruited to the site of activation resulting in expression 
of adhesion molecules by endothelial cells and homing of monocytes and lymphocytes 
to and subsequently activation of different chemokine and cytokine pathways in the 
intima.  Differentiated macrophages and dendritic cells become lipid-laden foam cells 
that accumulate in the proteoglycan layer of the intima and eventually form a fatty streak 
(Figure 1). Progression of a fatty streak towards an atherosclerotic plaque starts with 
pathological intimal thickening through accumulation of small lipid pools underneath 
the foam cell layers. These small lipid pools may flow together, forming an atherosclerotic 
plaque. Connective tissue is formed on the surface of the atherosclerotic lesion by type I 
collagen deposition by smooth muscle cells, establishing stable fibrous cap.  The plaque 
may develop a necrotic core due to apoptosis and necrosis of foam cells, which ultimately 
may lead to disruption of the fibrous cap covering the atheroma. 
During the progression towards an atherosclerotic plaque, neoangiogenesis from 
the vasa vasorum to the base of atherosclerotic lesion results in additional entrance 
sites for inflammatory cells, increasing the local inflammatory response and the risk 
of intraplaque bleedings (Figure 1).
Ischemic heart disease: myocardial infarction (MI). Prolonged myocardial ischemia 
results in cell death MI, initiating an inflammatory response ultimately leading to scar 
formation (6-11). During the first inflammatory phase of myocardial ischemic damage, 
platelets are activated to prevent bleeding and release growth factors to aid the repair 
process. Neutrophils are the first immune cells entering the myocardium, clearing the 
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infarct site from dead cells and debris, followed by monocytes (Figure 2). In addition, 
neutrophils contribute to the production of reactive oxygen species, which amongst 
others activate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), 
a transcription factor that regulates genes involving pro-inflammatory cytokines, 
chemokines, matrix metalloproteinases, growth factors and genes involved in cell survival 
and proliferation. Besides reactive oxygen species, the Toll-like receptor-mediated pathway 
and the complement cascade contribute to NF-κB activation. After the clearance of 
the infarct site from debris and the activation of pro-survival and reparative signaling 
cascades, the inflammatory phase progresses into the proliferative phase in which the 
initial inflammation reaction is directed towards a healing process (Figure 2). 
Figures 
 
Figure 1. Lesion types of atherosclerosis and a proposed sequence of their development. A: 
Adaptive intimal thickening characterized by smooth muscle cell accumulation within the intima. 
B: Intimal xanthoma corresponding to the accumulation of foam cell macrophages within the 
intima. Pathological thickening in C denotes the accumulation of extracellular lipid pools in the 
absence of apparent necrosis. D: Fibroatheroma indicating the presence of a necrotic core. The 
necrotic core and surrounding tissue may eventually be calcified, which forms fibrocalcific 
plaque shown in E. Because some of the advanced lesion types (fibroatheromas and fibrocalcific 
plaques) evolve simultaneously in life, their interrelationships are difficult to resolve in autopsy 
studie. Movat pentachrome stain. Reproduced with permission from (4), Copyright 
Massachusetts Medical Society. 
Figure 1. Lesion types of atherosclerosis and a proposed sequence of their development. A: 
Adaptive intimal thickening characterized by smooth muscle cell accumulation within the 
intima. B: Intimal xanthoma corresponding to the accumulation of foam cell macrophages 
within the intima. Pathological thickening in C denotes the accumulation of extracellular 
lipid pools in the absence of apparent necrosis. D: Fibroatheroma indicating the presence of a 
necrotic core. The necrotic core and surrounding tissue may eventually be calcified, which forms 
fibrocalcific plaque shown in E. Because some of the advanced lesion types (fibroatheromas 
and fibrocalcific plaques) evolve simultaneously in life, their interrelationships are difficult to 
resolve in autopsy studie. Movat pentachrome stain. Reproduced with permission from (5), 










The recruitment of both neutrophils and monocytes is reduced and lymphocyte 
antigen 6C (Ly-6C)low macrophages clear the apoptotic neutrophils from the infarct 
site. In addition, the presence of anti-inflammatory factors such as interleukin-10 
and transforming growth factor β is increased, further stimulating the removal 
of inflammatory leucocytes. Also, these factors are important for the recruitment 
of myofibroblasts and the production of extracellular matrix proteins for scar 
tissue formation.
Figure 2. In the infarcted myocardium, dying cardiomyocytes and damaged matrix release 
DAMPs that activate TLR signaling in myocardial cells, triggering an inflammatory reaction. 
Activation of the complement cascade and ROS generation also help initiate the inflammatory 
reaction. Dying and surviving cardiomyocytes, endothelial cells, resident cardiac fibroblasts, 
resident mast cells and newly recruited neutrophils monocytes and platelets participate in the 
post-infarction inflammatory response. However, their relative contributions remain unclear. 
Leukocytes are recruited through activation of a multistep adhesion cascade. Capture (1) of 
circulating leukocytes by activated endothelial cells is followed by rolling (2), mediated through 
interactions involving the selectins. Rolling leukocytes are activated (3) by chemokines bound to 
proteoglycans (PG) on the endothelial surface. Activated leukocytes express integrins and adhere 
to endothelial cells (4). Strengthening of the adhesive interaction (5) between leukocytes and 
endothelial cells is followed by transmigration of the cells into the infarcted area (6). 
Figure 2. In the infarcted myocardium, dying cardiomyocytes and damaged matrix release 
s that activate TLR signaling in myocardial cells, triggering an inflammatory 
reaction. Activation of the complement cascade and ROS generation also help initiate the 
inflammatory reaction. Dying and surviving cardiomyocytes, endothelial cells, resident 
cardiac fibroblasts, resident mast cells and newly recruited neutrophils monocytes and 
platelets participate in the post-infarction inflammatory response. However, their relative 
contributions remain unclear. Leukocytes are recruited through activation of a multistep 
adhesion cascade. Capture (1) of circulating leukocytes by activated endothelial cells is 
followed by rolling (2), mediated through interactions involving the selectins. Rolling 
leukocytes are activated (3) by chemokines bound to proteoglycans (PG) on the endothelial 
surface. Activated leukocytes express integrins and adhere to endothelial cells (4). 
Strengthening of the adhesive interaction (5) between leukocytes and endothelial cells is 
followed by transmigration of the cells into the infarcted area (6). Abbreviations: DAMPs, 
danger-associated molecular patterns; TLR, Toll-like receptor; ROS, reactive oxygen species 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cardiology (10), 
copyright (2014)
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During the proliferation phase the expression of the angiogenic factor hypoxia-
inducible factor 1 results in neoangiogenesis, facilitating oxygen delivery to the injured 
tissue and maintaining cell metabolism. These processes lead to the resolution of the 
pro-inflammatory environment and the formation of highly vascularized granulation 
tissue, initiating the transition towards the maturation phase in which the final 
collagen-rich scar is formed.
Endothelial cells proliferate to form an extensive microvascular network,stabilizing 
the scar by providing oxygen and nutrients. When the highly vascularized granulation 
tissue is replaced by a collagen-rich scar to replace the damaged heart muscle, the 
process of infarct healing is complete (6-11). 
Potential of cell-based therapy for the treatment of ischemic heart disease. The number 
of therapeutic strategies to treat MI has increased substantially in the past decades (12-15). 
Current treatment options for MI to ameliorate the effects of myocardial ischemia are 
diverse (16). In ST-elevation MI (STEMI), primary percutaneous coronary intervention 
(PCI) is indicated and the delay between the patients’ symptoms and reperfusion therapy 
should be kept at a minimum. When a primary PCI center is not available or when a 
PCI is not possible, thrombolysis should be initiated immediately. In case of multivessel 
disease or when the culprit coronary artery is unsuitable for PCI, emergency coronary 
artery bypass graft surgery (CABG) may be indicated.  In Non-STEMI (NSTEMI) patients, 
angiography is performed to evaluate whether there is a culprit lesion for which PCI or 
CABG may be indicated. Additionally, all (N)STEMI patients are treated with antiplatelet 
and fibrinolytic therapy, beta-blockers, statins and angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers. Also, both lifestyle interventions and risk 
factor management are provided to optimize cardiac rehabilitation and reduce the risk 
for a recurrent event. 
Patients with significant left ventricular dysfunction and ventricular arrhythmias 
or at risk of ventricular arrhythmias should be evaluated for implantable cardioverter 
defibrillator therapy with or without resynchronization therapy (16).
Despite these treatment options, MI patients are still prone to develop heart failure 
since there are no therapeutic options available to reverse the loss of functional 
myocardium (17). So far, the only curative option for advanced heart failure is heart 
transplantation. However, the number of transplant procedures is restricted by limited 
donor availability (18). Therefore, there is an unmet clinical need for new therapies to 
treat irreversibly damaged myocardium. 
In recent years cell-based regenerative therapy has emerged as a potential therapeutic 
option for ischemic heart disease (19). The ideal cell-based cardiac regenerative therapy 
utilizes a cell type that is easily accessible, is able to engraft into the infarcted site 
and survive, can differentiate into cardiomyocytes and endothelial cells, couple 
electromechanically to host myocardium, contribute in a meaningful manner to 










procedure. Additionally this cell type should have immunomodulatory properties in 
light of the extensive detrimental inflammatory processes that occur after MI, and 
must be autologous to avoid the need for pharmacological immune suppression. In 
search of this ideal form of cell-based therapy, a variety of cell types has been studied.
In 2001, Orlic et al reported that intramyocardial transplantation of bone marrow 
cells after MI in mice resulted in differentiation of these cells into cardiomyocytes 
and regeneration of the infarcted myocardium (20). However, these results remain 
controversial, as other labs were not able to reproduce them (21, 22). Since then, a 
large number of experimental studies has been performed indicating that cell-based 
therapy may improve cardiac function after MI (23, 24). The skeletal myoblast was one 
of the first cell types injected after experimental MI, which resulted in improvement 
of cardiac function (25). In addition, different stem cell populations derived from the 
bone marrow were studied. 
Mesenchymal stromal cells (MSCs) (26, 27), bone-marrow derived mononuclear 
cells (28, 29), hematopoietic stem cells (22) and endothelial progenitor cells (30, 31) 
all showed the potential to improve cardiac function when injected after MI. In 
particular MSCs have been evaluated as source for cell-based therapy after MI, since 
they are easily accessible and expendable, present limited risks of tumorigenicity, 
allow allogeneic use because of their immunomodulatory capacities and produce a 
combination of paracrine factors that diminish the deleterious effects of the post-
infarction inflammatory response. (32).
Although all of the above mentioned cell types engraft into the infarcted myocardium, 
they are not able to quantitatively differentiate towards cardiomyocytes, couple with 
the host cardiomyocytes or provide meaningful neomyocardiogenesis. So far, the 
only stem cell types known to have the capacity to differentiate into cardiomyocytes 
are the embryonic stem cell (ESC) and induced pluripotent stem cells (iPSCs) (33, 
34). Transplantation of ESC-derived cardiomyocytes has shown a beneficial effect on 
cardiac function (35), although this appears to be temporary (36).  Despite of their 
huge potential for cell-based therapy in patients, the use of ESCs remains controversial 
because of ethical issues, observed teratoma formation and immune rejection (37). 
However, recently the first in man application of ESC has been performed (38). 
The discovery of iPSCs by Takahashi et al. addresses the ethical and immune 
rejection issues since the patients’ own skin fibroblasts can be used for iPSC generation 
(34). iPSCs are able to differentiate towards cardiomyocytes and other cells of 
the cardiovascular lineages (39-41). Injection of these cells after MI did result in 
improvement of cardiac function (42-44).
Besides ESCs and iPSCs, it has become clear that the heart itself also contains 
different populations of cardiac progenitor cells (CPCs) which appear to be capable of 
cardiac regeneration (45). Beltrami et al. questioned the traditional view of the heart 
as a terminally differentiated organ by proposing that cardiomyocytes may re-enter 
the cell cycle and undergo mitotic division (46). Recent studies have confirmed this 
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finding (47-51), but it remains unclear what the exact number and turnover rate of 
newly formed cardiomyocytes is (52). Hsieh et al. suggested that progenitor cells may 
play a role in the process of cardiomyocyte renewal (53). However, the contribution 
of progenitor cells appears to be limited to injury-related cardiomyocyte replacement, 
as during normal ageing cardiac regeneration mainly occurs through pre-existing 
cardiomyocytes (53, 54).  The different CPCs populations residing in the heart that 
have been identified over the last few years are characterized by expression of several 
surface marker proteins, including c-Kit (55, 56), islet1 (57) and stem cell antigen-1 
(cardiomyocyte progenitor cells, or CMPCs) (58, 59). Additionally, cell populations have 
been characterized by expressing a combination of stem cell markers and the potential 
to grow as self-adherent clusters (cardiospheres) (60) or by their ability to exclude 
Hoechst dye (61, 62). Transplantation of these different cell populations (55, 63, 64) 
and cardiospheres (65-67) after MI all resulted in beneficial effects on cardiac function.
Besides CPCs, other progenitor cells which are important for the development 
of the heart, e.g. epicardium-derived cells (EPDCs) have been investigated. Both 
injection of EPDCs alone (68) and injection of a combination of EPDCs and CMPCs 
(69), contributed to functional improvement of heart function after MI.
Targeting hypercholesterolemia as treatment for ischemic heart disease. 
Hypercholesterolemia, either familiar or diet-induced, is an important risk factor for 
the development of ischemic heart disease due to the initiated inflammatory response 
by increased  blood levels of lipoproteins, e.g. LDL, leading to the development of 
atherosclerosis (4, 70). The APOE3*Leiden mouse model provides an opportunity to 
study the pathophysiology of diet-induced hypercholesterolemia and the development of 
atherosclerotic plaques. While on a high-cholesterol diet, these transgenic mice developed 
hypercholesterolemia and hyperlipidemia (71). A subsequent study by van Vlijmen et al. 
showed that after 14 weeks of high-cholesterol feeding, APOE*3 Leiden mice developed 
atherosclerotic plaques similar to humans (72). However, in these mice atherosclerotic 
plaques were mainly present in the aortic arch and carotid arteries, whereas no lesions 
were found in the coronary arteries as is the case in the clinical situation of CHD. 
So, despite the fact that APOE*3 Leiden mice develop atherosclerosis in a similar 
way as humans, this mouse model cannot be used to study the origin and development 
of a myocardial infarction. However, this model still provides us more insight in the 
development and pathophysiology of hypercholesterolemia and atherosclerosis, which 











Outline of the thesis
This thesis focuses on the potential of cell-based therapy in ischemic heart disease 
and the role of the inf lammatory response after MI. Chapter 2 reviews the specific 
myocardial inf lammatory events that occur following MI and explores the potential 
role of cell therapy, in specific of the MSC, to positively inf luence this process. In 
chapter 3 we studied the usefulness of a clinically relevant transient ischemia MI 
model in immunodeficient mice to investigate the potential of human stem cell therapy 
and compared this to the commonly used animal MI model via permanent ischemia. 
Besides a comparison of cardiac function between both MI models, infarct size and 
inf lammatory response were also evaluated. Next, in chapter 4 we aimed to extend 
our previous research regarding the positive therapeutic effects of MSC therapy after 
MI by injecting MSCs stimulated with the pro-inf lammatory cytokine interferon-γ, 
since pro-inf lammatory priming has shown additional beneficial effects in several 
experimental disease models. In addition to determining cardiac function, infarct 
size, cell engraftment and inf lammatory cell inf lux were also evaluated.
Chapter 5 evaluates the short-term effect of human CMPC (hCMPC) infusion on 
cardiac function in an animal MI model. Cells were isolated from human fetal heart 
tissue and infused into infarcted hearts. Afterwards, engraftment and differentiation 
capacities were evaluated by histology.
Chapter 6 discusses the effect of diet-induced hypercholesterolemia, one of the 
important risk factors for developing ischemic heart diseases, on both cardiac function 
and inflammation after myocardial ischemia-reperfusion injury.
Finally, chapter 7 provides an overview of the results described in this thesis, and 
discusses future perspectives. 
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Abstract
Myocardial infarction triggers reparative inf lammatory processes programmed to 
repair damaged tissue. However, often additional injury to the myocardium occurs 
through the course of this inf lammatory process, which ultimately can lead to heart 
failure. The potential beneficial effects of cell therapy in treating cardiac ischemic 
disease, the number one cause of death worldwide, are being studied extensively, both 
in clinical trials using adult stem cells as well as in fundamental research on cardiac 
stem cells and regenerative biology. This review summarizes the current knowledge 
on molecular and cellular processes implicated in post-infarction inf lammation and 
discusses the potential beneficial role cell therapy might play in this process. Due 
to its immunomodulatory properties, the mesenchymal stromal cell is a candidate 
to reverse the disease progression of the infarcted heart towards heart failure, and 











Ischemic heart disease including myocardial infarction (MI) is the number one 
cause of death worldwide (1). MI typically results from a (thrombotic) occlusion of a 
coronary artery leading to myocardial ischemia (2). Typically, after diagnosis of MI 
primary percutaneous coronary intervention (PCI) of the infarct related coronary 
artery is performed to achieve reperfusion, limit tissue necrosis and improve the 
clinical outcome. Additionally, reperfusion triggers the immune system to initiate an 
essentially regenerative signaling cascade programmed to repair the damaged tissue 
after removal of dead cells and matrix debris (3). However, this immune-mediated 
response needs to be tightly regulated to prevent additional myocardial tissue damage 
which may invoke congestive heart failure (4, 5). Although PCI limits tissue damage 
inf licted by myocardial ischemia, this intervention typically does not halt or even 
reverse the loss of functional myocardium (6). 
To limit (additional) damage to the myocardium after MI, novel therapeutic 
interventions involving cell-based therapies have emerged in order to increase our 
arsenal for treating ischemic heart disease (7). In this review we systematically 
summarize the current state of knowledge on the inflammatory response involved in 
post-MI inflammation and discuss how cell therapy may attenuate certain deleterious 
aspects of this response and may improve cardiac function after MI.
The post-infarction inflammatory response 
Myocardial ischemia results in cell death, initiating an inf lammatory response 
ultimately resulting in scar formation (8). This process of myocardial infarct healing 
occurs through three successive phases: the inf lammatory phase, the proliferative 
phase and finally the maturation phase (9, 10).
The inflammatory phase. The immune system comprises an innate and adaptive system. 
The innate immune system regulates the non-specific immediate response against invading 
pathogens and injury, whereas the adaptive immune system involves specific recognition 
of foreign antigens and progresses with a delay as it requires prior activation by innate 
immune cells. 
As a consequence, the first phase of the reparative process after MI is mediated by 
the innate immune system (10). Initially platelets are activated upon myocardial injury 
to prevent bleeding. Platelets aggregate locally to form a fibrin-rich matrix and release 
important growth factors such as platelet-derived growth factor (PDGF) and Platelet-
Factor 4 that aid the repair process (11). In parallel, platelets produce platelet activating 
factor thereby stimulating the influx and adhesion of neutrophilic granulocytes to the 
site of injury (12). Neutrophils are among the first innate immune cells to enter the 
myocardium, which occurs within hours after the ischemic event. Their recruitment is 
28
stimulated by Reactive Oxygen Species (ROS) produced by activated cardiac myocytes 
and vascular endothelial cells (10). ROS (including hydrogen peroxides, superoxide 
anions and hydroxy radicals) are formed by the incomplete reduction of molecular 
oxygen and activate the chemotactic cytokine interleukin (IL)-8 / chemokine (CXC 
motif) ligand 8 as well as the endothelial surface molecule intercellular adhesion 
molecule-1 (ICAM-1), together coordinating neutrophil recruitment. 
Upon arrival, neutrophils secrete proteolytic enzymes that clear the infarct from 
dead cells and debris (10, 13). However, the activated neutrophils also contribute to the 
production of ROS which react directly with cellular lipids, proteins and DNA released 
from the damaged cells. In this context ROS act as signaling intermediates that activate 
the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) resulting in the production of pro-inflammatory cytokines and chemokines, 
but also of growth factors important for tissue repair such as Transforming Growth 
factor-beta (TGF-b) (10, 14, 15). Tissue damage inflicted by ROS needs to be limited as 
early as possible as demonstrated in a study of MI in dogs using free radical scavenging 
catalase and the anti-oxidant enzyme superoxide dismutase-1. In this study it was 
shown that infarct size was reduced only when the treatment was given prior to 
coronary occlusion (16). 
It is however difficult to denote the exact role of neutrophils in myocardial 
repair. Smaller infarcts were observed upon myocardial reperfusion in experimental 
animals depleted of neutrophils, suggesting that neutrophils have a deleterious effect 
in myocardial injury followed by reperfusion (17). However, infarct sizes were not 
altered when neutrophil recruitment was prohibited in mice deficient for ICAM-1 
and P-selectin, despite a reduction in neutrophil trafficking (18). Initial neutrophil 
influx is followed by the recruitment of monocytes, which is mainly mediated by the 
chemokine monocyte chemo attractant protein-1 (MCP-1)/ chemokine (C-C motif) 
ligand 2. In a study in MCP-1 deficient mice, it was shown that the absence of MCP-1 
did not alter infarct size, but attenuated ventricular remodeling, reduced and delayed 
monocyte/macrophage recruitment and delayed replacement of cardiomyocytes with 
granulation tissue and diminished myofibroblast accumulation (19). Phenotypically 
monocytes can be distinguished in different subsets and numerous studies have tried 
to attribute different roles to distinct subsets as monocytes appear to be involved in 
both pathogenic as well as reparative inflammatory responses. In mice, monocytes 
that express high levels of the molecule lymphocyte antigen 6c (Ly-6C) are regarded as 
pro-inflammatory monocytes. In mouse MI studies these pro-inflammatory Ly-6Chigh 
monocytes are recruited from the bone marrow to the infarcted heart expressing the 
C-C chemokine receptor 2 (CCR2), where they remain in high numbers until three 
days after MI, scavenging debris and secreting inflammatory cytokines and matrix 
degrading proteases (20, 21). 
The recruitment of neutrophils and monocytes is thus crucial for the initiation of 










that are activated. Intracellular components released from necrotic cardiomyocytes are 
sensed by innate immune cells that become activated upon tissue entry (22). The most 
prominent pathways by which the innate immune system initiates a post-infarction 
inflammatory response are: 1) The Toll-like receptor (TLR)-mediated pathway; 
2) The complement cascade and; 3) The earlier mentioned ROS. These three pathways 
all converge to activate NF-kB, a transcription factor that drives the expression of 
numerous genes. In a resting cell the NF-kB dimer is sequestered in the cytoplasm 
as an inactive protein bound by the inhibitor of kB, IkB. Upon activation of the 
NF-kB pathway, the IkB protein is degraded, releasing the NF-kB dimer which then 
translocates to the nucleus where it regulates gene expression by binding specific 
promoter sequences. Since NF-kB regulates so many different genes ranging from 
pro-inflammatory cytokines, chemokines, matrix metalloproteinase (MMP) as well 
as genes involved in cell survival and proliferation, (23),(24) it is considered as one of 
the most important players throughout the whole process of tissue repair. A recent 
review summarizes several studies highlighting the participation of NF-kB in post-MI 
inflammation (24). A reduction of myocardial infarct size was observed after ischemia-
reperfusion in an experimental model where NF-κB activity was blocked by prohibiting 
DNA-binding using decoy oligodeoxynucleotides, whereas a recent report by Hamid et 
al. reported that prolonged activity of NF-κB in myocardial tissue results in a chronic 
inflammatory state with detrimental consequences for infarct healing (25). Both studies 
underscore the role of NF-κB in post-MI inflammation (26). 
TLRs are a family of heterodimeric transmembrane pattern recognition receptors 
that recognize and bind antigens derived from pathogens or damaged tissues, the so 
called damage-associated molecular patterns (DAMPs). Upon ligand binding most 
TLRs activate NF-κB leading to the expression of pro-inflammatory cytokines such 
as tumor necrosis factor-a (TNF-a), pro IL-1b and interferons. Among the TLRs 
identified, TLR1, 2, 4-6 and 11 are expressed on the cell surface, whilst TLR3 and 7-9 
are expressed in intracellular vesicles, mostly endosomes. TLRs are pre-assembled 
as low-affinity dimers which undergo a conformational change upon ligand binding. 
Although initially described as receptors that recognize pathogen-derived molecules, 
several non-pathogenic endogenous molecules have been identified to bind and activate 
TLRs. For instance TLR4 binds not only to lipopolysaccharide but also to certain 
heat shock proteins and extracellular matrix (ECM) remnants such as hyaluronan 
and fibronectin (27) suggesting a broad role for TLR4 in tissue injury and repair. It 
has been observed that TLR4 is upregulated in injured myocardium of both humans 
and mice (28). Also, in TLR4 deficient mice, MI induced hearts were characterized 
by reduced left ventricular remodeling with preserved systolic function, but without 
affecting the infarct size. The infarcted area showed increased collagen density with 
fewer macrophages and reduced cytokine levels and MMP activity, identifying TLR4 
as an important component of the post-MI remodeling process (29).
Next to TLR activation, the release of DAMPs also triggers the complement cascade. 
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The complement system is a network of soluble and surface bound proteins able of 
recognizing, tagging and eliminating microbial intruders and foreign cells via initiation 
of the immune response. The complement cascade consist of three main pathways 
which are all involved in immunopathological diseases (30). In a rat model of MI it was 
shown that ischemic myocardial injury activates the complement cascade, and mRNA 
and proteins of the complement pathway are upregulated in areas of MI (31),(32-34). 
The importance of complement pathway activation in mononuclear cell recruitment 
was shown in a canine model of cardiac ischemia in which upon cardiac reperfusion, 
the complement pathway induced migration of monocytes into the myocardium (35). 
Studies have been performed in which certain elements of the complement cascade 
have been inhibited using cobra venom or soluble human complement receptor to 
antagonize complement signaling. These studies showed a reduction in myocardial 
necrosis and a decrease in infarct size suggesting a role for the complement pathways 
in myocardial injury (36, 37). 
In conclusion, all actions combined result in recruitment of leucocytes to the 
infarcted area, the clearance of dead cells and debris and the activation of signaling 
cascades leading to the production of a variety of essential growth factors for repair 
of the infarcted area, and the transition towards the proliferative phase (38). 
The proliferative phase. At this stage neutrophils, mononuclear cells, endothelial cells 
and pericytes all work together to resolve the initial inflammatory reaction and direct 
it towards a healing process. Short–lived neutrophils become apoptotic and release 
mediators such as annexin A1 and lactoferrin that suppress further neutrophil recruitment 
(39). The Ly-6Chigh monocytes express the orphan nuclear hormone receptor, nuclear 
receptor subfamily 4, group a, member 1 (Nr4a1) which reduces the CCR2 dependent 
recruitment of Ly-6Chigh monocytes towards the infarct. In addition, Ly-6Chigh monocytes 
differentiate into Ly-6Clow macrophages in the local cardiac tissue. Ly-6Clow macrophages 
clear the apoptotic neutrophils and are associated with an increased presence of the 
anti-inflammatory factors IL-10, TGF-β and vascular endothelial growth factor (VEGF) 
countering the inflammatory response by recruitment of myofibroblasts for scar tissue 
formation and thereby contributing to infarct healing (40, 41). A recent study performed 
by Hilgendorf et al. indicated another important anti-inflammatory role for Nr4a1, as 
cardiac macrophages in Nr4a1-deficient mice showed a more inflammatory profile and as a 
result these animals had a decreased cardiac function and increased cardiac remodeling in 
contrast to wildtype controls following MI (41). Whilst Ly-6Chigh monocyte levels decrease, 
Ly-6Clow monocytes, resident in the cardiac tissue, peak 7 days after MI and afterwards 
also decrease. Ly-6Clow monocytes are also Nr4a1 dependent, as Nr4a1-deficient animals 
had no Ly-6Clow monocytes in either the cardiac tissue or the peripheral circulation. 
The role of Ly6Clow monocytes is still under investigation, but they are important in the 
inflammatory process by the clearance of endothelial necrotic cells via TLR-7 activation 










MI patients as mainly CD14+CD16- monocytes were present in the cardiac infarct tissue in 
the inflammatory phase after MI, while in the proliferative phase both CD14+CD16- and 
CD14+CD16+ monocytes were observed (43). Since CD14+CD16- monocytes in humans are 
comparable to Ly6Chigh monocytes in mice (21, 44), this indicates the monocyte response 
is comparable between species.
The uptake of apoptotic cells by macrophages induces the release of anti-
inflammatory factors such as IL-10 and TGF-b, and lipid mediators such as lipoxins 
and resolvins which further stimulate the removal of inflammatory leukocytes (23, 45). 
After MI, IL-10 becomes highly expressed, mainly by activated T lymphocytes and 
monocytes as described above. As IL-10 inhibits the secretion of IL-1a, IL-1b, TNF-a, 
IL-6 and IL-8, it suppresses the ongoing inflammation process (5, 23). In addition, IL-10 
induces the production of a group of peptidases involved in ECM degradation called 
tissue inhibitor of metalloproteinases (TIMPs), thereby promoting ECM remodeling 
(10, 46, 47). IL-10 deficient mice showed an increased mortality concomitant with an 
enhanced immune response during myocardial ischemia followed by reperfusion, as 
measured by a higher neutrophil recruitment, elevated plasma TNF-a and a higher 
expression of ICAM-1 (48). In a similar study elevated mRNA levels of TNF-a and 
MCP-1 were also observed in the infarcted heart of IL-10 deficient mice. However, in 
this study mortality rates were similar to wild type mice due to the variable effects of 
IL-10, affecting the production of a numerous cytokines such as IL-1 and IL-6 (49). 
Both IL-1a and IL-1b are upregulated in experimental models of MI and promote the 
inflammatory reaction by the induction of cytokine and chemokine production (10). 
In contrast, IL-6 appears to have a beneficial role in tissue repair (11). IL-6 protects 
cardiomyocytes against apoptosis and induces cardiomyocyte hypertrophy. IL-6 
expression is induced in the healing infarct, and can be produced by mononuclear 
cells, cardiomyocytes and fibroblasts within the ischemic myocardium (10, 50, 51). 
TGF-b is upregulated in experimental models of MI and initiates the transition 
from inflammation to fibrosis by pro-inflammatory cytokine suppression (38). The 
secretion of TGF-β will initiate fibroblast growth as well as angiogenesis, whereas 
MMPs and TIMPs produced by the activated macrophages aid in the extracellular 
remodeling of the regenerating cardiac tissue (5, 10). Angiogenesis is crucial to provide 
oxygen to the injured tissue and maintain cell metabolism (10). One of the most 
important angiogenic factors during the proliferative phase is hypoxia-inducible 
factor 1, expressed early after myocardial ischemia, which upregulates the chemokine 
stromal cell-derived factor 1-α (SDF-1) and its receptors CXCR4 and CXCR7 (52) and 
activates the release of VEGF, one of the key growth factors in neoangiogenesis (53). 
After SDF-1 is expressed, hematopoietic stem cells and endothelial progenitor cells are 
recruited to the ischemic myocardium where they improve angiogenesis as has been 
demonstrated by several studies (52, 54-58). PDGF signaling induces maturation of 
the neovessels via the formation of a mural coat of pericytes surrounding the vessel. 
Withdrawal of PDGF from this process leads to apoptosis of the endothelial cells (59). 
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Inhibition of TGF-b during the early inflammatory phase after myocardial injury 
results in a significant increase in mortality and an exacerbated left ventricular 
dilatation via enhanced cytokine synthesis in mice (60) Moreover, TGF-b inhibits 
immune cell proliferation and stimulates fibroblasts to produce ECM proteins such 
as collagens, fibronectin, tenascin and proteoglycans and ultimately suppresses 
matrix degradation via inhibition of proteinases such as plasminogen activators and 
collagenases while stimulating production of proteinase inhibitors such as plasminogen 
activator inhibitor-1 and TIMPs (61-63). Resident cardiac fibroblasts entering the 
infarcted tissue differentiate to myofibroblasts that express contractile proteins such as 
a-smooth muscle actin. Myofibroblast differentiation is induced by mechanical stress, 
TGF-β/mothers against decapentaplegic homolog 3 (Smad3) signaling and alterations 
in the composition of the ECM such as upregulation of ED-A fibronectin (64, 65). 
These myofibroblasts are predominantly present in the infarct border zone and have a 
high proliferative capacity (10, 66). They are the main source of ECM proteins needed 
to generate a collagen scar (67). Induction of the pro-inflammatory cytokine TNF-a 
diminishes ECM collagen synthesis followed by an increase of the MMP activity of 
cardiac fibroblasts (10, 68). However, TNF-a deficient mice are protected from cardiac 
rupture and chronic dysfunction following infarction (69), indicating the pleiotropic 
role of the cytokine. 
One of the important ECM constituents is hyaluronan, a high molecular weight 
polymer under physiologic conditions, which becomes degraded upon tissue injury. 
Hyaluronan fragments stimulate endothelial cells and macrophages to secrete pro-
inflammatory cytokines and chemokines and clearance of these fragments precedes 
the resolution of the inflammatory phase (10, 70, 71). Finally, there is an accumulation 
of mast cells during cell proliferation and fibrosis (72). The exact role of mast cells in 
the process of cardiac inflammation and repair is still under investigation, but one 
function of mast cells might be the regulation of fibrosis by the secretion of MMPs 
(73), thereby inducing tissue remodeling. The summation of these processes finally 
leads to the formation of highly vascularized granulation tissue and abolition of the 
pro-inflammatory environment enabling repair. 
The maturation phase. The formation of the scar, initiated during the proliferative phase, 
is followed by its maturation when endothelial cells have proliferated to form an extensive 
microvascular network. Only a part of these vessels mature through the mural wall 
formation by pericytes and myofibroblasts. These mature vessels aid scar stabilization by 
providing oxygen and nutrients (23). However, the remainder of neovessels do not mature 
and undergo apoptosis together with the remaining myofibroblasts (64). The highly-
vascularized granulation tissue formed during the inflammatory phase, is finally replaced 
by a collagen-rich scar, completing the process of infarct healing (10). The site of coronary 
occlusion, duration of ischemia and timing of reperfusion all influence the inflammatory 










After completion of the reparative response, some fibroblasts remain in the non-
infarcted myocardium and may become activated via increased wall stress where 
they contribute to ventricular remodeling and ventricular dysfunction by producing 
matrix proteins and proteases (64). Increasing the number of myofibroblasts as well 
as the number of capillaries by blocking frizzled signaling via the proto-oncogene 
protein Wnt3a and protein Wnt5a antagonizing peptides reduced infarct size and 
increased infarct thickness in a mouse model of MI, suggesting that preservation 
of cardiac function after MI can (amongst others) be influenced by modulation of 
myofibroblasts (74). 
In conclusion, inflammatory processes play a crucial role initially clearing the 
debris of apoptotic cells but also regulating essential repair mechanisms to form 
mature scar tissue. However, an elaborate immune response clearing as much damaged 
cellular tissue as possible also induces undesirable collateral damage to surrounding 
healthy tissue. 
Therapeutic approaches targeting cardiac inflammation and ischemia–reperfusion 
injury after myocardial ischemia. The progress made in understanding cardiac 
inflammation initiated experimental studies aiming to modulate the unwanted cardiac 
tissue injury induced by post-MI inflammation and reperfusion therapy. Initial studies 
targeting pathways of oxidation, inflammation, sodium-hydrogen exchange, nitric oxide 
metabolism and metabolic pathways showed positive results on clinical parameters such 
as reduction of infarct size; however these results need confirmation in large trials (75, 
76). The purine analogue acadesine, which increases adenosine levels in energy-deprived 
tissues, has been studied as a pharmalogical intervention in an ischemia-reperfusion setting 
(77). A meta-analysis summarizing all studies that have tested acadesine in 4043 patients 
undergoing coronary artery bypass grafting (CABG) surgery, suggested a 27% reduction 
of the perioperative occurrence of MI (3.6% vs 4.9%, P=0.02) and a 26% decrease in the 
combined outcome of stroke/MI/cardiac death (7.6% vs 4.6%, P=0.04) (78). However, the 
largest trial performed called the Reduction in cardiovascular Events by acaDesine trial in 
subjects undergoing CABG surgery (RED-CABG), was stopped after 3080 of the originally 
projected 7500 study participants were randomized because of a low expectancy to obtain 
statistically significant differences. This underscores that beneficial effects are variable. 
One of the earliest results of pharmacological intervention to inhibit the inflammatory 
response after MI was described by Roberts et al. who infused multiple doses of the 
anti-inflammatory drug methylprednisolone in patients with MI and reported an 
augmentation of the infarct size and accentuation of malignant arrhythmias. These 
catastrophic results of the methylprednisolone study made clear that an absolute 
suppression of the immune system after MI is not desirable for it also interferes with 
the reparative aspects of the immune response (23, 79). 
A growing number of alternative promising therapeutic interventions targeting the 
cardiac inflammation process, including ischemic pre- or post-ischemic conditioning, 
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has been proposed and in part already investigated in patients or is about to be 
examined in clinical trials (80-82). Recently, Padfield et al. determined the effects 
of etanercept, a TNF-α antagonist, in patients after MI. Whereas, they observed a 
modest anti-inflammatory effect possibly through a decrease in neutrophil recruitment 
and IL-6 concentrations, TNF-α levels were increased as were platelet activators 
and aggregators, making it less suitable as a therapeutic candidate to treat MI (83). 
In another study MI patients were treated with intravenous immunoglobulin after 
PCI, however without any beneficial effect on either cardiac function or remodeling 
(84). A large trial investigating the effects of pexelizumab, an antibody binding the 
C5 component of complement, did not influence mortality or development of heart 
failure in cardiac patients (85). 
Other promising therapeutic interventions showed contrasting results. The 
immunosuppressive drug cyclosporine that inhibits the opening of mitochondrial 
permeability-transition pores caused smaller infarct sizes and attenuated left 
ventricular remodeling in initial clinical trials when administered after primary PCI 
(86, 87). However this was not reproduced in a more recent trial where cyclosporine 
was injected before thromobolytic treatment (88). Blockade of the IL-1 receptor by 
anakinra attenuated cardiac remodeling in a first small pilot study in MI patients (89). 
A second study however, did not confirm these results (90).
So far, the effects of different anti-inflammatory therapies are incongruent and their 
clinical applicability remains unclear. More importantly, this therapeutic approach 
will only attenuate the results of the inflammation process itself, among which the 
remodeling process. Here lies a role for the still emerging field of cell-based therapy, as 
this may influence the post-MI inflammation process, but also potentially regenerate 
the infarcted tissue (91).
Cell-based therapy
While the amount of therapeutic strategies to treat ischemic events has increased 
dramatically the past decade, patients are often still prone to develop heart failure, 
since there are no therapeutic options available to reverse the loss of functional 
myocardium. Therapeutic cell therapy has the advantage that it can be delivered locally 
into infarcted tissue, either as a cell suspension or on a supportive scaffold. Additionally, 
genetic modification allows for cells to be custom-tailored to improve results. 
Moreover, certain stem cell populations such as mesenchymal stromal cells (MSCs) 
have the additional advantage of diminishing the deleterious effects of the inflammatory 
response that accompanies repair by secretion of different paracrine factors acting 
on several immune cell populations (92, 93). However, the potential of cell therapy 
to influence post-MI inflammation has not been studied extensively yet, leaving for 
the moment a gap in our knowledge about the effect and capacity cell therapy might 










was accelerated a decade ago by a preclinical study that reported improved cardiac 
regeneration upon infusion of bone marrow-derived cells into a cardiac ischemic 
mouse heart (94). These results initiated a new area of research, exploring the potential 
of cell therapy to regenerate the diseased heart and clinical trials quickly followed. 
The ideal cardiac regenerative therapy involves a cell type that is easily accessible, 
produces the optimal combination of paracrine factors, is able to engraft in the injured 
cardiac tissue niche, can possibly even differentiate into a cardiomyocyte or other 
desired cardiac cell types, and can be delivered via a safe and minimally invasive 
procedure. In search for this cell type, a variety of cell populations are being studied, all 
initially aimed toward regenerating cardiac tissues, each having their own advantages 
and limitations (95). 
Transplantation of various cell types such as hematopoietic and non-hematopoietic 
bone marrow-derived stem cells as well as MSCs and other adult stem cells has 
been performed in experimental and clinical studies with the purpose to stimulate 
neoangiogenesis (96). It is reported that therapeutic cell therapies can regulate tissue 
inflammation through paracrine mechanisms acting on angiogenesis, apoptosis and 
scar formation and are able to potentiate recruitment of endogenous stem cells to the 
site of injury (91, 93). In addition, there are cell types that have proven to be able to 
form de novo cardiomyocytes, such as embryonic stem cells (ES), induced pluripotent 
stem cells (iPS) and cardiac progenitor cells (CPCs) (97). The CPCs can be isolated 
from the adult heart and show spontaneous electrical activity and action potentials 
upon appropriate in vitro differentiation (98).
In the cardiac field, the effect of cell therapy has been studied in different animal 
models, but studying inflammation has not been a main focus in these studies (Table 1).
Mesenchymal stromal cells
Over the last years many studies have focused on the therapeutic potential of MSCs 
in different diseases in animals and humans, due to their versatile nature which 
includes their immunomodulatory capacities. This cell type was first described 
by Friedenstein et al. in 1968 and has already been studied in clinical trials (99). 
The MSC is a rare population of multipotent cells, present in bone marrow and 
other mesenchymal tissues like adipose tissue. MSCs are poorly defined but ex vivo 
expanded MSC populations are traditionally characterized by the presence of surface 
antigens CD90, CD73, CD105 and major histocompatibility complex (MHC)-I and 
the absence of characteristic hematopoietic cell surface antigens such as CD45, 
CD34, CD80 and MHC-II. MSCs are capable to differentiate into multiple mature 
cell lineages including chondrocytes, osteoblasts and adipocytes. Due to its limited 
plasticity and restricted lifespan the MSC has a major theoretic advantage regarding 
safety compared to the ES and IPS cell, with a reduced risk of tumorigenicity, a major 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































their potential to regenerate damaged tissues, the MSC is additionally capable of 
dampening deleterious aspects of the immune response that accompanies injury. 
Inhibition of undesired immune responses by MSC infusion has been observed in 
experimental animal models for various diseases and underscores the potential of 
MSCs for clinical immune regulation (100). The clinical applicability of MSCs for 
immunological disease was initially shown in patients with graft-versus-host disease 
(GvHD) after bone marrow transplantation (101) . In a successive phase II study it 
was found that MSC administration improved the manifestations of GvHD in the 
majority of patients (102). These positive results of MSC therapy led to MSCs entering 
various clinical trials. Notwithstanding the positive effects of MSCs, the cellular and 
molecular mechanisms responsible are complex, probably multifactorial in nature 
and poorly understood. 
MSCs are immunosuppressive in vitro, evidenced by their ability to suppress the 
proliferation of T cells and their effect on cytokine profiles (103-105). Furthermore, 
MSCs are able to induce the formation of CD4+CD25+FOXP3+ regulatory T cells (106) 
and interfere with the differentiation, maturation and function of antigen presenting 
dendritic cells, thereby directly affecting processes such as immunity and tolerance 
(107). Huang et al. showed that neither infusion of allogenic nor syngeneic MSCs after 
MI in rats elicited a significant immune response, confirming the lack of immunogenic 
surface antigen expression or expression of antigens in an immunoregulatory fashion 
on such MSCs. Syngeneic MSC therapy improved cardiac function up to 6 months 
after infusion when compared to controls, whereas allogeneic MSC therapy improved 
cardiac function up to 3 months only. However, in vitro treatment before infusion of 
MSCs with 5-azacytidine, VEGF or TGF-β in an effort to stimulate differentiation 
towards myogenesis, endothelial cells or smooth muscle cells respectively, altered the 
immunogenic surface antigen expression profile of these cells, potentially triggering 
an immune response in vivo after allogeneic MSC infusion (108).
We recently demonstrated that MSCs act on monocyte differentiation, promoting 
the formation of anti-inflammatory IL-10 producing cells with low antigen presenting 
capacity (109). MSCs have also been reported to inhibit the proliferation of B lymphocytes 
upon anti-Ig antibody, soluble CD40 ligand or cytokine-mediated activation (110) and 
have been suggested to inhibit IL-2- and IL-15-induced natural killer-cell proliferation 
(111). In summary, these studies demonstrate the immunomodulatory capacities of 
MSCs in vitro, however the biological relevance of these findings in vivo is still largely 
unknown (112).
The first in vivo results were obtained in an experimental model of GvHD in which 
systemically infused MSC improved survival of mice transplanted with haplo-identical 
hematopoietic stem cell grafts (113, 114). However, in another study injection of a 
single dose of MSCs did not ameliorate GvHD (115). In the cardiac field, MSC infusion 
has been studied in different animal models. MSC transplantation after MI in a rat 










process, which may be explained by the anti-inflammatory properties of MSCs as the 
expression of TNF-α, IL-1β and IL-6 was reduced in these animals (116). Infusion of 
MSCs in a rat MI model using a langendorff apparatus also resulted in the highest 
preservation of cardiac function when compared to controls, most likely by a decrease 
of the pro-inflammatory cytokines TNF-α, IL-1 and IL-6. In addition, apoptosis was 
reduced, suggesting a beneficial role for MSC in apoptotic signaling, possibly via a 
signal transducer and activator of transcription 3 pathway (117). This decrease in the 
pro-inflammatory cytokines TNF-α, IL-1 and IL-6 was also observed after injecting 
MSCs combined with either atorvastatin (118) or simvastatin, in a Chinese swine MI 
model (119). Herrmann et al. showed that infusion of MSCs, both naïve cells and cells 
pretreated with TGF-α decreased infarct size and preserved cardiac function, possibly 
through lowering of the TNF-α, IL-1β and IL-6 expression and increasing VEGF 
expression in a rat MI model (120). The increased expression of VEGF by MSC therapy 
was also demonstrated after application of MSC/silk fibroin/hyaluronic acid patches in 
an MI model in rats, in addition to a decreased inflammatory response as demonstrated 
by reduced CD 68 expression (121). Kim et al. showed preservation of cardiac function 
by infusion of MSCs as well, with enhanced MSC engraftment and cardiac function 
preservation after TNF-α stimulation (122). Lee et al. infused MSCs in an experimental 
MI mouse model where cells were afterwards entrapped in the lungs forming micro-
emboli (123). Subsequently, signals from the injured heart induced MSCs to secrete the 
anti-inflammatory protein tumor necrosis factor-inducible gene (TSG)-6 protein which 
suppresses the excessive and thereby deleterious inflammatory response involved in 
cardiac ischemia. This limited the protease release by macrophages and neutrophils, 
decreasing the damage to cardiomyocytes. Ultimately, an improvement of cardiac 
function and a decrease in scar formation of the left ventricle was observed. TSG-6, 
secreted by MSCs, has been shown to be a key anti-inflammatory factor in many other 
experimental disease models such as bleomyocin-induced lung injury, sterile cornea 
injury, and zymosan-induced peritonitis (124-127). 
The importance of the SDF-1 release by MSCs in the process of cardiac repair of 
MI was recently demonstrated in novel MI model in conditional cardiac myocyte 
CXCR4 null mice (128). In absence of CXCR4, the SDF-1 receptor, preservation of 
cardiac function by MSCs is no longer observed, possibly due to a decrease in the 
recruitment of stem cells or an increase in apoptosis. An earlier study injected MSCs 
that over-expressed SDF-1, which resulted in increased angiogenesis through VEGF 
expression and subsequently preservation of cardiac function (129).
Dayan et al. showed that MSC therapy after MI in a mouse model decreased the 
number of monocytes and pro-inflammatory M1 phenotype macrophages. Also, in 
vitro and in vivo data demonstrated that the amount of M2 phenotype macrophages, 
which are associated with an anti-inflammatory phenotype, was increased, which was 
thought to be mediated by MSC secretion of the anti-inflammatory factor IL-10 (130). 
This MSC-mediated switch from M1 phenotype to M2 phenotype macrophages was 
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recently confirmed by another group (131). In vitro experiments proposed that the 
modulation of macrophages may be dependent on cell-to-cell contact, as the secretion 
of reparative cytokines was highest in cultures of MSCs mixed with macrophages (131). 
While the therapeutic effectiveness of MSCs has been shown in a number of studies 
as described above, the mechanisms through which MSCs act remain still unknown. 
Purported beneficial immunomodulatory factors derived from MSCs in addition to 
TSG-6, include inducible nitric oxide synthase, indoleamine dioxygenase, CCL2, 
SDF-1, IL-10 and prostaglandin E2. In addition, immunomodulatory effects may rely 
on pathways acting on specific immune cell populations or via cell-cell contact with 
dendritic cells, macrophages or other cells of the immune system (91, 92, 112, 131-133). 
Clearly this must be studied more intensively and much progress will be made when 
the in vivo fate of MSCs can be determined to clarify the cellular interactions that are 
made during the initiation and ongoing process of repair.
Clinical trials of MSCs. MSC therapy is at present being studied in various clinical trials 
for their efficacy in inflammatory and degenerative disorders. However, when entering 
the clinical arena potential risks have to be taken into account: the immunogenicity of 
the cells, the biosafety of medium components, the risk of ectopic tissue formation and 
potential in vitro transformation of cells during expansion (134). 
The ClinicalTrials.gov web-based resource, supervised by the NIH has summarized 
a large number of clinical trials that involve MSC therapy targeted against various 
diseases.
One of the key clinical trials performed is a phase II trial in which fifty-five patients 
with steroid resistant acute GvHD were treated with MSCs (102). In the sixty months 
follow up, infusion of in vitro expanded MSCs was considered a possibly effective 
therapy for this specific patient group. The mode of action of MSCs in GvHD seems 
highly related to their immunomodulatory properties.
In the cardiac field MSC therapy has also been evaluated in numerous studies (135). 
In 2004 a study of autologous bone marrow-derived MSC infusion in patients with 
acute MI was performed (136). In sixty-nine patients undergoing PCI after acute MI 
significant improvements in left ventricular function were found, which were assessed 
by echocardiographic monitoring. The first phase-I, randomized, double blind, placebo-
controlled, dose-escalation study of intravenous allogeneic adult MSCs in patients 
with acute MI was completed in 2009, suggesting it was safe to use allogeneic MSCs in 
patients after acute MI (137). The same group reported in 2012 a direct comparison of 
autologous versus allogeneic bone marrow-derived MSCs in ischemic cardiomyopathy 
patients showing low rates of treatment-emergent serious adverse events, including 
immunologic reactions. A recent trial in ischemic cardiomyopathy patients showed 
no adverse effects of MSC injection and encouraging beneficial results, though the 
study size was small (138). Injection of MSCs in chronic ischemic cardiomyopathy 










and decreased scar size, however due to lack of placebo and small study size results 
were not conclusive (139). Our group recently reported that intramyocardial injection 
of autologous MSCs using the NOGA injection system in acute MI patients was safe 
up to 5 years after injection, and was associated with improved cardiac function as 
compared to baseline (140). In aggregate, the MSC injection favorably affected patient 
functional capacity, quality of life, and ventricular remodeling (141).
The current experimental and clinical data available indicate that MSC therapy is 
feasible and safe, and neither early toxicity nor later side effects have been found to 
date. However, long-term follow up studies in larger patient cohorts are warranted to 
give definitive answers whether long-term adverse events may occur (142). The latest 
findings suggest that patients receiving cell therapy mainly experience beneficial results 
on clinical outcomes instead of objective parameters regarding cardiac function (135). 
At present it is not clear whether the beneficial effect of MSCs in cardiac patients is 
also caused by a beneficial effect on post-MI inflammation, or by other mechanisms. 
More research is needed to address this issue.
Summary and future perspectives
This review describes the role of the immune system in the healing processes 
following an acute ischemic event. The inf lammatory response that occurs after MI 
is a precarious balance, since it is indispensable in the clearance of cell debris and 
ultimately the formation of a collagen scar but the pathways necessary for a timely 
initiation, suppression, resolution, and containment of the inflammatory response can 
also cause additional injury to the heart. When certain aspects of this inf lammatory 
process triggered by cardiac injury are excessive, ultimately infarct expansion and 
adverse remodeling of the infarcted heart can occur (143, 144). However, it is not fully 
known if suppression of the detrimental part of the inf lammatory response would 
prevent the adverse remodeling and concomitant worse outcome in patients with 
MI and if this therapeutic goal can be reached clinically. Modulating the immune 
response after myocardial damage is a road less travelled that might be a promising 
therapeutic option for cardiac disease. Of all cell types, the MSC currently seems a 
suitable candidate for this specific goal, based on the proven immunomodulatory 
properties, in addition to the ability to secrete angiogenic factors such as VEGF (145), 
important for neoangiogenesis (146). Infusing MSCs in the ischemic myocardium 
therefore might not only improve cardiac function via dampening excessive immune 
responses but also induce growth of new vasculature. Recapitulating the studies on the 
physiologic function of MSCs in regulating the immune system in the hematopoietic 
niche and their ability to modulate immunity in cardiac disease might be a feasible 
option to move forward (147-149). 
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Abstract
Myocardial infarction (MI) animal studies are used to study disease mechanisms 
and new treatment options. Typically, MI is induced by permanent occlusion of the 
left anterior descending artery. Since in MI patients coronary blood f low is often 
restored new experimental models better ref lecting clinical practice are needed. 
Here, permanent ischemia MI (PI group) was compared with transient ischemia 
(45 minutes) (IR group) in immunodeficient NOD/Scid mice. Cardiac function, infarct 
size, wall thickness and total collagen deposition were significantly reduced only in 
PI mice. Cardiac inf lammatory cells and serum cytokine levels were less dynamic 
in IR animals compared to PI. So although IR better ref lects clinical practice, it is 
secondary to PI for investigating cell therapy, since it induces too little damage to 
provide a measurable therapeutic window. MI did result in significant changes in 
the inf lammatory state, indicating this immunodeficient mouse strain is valuable 











As cardiovascular diseases, including myocardial infarction (MI), remain one of 
the leading causes of death globally (1), the search for new therapies continues. Cell 
therapy has emerged over the past years as a potential treatment modality for MI 
patients in addition to conventional treatment (2). Before the various candidate cell 
types are to be applied in clinical trials, they have to be investigated in experimental 
disease animal models (3-7). To mimic future clinical use of these cells as much as 
possible, typically human cells are studied in animal models. To avoid rejection of these 
infused cells by the immune system of the host and to avoid the use of pharmalogical 
immune suppression, immunodeficient animals such as the non-obese diabetic/
severe combined immunodeficient (NOD/Scid) mice strain are used. The SCID 
mutation results in an impaired T and B cell lymphocyte development which allows 
transplantation of different cell-types originating e.g. from peripheral blood, bone 
marrow or organs (8). MI in mouse models typically is induced through permanent 
ligation of the left anterior descending artery (LAD). However, in current clinical 
practice rapid restoration of coronary blood f low is the cornerstone of MI treatment, 
rendering the permanent coronary artery ligation mouse model less representative 
of the clinical situation. 
Tissue inflammation is an important element in cardiac remodeling after MI. 
Coronary artery occlusion induces an inflammatory cascade which can be divided 
in three partially overlapping phases of inflammation, proliferation and maturation 
(9). Reperfusion of infarcted cardiac tissue leads to an increased and accelerated 
inflammatory response possibly deteriorating cardiac remodeling (10). 
In the present study MI induced by permanent coronary occlusion of the LAD 
(PI group) was compared with ischemia-reperfusion MI by transient ligation of the 
LAD (IR group). MI was induced in the immunodeficient NOD/Scid mice, a strain 
necessary to study the effects of human cell therapy. In both MI models cardiac 
function was assessed by magnetic resonance imaging (MRI) and pressure-volume 
(PV) loop measurements. Furthermore infarct size was assessed by MRI and histology 
and parameters of local and systemic inflammatory response were investigated to 
determine the relevance of this immunodeficient mice strain in MI research.
Methods
Animals. Experiments were performed in 8- to 10-weeks-old male NOD/Scid mice 
(Charles River Laboratories, Maastricht, the Netherlands). Experiments were approved 
by the Committee on Animal Welfare of the Leiden University Medical Center and 
conformed to the Guide for the Care and Use of Laboratory as stated by the U.S. 
National Institutes of Health. Animals were housed in filter top cages and were given 
standard diet and water with antibiotics and antimycotics ad libitum.
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MI model. MI was induced in NOD/Scid mice by permanently (PI group) or transiently 
(45 minutes) (IR group) ligating the LAD. Sham-operated animals were used to determine 
baseline characteristics (Sham group). Mice received 100µL NaCl, containing 2 µg 
buprenorphine, subcutaneously before surgery and again 12 hours after surgery. The 
permanent ligation MI model was induced as described earlier (11). Briefly, animals were 
anesthetized with 5% isoflurane for induction and kept anesthetized with 1.5-2% isoflurane 
in oxygen for the remainder of the surgical procedure, intubated and ventilated using a 
rodent ventilator (model 845, Harvard Apparatus, Holliston, MA, USA) with 160 breaths 
per min and a stroke volume of 220 mL. A left thoracotomy was performed and the LAD 
was ligated using a 7-0-prolene suture (Johnson and Johnson, New Brunswick, NJ, USA). 
For the permanent ligation experiment (PI group), the location of the LAD ligation was 
1 mm caudally from the tip of the left auricle. For the transient ligation and subsequent 
reperfusion experiment (IR group), the LAD was transiently ligated for 45 minutes 
directly underneath the tip of the left auricle to induce maximum damage, followed by 
reperfusion. To allow reperfusion of the LAD after 45 minutes, the ligation was fixed on 
a tube placed directly on the LAD. Ischemia was confirmed by myocardial blanching. 
The chest was left open during the entire ischemic period. Based on pilot data transient 
ligation was performed for 45 minutes, since an ischemia duration ≥50 minutes resulted in 
unacceptable high mortality rates (100%, either during the ischemic period or afterwards 
in the first week after the procedure). Five minutes after LAD ligation in the PI group or 
5 minutes after reperfusion in the IR group, animals received 15μL phosphate-buffered 
(PBS) saline intramyocardially to mimic intramyocardial cell therapy. Directly after 
ligation in the PI group or 35 minutes after LAD ligation in the IR group, mice received 
an intraperitoneal injection of lidocaine (6 mg/ kg) to prevent cardiac arrhythmias (12). 
Afterwards, the chest was closed and animals were allowed to recover. Sham animals 
were operated in parallel, but without LAD ligation and intramyocardial injection, and 
were used to determine baseline characteristics (Sham group). 
The mortality rate of the IR group was 33.3% at the end of the experiment, with 25% 
mortality during the ischemic period or afterwards at the same day of the procedure 
and 75% mortality during the follow up period of the experiment or during MRI 
measurements.
The mortality rate of the PI group was 41.2% at the end of the experiment, with 
14.3% mortality during the procedure or afterwards at the same day of the procedure 
and 85.7% mortality during the follow up period of the experiment or during MRI 
measurements.
The mortality rate of the Sham group was 25% at the end of the experiment 
with 100% mortality during the follow up period of the experiment or during MRI 
measurements.
Cardiac MRI. Cardiac parameters were assessed 2 and 14 days post-MI using a 7-Tesla 










for induction and kept anesthetized with 1.5-2% isoflurane in oxygen for the remainder 
of the procedure and placed on a respiration detection cushion connected to a gating 
module to monitor respiratory rate (SA Instruments, Inc., Stony Brook, NY, USA). Image 
reconstruction was performed using BrukerParaVision5.1 software (BrukerBiospin, 
Ettlingen, Germany). To evaluate cardiac function, a high-resolution 2D FLASH cine 
sequence was used to acquire a set of 9 contiguous 1 mm slices in short-axis orientation 
covering the entire heart. Imaging parameters were: echo time of 1.49 ms, repetition 
time of 5.16 ms, field of view (26 mm)2 and a matrix size of 144x192. To determine infarct 
size, contrast enhanced MRI imaging was performed after injection of a 150 µL bolus 
(0.5 mmol/ml) of gadolinium-DPTA (Gd-DPTA, Dotarem, Guerbet, the Netherlands) via 
the tail vein. A gradient echo sequence (FLASH) was used to acquire a set of 14 contiguous 
0.7 mm contract-enhanced slices in short-axis orientation covering the entire heart. 
Imaging parameters were: echo time of 1.9 ms, repetition time of 84.16ms, field of view 
(33 mm)2 and a matrix size of 192x256. All MRI data were analysed with the MASS for 
Mice software package (MEDIS, Leiden, the Netherlands). Endocardial and epicardial 
borders were manually delineated and a reference point was positioned by an investigator 
blinded to the experimental status of the data (PI group n=5, IR group n=5, Sham group 
n=5, overall 15 mice for statistical analysis). 
Left Ventricular (LV) Function by PV Loops. At day 15 after MI, mice were anesthetized 
again with 5% isoflurane for induction and kept anesthetized with 1-1.5% isoflurane in 
oxygen for the remainder of the procedure. Via the right carotid artery, a 1.2F pressure-
conductance catheter (standard; ScisenseInc, London, Canada) was introduced and 
positioned in the LV. The conductance catheter was connected to a PV control unit FV 896B 
(ScisenseInc, London, Canada) for online display and recording of LV pressure and volume 
signals. Parallel conductance and LV PV signals were measured as described previously 
(11, 13). All data were acquired using Powerlab 8/30 Model ML870 (ADInstruments, 
Spechbach, Germany) and LabChart 7 software (ADInstruments, Spechbach, Germany). 
Data were analyzed with custom-made software by an investigator blinded to the 
experimental status of the data (PI group n=5, IR group n=5, Sham group n=5, overall 
15 mice for statistical analysis). 
Histological infarct size. After PV loops hearts were dissected, fixed and cut as 
described earlier (PI group n=4, IR group n=4, Sham group n=4, overall 12 mice for 
statistical analysis) (11). The extent of total collagen deposition after MI was evaluated 
by staining with picro-sirius red (0.5 gram Sirius red in 500 ml saturated aqueous 
solution of picric acid) for one hour. Total collagen deposition was determined by the 
area stained tissue within the LV as a percentage of the whole LV. This analysis was 
performed on photomicrographs taken at a 2-fold magnification of 15-20 sections 
covering the entire heart from apex to base. The area of Sirius red staining was 
measured by an observer blinded to the experimental status of the samples, using 
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the ImageJ software package (National Institutes of Health, Bethesda, MA, USA). 
The effect of MI on LV wall thickness was assessed on the same sections. This analysis was 
performed on three equidistant sections between the apex and ligature (at the midpoint 
between the LAD ligature and the apex, between the midpoint and the LAD ligature 
and between the midpoint and apex). Wall thickness was measured at 2 separate border 
zone areas, at the midpoint of the infarct region and averaged for all 3 measurements. 
Measurements were performed perpendicular to the infarcted wall.
Cardiac inflammatory response. In parallel to the above described experiment, MI was 
induced by PI or IR in mice that were sacrificed on days 1, 3, and 7 after MI (n=3 mice 
per time point, overall PI group n=9, overall IR group n=9). Non-operated animals were 
used as controls to determine base line characteristics at 1 time point (Control group, 
n=3, overall 21 mice for statistical analysis). Hearts were harvested in total, minced with 
fine scissors, and placed into a solution of 2% collagenase IA (Sigma-Aldrich, Saint Louis, 
MO, USA) in PBS and shaken at 37 ° C for 1 h. The cell suspension was then triturated 
through a nylon mesh and centrifuged in PBS at 300 g for 10 min at 4°C. Red blood 
cells in the cell pellet were lysed with lysis buffer and the cells were washed in PBS and 
subsequently resuspended in medium containing IMDM (Lonza, Verviers, Belgium) 
supplemented with 2.5% fetal calf serum (FCS; Greiner Bio-one, Monroe, NC, USA) and 
Penicillin/Streptomycin (P/S; Invitrogen Corp., Paisley, UK). Total cardiac cell numbers 
were determined with a Sysmex cell counter (Sysmex America, Inc. Mundelein, Illinois, 
USA). The resulting single-cell suspensions were stained for flow cytometry with primary 
antibodies for 30 minutes at 4°C in darkness and the cells were washed with PBS/1% human 
Albumin (Sanquin, Leiden, The Netherlands) before analysis using a FACSCanto II (BD 
Biosciences, San Diego, CA, US). The following antibodies were used: anti–CD90-APC, 
53–2.1, -B220-APC, RA3-6B2, –CD49b-APC, DX5, –NK1.1-APC, PK136, –Ly-6G-APC, 
1A8, CD11b-eFluor 450, M1/70, –F4/80-FITC,–CD11c-FITC, HL3, – I-Ab -FITC, AF6-
120.1, –Ly-6C-PE, AL-21, –CD11c-PE, HL3 (all above antibodies are from BD Biosciences) 
and C1:A3-1 (ABD Serotec, Kidlington, UK). Monocytes were identified as CD11b high 
(CD90/B220/CD49b/NK1.1/Ly-6G) low. They were further divided into Ly-6C high/low 
(F4/80/I-Ab /CD11c) low as previously described (14, 15). Macrophages were identified as 
CD11b high, F4/80 high. Dendritic cells were identified as CD11b, I-Ab and CD11c high. 
Neutrophils were identified as CD11b, Ly-6G high. Monocyte and macrophage/dendritic 
cell numbers were calculated as the total cells multiplied by the percentage of cells within 
the monocyte/macrophage gate. The analysis of the acquired data was done with FlowJo 
software version 7.6.1 (Tree Star Inc. Ashland, OR, USA). 
Cytokine Measurements. Cytokine measurements were performed on peripheral blood 
from the same mice that were used to determine the cardiac inflammatory response. Mice 
were sacrificed on days 1, 3, and 7 after MI (n=3 mice per time point, overall PI group 










base line characteristics (Control group, n=3, overall 21 mice for statistical analysis). 
Peripheral blood was drawn via cardiac puncture and collected in eppendorf tubes to 
let the blood coagulate >2 hours at room temperature. Subsequently, the samples were 
centrifuged to separate the blood clot from the serum and the serum was stored at -80 °C 
until cytokine determination. Cytokine concentrations were measured using the Bio-
PlexMouse Cytokine 23-plex Panel assay (Bio-Rad laboratories, Inc, Hercules, CA, USA). 
Statistical Analysis. Numerical values were expressed as means ± standard deviation (SD). 
Comparison of MRI parameters between the PI, IR and Sham group was performed using 
two-way repeated-measures analysis of variance (ANOVA), with Bonferroni correction. 
Comparison of the remaining parameters between the PI, IR and Sham or Control group 
was performed using one-way ANOVA, with Bonferroni correction.
Results
MRI: infarct size and cardiac function. Both 2 and 14 days after MI, the infarct size 
in animals that were subjected to PI (n=5) was significantly larger than in the IR model 
(n=5) (Figure 1A). This difference in damage between both MI groups was reflected by 
the cardiac function in the two models. Two days after MI, ejection fraction decreased 
significantly in the PI group, with a further deterioration of function 14 days after MI 
(Figure 1B). Both end-diastolic and end-systolic volumes tended to increase in the PI 
group 2 days post-MI and reached significance at day 14 after MI, when compared to 
the IR and Sham group (Figure 1C, D). Likewise, stroke volume, cardiac output, wall 
thickening and wall motion deteriorated significantly in PI animals at day 14 days after 
MI (Table 1). In contrast, cardiac function parameters in IR animals did not significantly 
differ from those in Sham animals.
In accordance with the MRI data, PV loop measurements 15 days after MI showed 
a significant deterioration in cardiac function in the PI group, but not in the IR group 
(Table 2). 
Histology: Infarct size. Consistent with the observed difference in infarct size observed 
by MRI, animals that were subjected to PI (19.0 %) showed a significant increase in total 
collagen deposition 15 days after MI, as opposed to the IR (2.7 %) and Sham group (0.3 %) 
(n=4 in all groups) (Figure 2A-D). In addition, quantification of wall thickness showed a 
significant thinning of the LV wall after MI in the PI group (0.43 mm), but not in the IR 
group (0.83 mm), where wall thickness was comparable to the Sham group (0.88 mm) 
(Figure 2E). 
Cardiac inflammatory response. The effect of MI on the local influx of inflammatory 
cells in both the PI and IR group was assessed by flow cytometry and compared to non-
operated control animals. Flow cytometric analyses on single cell heart digests revealed 
62













SV, µL 20.9 ± 4.0 21.3 ± 2.8 25.2 ± 2.8 19.5 ± 4.9 *, # 27.6 ± 5.2 29.5 ± 1.8
CO, mL/min 14.3 ± 2.7 14.6 ± 1.9 17.2 ± 1.9 13.4 ± 3.4 *, # 18.9 ± 3.6 20.2 ± 1.3
ED wall 
thickness, mm
0.74 ± 0.04 0.74 ± 0.06 0.69 ± 0.06 0.60 ± 0.07 # 0.67 ± 0.08 0.70 ± 0.04
ES wall 
thickness, mm
0.99 ± 0.08 1.12 ± 0.10 1.06 ± 0.10 0.77 ± 0.11 *, # 1.09 ± 0.07 1.17 ± 0.05
Wall 
thickening, %
37.1 ± 8.7 # 54.4 ± 10.5 59.9 ± 12.0 29.5 ± 11.0 *, # 67.7 ± 20.5 70.2 ± 13.7
Wall motion, 
mm
0.46 ± 0.10 *, # 0.65 ± 0.11 0.68 ± 0.06 0.30 ± 0.11 *, # 0.72 ± 0.02 0.74 ± 0.05
Abbreviations: SV, stroke volume; CO, cardiac output; ED, end-diastolic; ES, end-systolic. N=5 per group. 
Data are expressed as mean ± SD. * = p<0.05 versus IR; # = p<0.05 versus Sham
Figure 1. Assessment of LV function and volumes with MRI. MRI analysis of delayed contrast-
enhanced images showed a significant difference in infarct size (A) between the PI and IR 
group, both at t=2 and t=14. Assessment of LV function of the PI, IR and Sham group at t=2 
and t =14: ejection fraction (B), end-diastolic volume (C) and end-systolic volume (D). N=5 per 










significantly increased neutrophil frequencies in the PI group on the first day after MI, 
which declined thereafter (Figure 3A). Cardiac inflammatory monocyte populations 
however, were significantly reduced in both the PI and IR group at both day 1 and 3 after 
MI. The frequency of non-inflammatory monocytes was reduced as well in both groups, 
but the kinetic for this cell population was slower as it was only significant 3 days after MI.
Cardiac macrophages and dendritic cell frequencies in either of the MI groups, 
however, did not significantly deviate from the control group, suggesting these cell 
types are less relevant in the cardiac inflammatory process within the first week after 
MI (Figure 3B).
Cytokine measurements. In the PI group the average serum levels of the known relevant 
pro-inflammatory cytokines tumor necrosis factor a (TNF-a), interleukin (IL)-1b, and IL-6, 
and the anti-inflammatory cytokine IL-10 were found to be increased at day 1 post-MI, 
and these serum levels gradually decreased thereafter. Statistically these differences 






HR, bpm 398 ± 66 542 ± 20 473 ± 17 0.184 0.042
CO, mL/min 7.6 ± 1.9 12.5 ± 2.7 14.0 ± 1.0 0.007 0.001
ESV, µL 59 ± 23 14 ± 2 13 ± 2 0.000 0.000
EDV, µL 79 ± 21 42 ± 7 43 ± 2 0.002 0.003
ESP, mmHg 65 ± 12 70 ± 11 76 ± 3 1.000 0.258
EDP, mmHg 15 ± 7 4 ± 9 9 ± 6 0.107 0.605
Tau, ms 16 ± 7 14 ± 1 13 ± 2 1.0000 1.000
dP/dtMAX, mmHg/s 3774 ± 1615 5259 ± 714 5664 ± 1141 0.231 0.090
-dP/dtMIN, mmHg/s 3033 ± 1419 4239 ± 712 4819 ± 961 0.301 0.065
SW, mmHg. µL 1121 ± 483 1951 ± 172 2186 ± 333 0.009 0.001
EF (%) 26 ± 10 66 ± 3 69 ± 4 0.000 0.000
ESPVR
Slope: EES, mmHg/µL 3.83 ± 0.61 3.66 ± 1.17 3.23 ± 0.34 1.000 0.769
Intercept: ESVINT, µL 63 ± 30 20 ± 16 11 ± 10 0.019 0.005
EDPVR
Slope: EED, mmHg/µL 1.04 ± 0.51 0.56 ± 0.22 0.43 ± 0.17 0.135 0.043
Intercept: EDVINT, µL 77 ± 22 54 ± 25 22 ± 52 0.951 0.094
Abbreviations: CO, cardiac output; dP/dtmax, maximum rate of pressure increase; dP/dtmin, maximum rate 
of pressure decrease; EDP, end-diastolic pressure; EDPVR, end-diastolic pressure-volume relationship; Eed, 
end-diastolic stiffness; ; EDV, end-diastolic volume; EDVint, end-diastolic volume intercept; EF, ejection 
fraction; ESP, end-systolic pressure; ESPVR, end-systolic pressure-volume relationship; Ees, end-systolic 
elastance; ESV, end-systolic volume; ESVint, end-systolic volume intercept; HR, heart rate; SW, stroke work;
Tau, relaxation time constant. N=5 per group. Data are expressed as mean ± SD.
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Figure 2. Histological quantification of total collagen deposition and wall thickness. Photos 
of representative sections of the hearts of PI (A), IR (B) and Sham (C) mice 15 days after MI 
showing total collagen deposition (red) by Sirius red staining. Quantification of Sirius red 
staining (D). Quantification of LV wall thickness (E). N=4 per group. Data are expressed as 









&Figure 3. Flow cytometric analysis of inflammatory cells. MI in the PI model induces marked neutrophil recruitment and an egress of monocytes (A) within 7 days after injury measured via 
flow cytometry on whole heart digests. Cardiac macrophages and dendritic cell percentages 
are unaltered after myocardial injury (B). N=3 per group. Data are expressed as mean ± SD. # 
= p<0.05 versus Control.
did not meet significance (Figure 4A). In the IR group injury induced lower levels of 
these cytokines but these seemed to be sustained for a longer period. In addition, the 
other cytokines that were measured via ELISA were IL-5, monocyte chemotactic protein 
(MCP)-1, macrophage inflammatory protein (MIP)-1b, granulocyte-colony stimulating 
factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), IL-12(p40), 
keratinocyte chemoattractant (KC), RANTES, IL-17, and IL-2, of which MCP-1, MIP-1b, 
G-CSF appeared to be more dynamic in the PI group compared to the IR group, although 
this was not significantly different (Figure 4B). 
Discussion
Key findings of the current study are that MI by IR results in 1) a non-significant 
deterioration of cardiac function and remodeling compared with Sham animals, 2) 
a reduced population of cardiac inf lammatory cells, 3) limited dynamics in serum 
cytokine levels and 4) non-significant total collagen deposition and wall thinning. 
So, despite the resemblance of the IR model to the current clinical practice, this 
study demonstrates its role for cell therapy optimization is limited, since IR fails to 












































































































































































Earlier research by Vandervelde et al. already showed less pronounced remodeling 
in mouse hearts subjected to transient ligation, when compared to permanent ligation 
(16). A more recent study, which compared transient ligation to permanent ligation 
by cryoinfarction showed the same results (17). However, it should be noted that 
permanent ligation by cryoinfarction is mechanistically different to permanent ligation 
used in this study. Permanent ischemia by cryoinfarction resulted in a prolonged 
remodeling period and excess remodeling, when compared to transient ligation (17). 
Although cardiac function was not investigated in both studies, the possible difficulties 
in testing a therapeutic intervention due to less damage were discussed. 
Our findings on infarct size differences between the PI and IR group were consistent 
with other studies, which also showed a significantly larger infarct size after permanent 
ligation, measured by both contrast-enhanced MRI (18) and histological staining (18, 
19). Furthermore, we found that only PI resulted in significant thinning of the LV wall, 
which was also in line with earlier research (16). Solely based on the small decline in 
cardiac function and the limited cardiac remodeling after MI, IR induces little damage, 
while ischemia durations ≥50 minutes resulted in unacceptable high mortality rates 
in a pilot study. The mostly observed cause of death in this pilot study was death by 
cardiac arrhythmia, monitored by 3-lead EKG (data not shown). Overall, IR leaves a 
small window for therapeutic intervention. 
Besides the effect of PI and IR on cardiac function and remodeling, we also 
investigated and compared the inflammatory response. After occlusion of a coronary 
artery several chemokine and cytokine cascades are activated during the first phase 
of cardiac inflammation, the inflammatory phase. Subsequently dead cells and matrix 
debris are removed from the wound by neutrophils and macrophages. This is followed 
by the deposition of extracellular matrix proteins and formation of an extensive 
microvascular network during the proliferation phase of cardiac inflammation. 
Afterwards, maturation of the scar follows and a collagen-based scar is formed (9, 
20) during the final maturation phase.
After MI inflammatory monocytes present in the cardiac tissue give rise to 
macrophages, while the role of non-inflammatory monocytes is not yet clear (21). In 
the current study the frequency of the inflammatory and non-inflammatory monocytes 
was reduced in both models within the first week after MI, suggesting the inflammatory 
monocytes are indeed differentiating into macrophages. However, no increased number 
of macrophages in the cardiac tissue in either the PI or the IR model was observed. 
In addition, a significant influx of neutrophils in the PI group was detected. This is 
in contrast to earlier studies by Luo et al. and Vandervelde et al. where an increased 
influx of macrophages and neutrophils was observed after reperfusion compared to 
permanent ligation (16, 18). Also no increase in dendritic cell numbers was detected 
here, as opposed to observations in other experimental settings (22). 
In the current study, the upregulation of inflammatory cytokines after MI, initiating 
the inflammatory process, was modest compared to earlier research (20, 23). However, 
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a direct comparison in cytokine levels between the PI and IR group suggests that the 
extent of injury dictates the systemic inflammatory response, since the limited cardiac 
damage in the IR model related to the less dynamic changes in the cytokine profile. The 
observed differences in inflammatory response between this study and earlier research 
may be explained by the difference in immune systems between the mice strains used. 
Since the primary goal of the current study was to investigate human cell therapy in 
a more clinically relevant MI model immunodeficient mice were used, which have an 
impaired repertoire of immune cells, capable of performing innate immunity only. 
Despite of this impaired immune response in NOD/Scid mice, this study shows that 
inducing MI still results in significant changes in the immune state of these animals, 
indicating this mouse strain can still be valuable to study human cell therapy. 
Conclusions
MI by transient ligation results in a limited loss of cardiac function, minimal cardiac 
remodeling and a less dynamic inf lammatory response, compared to the most widely 
used model of permanent ligation. So, although a model of transient ligation may 
better mimic the clinical situation, the limited myocardial damage renders it less 
suitable to study novel therapies including stem cell therapy. Furthermore even in the 
immunodeficient mice strain used, MI does significantly alter the inflammatory state.
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Abstract
Background: Human mesenchymal stromal cells (MSCs) have been reported to 
preserve cardiac function in myocardial infarction (MI) models. Previously, we found 
a beneficial effect of intramyocardial injection of unstimulated human MSCs (uMSCs) 
on cardiac function after permanent coronary artery ligation. In the present study we 
aimed to extend this research by investigating the effect of intramyocardial injection of 
human MSCs pre-stimulated with the pro-inflammatory cytokine interferon-gamma 
(iMSCs), since pro-inf lammatory priming has shown additional salutary effects in 
multiple experimental disease models. 
Methods: MI was induced in NOD/Scid mice by permanent ligation of the left anterior 
descending coronary artery. Animals received intramyocardial injection of uMSCs, 
iMSCs or phosphate-buffered saline. Sham-operated animals were used to determine 
baseline characteristics. Cardiac performance was assessed after 2 and 14 days using 
7-Tesla magnetic resonance imaging and pressure-volume loop measurements. 
Histology and q-PCR were used to confirm MSC engraftment in the heart. 
Results: Both uMSC and iMSC therapy had no significant beneficial effect on cardiac 
function or remodeling in contrast to our previous studies. 












Cardiovascular disease (CVD) is the main mortality cause in the western world (1). Over 
the past decade, studies have explored the potential of cell therapy as a novel treatment 
option for coronary artery disease. Various cell types including bone marrow-derived 
mononuclear cells (2), human mesenchymal stromal cells (MSCs) (3-5), embryonic 
stem cells (6), induced pluripotent stem cells (7), skeletal myoblasts (8)  and cardiac 
progenitor cells (9) have been studied, showing varying results in both animal models 
and in patients (10-12). MSCs constitute an attractive therapeutic cell type in view of 
their immunomodulatory and anti-inflammatory properties, easy expandability and 
their ability to support tissue regeneration (13, 14). The reported improvement in heart 
function by MSC administration seems mostly attributed to paracrine mechanisms 
(15), leading to neoangiogenesis (16), anti-apoptotic effects (17) and attenuation of the 
ventricular remodelling process (18). Previously, we reported beneficial therapeutic 
effects of injection of unstimulated human MSCs (uMSCs) from CVD patients in a 
myocardial infarction (MI) model in NOD/Scid mice (4, 19). In the present study we 
aimed to extend this research by assessing the effect of pre-stimulating the human 
MSCs (iMSCs) with the pro-inflammatory cytokine interferon gamma (IFN).
Recent studies in animal models of graft–versus-host disease (GVHD) and colitis 
indicated that pre-stimulation of MSCs with IFN enhances their therapeutic effect (20, 
21). The mechanism of this reported therapeutic benefit is not known but the role of 
immunomodulatory proteins that are upregulated by IFN including indoleamine 2,3 
dioxygenase (IDO) and inducible nitrix oxide synthase, is currently being investigated 
(20-25). We hypothesized that IFN pre-stimulation of MSC also enhances their 
beneficial effect on cardiac function in a NOD/Scid model of MI. Also, as MI causes 
the influx of inflammatory cells into the injured myocardium (26), we investigated 
whether the inflammatory cell influx was altered by uMCs and iMSCs  administration.
Materials and Methods
Details about the materials and methods are described in the Supplemental Materials 
and Methods at the end of this chapter.
Animals. All experiments were approved by the Committee on Animal Welfare of the 
Leiden University Medical Center (LUMC) and conformed to the Guide for the Care and 
Use of Laboratory Animals as stated by the U.S. National Institutes of Health. To avoid 
rejection of transplanted human cells, 8- to 10-weeks-old male NOD/Scid mice (Charles 
River Laboratories, Maastricht, the Netherlands) were used.
Primary cultured MSCs. Bone marrow aspiration procedures were performed in 
accordance with the Helsinki Declaration and were approved by the ethics committee 
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of LUMC. All MSC donors provided informed consent. Bone marrow-derived MSCs 
were obtained from three non-cardiac patients undergoing orthopedic surgery. IFN 
stimulation of MSCs was performed by adding 500U/ml IFN (Sigma-Aldrich Chemie 
BV, Zwijndrecht, the Netherlands) to the culture medium for 7 days.
Immunophenotyping of cultured MSC was performed using the following primary 
antibodies: CD90, CD73, MHC-I, CD34, CD45, CD31, CD80, MHC-II (BD Biosciences, 
San Diego, USA), and CD105 (Ancell Corp., Bayport, MN, USA). MSCs from passages 
4 to 5 were used for transplantation experiments after lentiviral transduction with a 
human vector expressing the enhanced green fluorescent protein (eGFP) gene. The 
cells transduced with lentivirus for eGFP, transmitted the eGFP signal in the FITC 
channel of the FACSCanto II (BD Biosciences, San Diego, CA, USA).
In vitro differentiation. To test the ability of uMSCs and iMSCs to differentiate into 
osteogenic and adipogenic lineages, cells were incubated in appropriate differentiation 
media. MSCs were stained for alkaline phosphatase activity with Fast Blue (Sigma-Aldrich 
Chemie BV, Zwijndrecht, the Netherlands) and for calcium deposition with Alizarine Red 
(MP Biomedicals LLC, IllkirchCedex, France.) Formation of lipid droplets was visualized 
with Oil-red O staining (Sigma-Aldrich Chemie BV, Zwijndrecht, the Netherlands).
Suppression of PBMC proliferation by MSCs. Cultured MSCs were plated in graded doses in 
96-well flat-bottom plates (Corning, Life Sciences). Human peripheral blood mononuclear 
cells (PBMC) isolated from buffy coats (1.0 x 105/well) were added to the MSCs and 
stimulated with human T-activator CD3/CD28 dynabeads (Invitrogen Corp., Paisley, UK) 
in a bead:cell ratio 1:5. The cultures were harvested on a glass fiber filter and thymidine 
incorporation was measured with a liquid scintillation counter (Wallac, Turku, Finland). 
MI induction and Cell injection. Mice received buprenorphine subcutaneously before 
surgery and again 12 hours after surgery. MI was induced as described previously (9). 
Briefly, animals were anesthetized with 5% isoflurane for induction, subsequently 
intubated and kept anesthetized with 1.5-2% isoflurane in oxygen for the remainder 
of the surgical procedure. After a left thoracotomy, the left anterior descending (LAD) 
coronary artery was ligated 1 mm caudally from the tip of the left auricle using a 7-0-
prolene suture (Johnson and Johnson, New Brunswick, NJ, USA). 
Five minutes after LAD ligation the animals received either 2×105 uMSCs in 15 
μL phosphate-buffered saline (PBS) (uMSC group), 2×105 iMSCs in 15 μL PBS (iMSC 
group) or 15 μL PBS containing no cells (PBS group). Intramyocardial injections were 
performed at 3 sites in the infarcted area (5 μL per site).
Sham-operated animals were operated in parallel to determine baseline 
characteristics (Sham group).
Cardiac Magnetic Resonance Imaging (MRI). Cardiac parameters were assessed 2 and 










pre-anesthetized as described above and kept anesthetized with 1.5-2% isoflurane in 
oxygen for the remainder of the procedure. All data were analysed with the MASS for 
Mice software package (Leiden, the Netherlands). The endocardial and epicardial borders 
were delineated manually (uMSC group n=12, iMSC group n=7, PBS group n=7, Sham 
group n=10), after which left ventricular (LV) end-diastolic volume (EDV), LV end-systolic 
volume (ESV) and ejection fraction (EF) were computed.
Pressure-Volume (PV) measurements. Fifteen days after MI, mice were anesthetized 
again as described above and kept anesthetized with 1-1.5% isoflurane in oxygen for 
the remainder of the procedure. A 1.2F pressure-conductance catheter (ScisenseInc, 
London, Canada) was introduced via the right carotid artery and positioned in the LV. 
The conductance catheter was connected to a PV control unit FV 896B (ScisenseInc, 
London, Canada). Parallel conductance and LV pressure-volume signals were measured 
as described previously (9). All data were acquired using Powerlab 8/30 Model ML870 
(ADInstruments, Spechbach, Germany) and LabChart 7 software (ADInstruments, 
Spechbach, Germany). Data were analyzed off-line (uMSC group n=7, iMSC group n=7, 
PBS group n=5, Sham group n=7).
Histology. At day 15 post-MI, mice were weighed, sacrificed after PV loop measurements 
and hearts and lungs were removed. Lungs were weighed immediately after excision, 
freeze-dried for 24 hours and then weighed again. The wet weight/dry weight ratio was 
used as a measure of pulmonary congestion. 
Per group 5 hearts were fixed by immersion in buffered 4% paraformaldehyde and 
embedded in paraffin. Serial transverse sections of 5 μm were cut along the entire long 
axis of the LV for (immuno)histological analyses. MSC engraftment was detected by 
immunostaining with a rabbit anti-GFP antibody (A11122, Invitrogen, Paisley, UK), 
followed by a biotinylated goat anti-rabbit IgG(E0432, Dako, Glostrup, Denmark) and 
a Qdot 655 streptavidin-conjugated (Q10121MP, Invitrogen, Paisley, UK) antibody. 
Real-time Polymerase Chain Reaction (PCR). Per group, 5 hearts were used for DNA 
extraction to determine MSC engrafment rate by quantification of human genomic 
DNA in mouse hearts (27). DNA concentrations were measured using NanoDrop 1000 
(NanoDrop products, Wilmington, DE, USA). 
PCR reactions were performed in a volume of 10 µL, containing 5 µL Universal 
PCR Master Mix (Applied Biosystems, Carlsbad, CA, USA), 900 nM forward and 
reverse primers, 250 nM TaqManprobe and 50 ng of target template. Standard curves 
were generated by serially diluting human genomic DNA (Roche, Basel, Switzerland) 
in murine genomic DNA. 
Flow cytometry. From each treatment group, mice not subjected to functional and 
histological analysis were used for flow cytometric analysis of cardiac inflammatory cell 
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invasion. Mice were sacrificed on days 1, 3, and 7 after MI. Each time point, 3 hearts 
were harvested per group. Sham animals were used as controls to determine base line 
characteristics. Total cardiac cell numbers were determined with a Sysmex cell counter 
(Sysmex America, Inc. Mundelein, Illinois, US). Single-cell suspensions were stained 
for flow cytometry with primary antibodies before analysis using a FACSCanto II (BD 
Biosciences, San Diego, CA, USA). The following antibodies were used: anti–CD90-APC, 
53–2.1,–B220-APC, RA3-6B2, –CD49b-APC, DX5, –NK1.1-APC, PK136, –Ly-6G-APC, 
1A8,  CD11b-eFluor 450, M1/70,–CD11c-FITC, HL3, – I-Ab -FITC, AF6-120.1, –Ly-6C-PE, 
AL-21, –CD11c-PE, HL3 (all above antibodies are from BD Biosciences), –F4/80-FITC, 
C1:A3-1 (ABD Serotec, Kidlington, UK). Monocytes were identified as CD11b high (CD90/
B220/CD49b/NK1.1/Ly-6G) low (F4/80/I-Ab /CD11c) low Ly-6C high/low as previously 
described (26, 28). Macrophages were identified as CD11b high, F4/80 high. Dendritic 
cells were identified as CD11b, I-Ab and CD11c high. Neutrophils were identified as CD11b, 
Ly-6G high. The analysis of the acquired data was done with FlowJo software version 7.6.1 
(Tree Star Inc. Ashland, OR, USA).
Statistical Analysis. Numerical values were expressed as means ± standard deviation (SD). 
Comparison of MRI parameters and inflammatory cells between the uMSC, iMSC, PBS 
and Sham groups was performed using two-way repeated-measures analysis of variance 
(ANOVA), with Bonferroni correction. Comparison of the remaining parameters was 
performed using one-way ANOVA with Bonferroni correction.  
Results
Characterization of MSCs. The uMSCs in vitro expressed the established surface 
marker profile: CD90+, CD73+, MHC-I+, CD105+, and CD45-, CD34-, CD80- 
(Figure 1A). In addition, all (u/i)MSCs were able to differentiate into osteoblasts 
and adipocytes (Figure 1B) and demonstrated an inhibitory capacity on PBMC 
proliferation (Figure 1C), confirming the definition and behavior of true MSCs. 
The transduction efficiency of the (u/i)MSCs used was 100% which was analyzed 
by bright light microscopy and flow cytometry (Figure 1D).
After IFN stimulation, iMSCs expressed MHC II (Figure 2A), while the other 
expressed surface markers were comparable to uMSC (data not shown). The in vitro 
differentiation capacity toward osteoblasts and adipocytes was similar between iMSCs 
and uMSCs for all MSC sources used (data not shown). The IFN stimulation upregulated 
the expression of the intracellular enzyme indoleamine 2,3dioxygenase (IDO) as shown 
by immunohistochemistry (Figure 2B).
Effect of MSC therapy on cardiac function. Two and 14 days after inducing MI, LVEF 
decreased in all MI groups when compared to Sham as assessed by MRI (Figure 3A). 










Figure 1. Characterization of primary cultured MSCs. A: In vitro characterization of MSCs 
consisting of the specific surface marker antigen panel measured by flow cytometry. B: The 
differentiation capacity of MSCs towards osteoblasts shown by alkaline phoshatase activity and 
towards adipocytes shown by lipid droplets staining via Oil Red O. C: The inhibitory capacity 
of proliferation of activated peripheral blood mononuclear cells measured by 3H-thymidine 
uptake in counts per minute (CCPM). D: Bright light and fluorescence microscopy and flow 
cytometric analysis of eGFP labeling of lentivirally transduced MSCs.
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Figure 2. Stimulation of MSCs with the pro-
inflammatory cytokine interferon gamma 
(IFN). A: From left to right: Immunostaining 
of iMSCs for HLA-DR in red (PE) and 
nuclei in blue (DAPI) and expression of 
HLA-DR as measured by flow cytometry. 
B: Immunostaining of iMSCs for the 
immunomodulatory enzyme IDO in green 
(ALEXA 488 nm) and nuclei in blue (DAPI). 
(Figure 3B and C). There were no differences between the uMSC group, the iMSC group 
or the PBS group for either EF, EDV or ESV at 2 or 14 days post MI.
These findings were confirmed by PV loop measurements 15 days after MI. LV EDV 
and ESV were significantly increased in all animals subjected to MI when compared 
to Sham. End-systolic pressure was significantly decreased in all MI groups, while 
the end-diastolic pressure was comparable for all four groups (Figure 3D). There were 
no differences between the uMSC, iMSC and the PBS group, indicating no beneficial 










Figure 3. Cardiac function as assessed by 7 T MRI. Cardiac function 2 and 14 days after 
myocardial infarction in uMSC and iMSC treated animals (uMSC and iMSC, resp.), PBS 
treated animals (PBS) and Sham-operated animals (Sham) (panel A-C). A: Left ventricular 
ejection fraction. B: End-diastolic volume. C: End-systolic volume. Data are expressed as mean 
± SD. # = p<0.05 versus Sham. D: Pressure-Volume loops of all treatment groups at day 15 
after MI. The oblique lines represent the end-systolic (Ees) and end-diastolic (Eed) pressure–
volume relations.
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Engraftment. Histological analysis showed that both uMSCs and iMSCs engrafted into 
the myocardium at 15 days after injection, predominantly in the infarcted anterolateral 
wall (Figure 4A). Quantitative assessment of histological sections revealed similar 
engraftment rates for the two cell groups (3.2% and 2.8% of injected cells for uMSC and 
iMSC, respectively, Figure 4B). In addition, we performed q-PCR for human ALU repeats 
to determine cell engraftment of the human MSCs in the mouse hearts. q-PCR showed a 
small, but not significantly different, percentage of human genomic DNA in both uMSC 
and iMSC treated animals (Figure 4C). Tissue from mice hearts injected with PBS and 
Sham-operated animals were used as control. 
Figure 4. Assessment of engraftment of injected MSCs in mouse hearts 15 days after injection 
into the infarcted myocardium. A: Immunofluorescent staining of engrafted eGFP-labeled MSCs 
in red (Qdot 655) and nuclei in blue (hoechst 33342). B: Histological quantification of uMSC 
and iMSC engraftment (uMSC and iMSC resp.). PBS treated animals (PBS) and Sham-operated 
animals (Sham) were used as controls. C: Quantitative PCR for human genomic DNA in mouse 
hearts in animals treated with uMSC, iMSC, PBS and sham-operated animals. Data are expressed 










Pulmonary congestion and body weight. Body weight was similar in all animals prior 
to surgery and did not significantly change between MI groups and the Sham-operated 
animals at day 15 post MI (Figure 5A). In addition, no significant differences were observed 
in the amount of lung fluid between all MI groups and the Sham group (Figure 5B).
Figure 5. Physical parameters 15 days after myocardial infarction. Parameters in uMSC and 
iMSC treated animals (uMSC and iMSC, resp.), PBS treated animals (PBS) and Sham-operated 
animals (Sham). A: Weight loss.  B: Amount of pulmonary fluid. Data are expressed as mean 
± SD. There were no significant differences between the uMSC, iMSC, PBS and Sham group.
Inflammatory cell influx in the infarcted heart. In the MI groups the frequency of 
inflammatory cells in the heart did not significantly deviate from the Sham group. 
However, a trend of increased influx of neutrophils and non-inflammatory monocytes was 
found and a decreased presence of inflammatory monocytes, macrophages and dendritic 
cells on the first day after MI. This was not significantly different when comparing all 
MI groups to Sham animals. Most importantly, no difference between the PBS group 
and either of the 2 MSC treatment groups or between the groups themselves could be 
shown (Figure 6). 
Discussion
The main findings of this study are: (1) stimulation of human bone marrow-derived 
MSCs with IFN does not alter their differentiation capacity; (2) uMSCs and iMSCs 
engraft in infarct myocardium and (3) neither treatment with uMSC nor iMSCs 
improves cardiac function after MI. Although we hereby confirmed the engraftment 
rate of our earlier findings, we now had discordant results with regard to cardiac 
function (4, 19). 
In an attempt to explain why we could not reproduce our previous results, we 
compared the two study designs. For both studies, 8-10 week-old male NOD/Scid mice 
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Figure 6. Flow cytometric analysis of inflammatory cells in the heart 15 days after myocardial 
infarction. Analysis in uMSC and iMSC treated animals (uMSC and iMSC, resp.), PBS treated 
animals (PBS) and Sham-operated animals (Sham). Data are expressed as mean ± SD. There 
were no significant differences between the uMSC, iMSC, PBS and Sham group.
from Charles River Labs (Maastricht, NL) were used. Although physically at a different 
location, the mice were housed under identical conditions. The source of the MSCs 
used in the present study (orthopaedic surgery patients without known cardiac disease) 
differed from the MSCs we used previously (ischemic heart disease patients). However, 
the phenotypic (in vitro surface marker expression profile) and functional (osteogenic 
and adipogenic differentiation and immunomodulatory capacity) characteristics of 
the MSCs used in both studies were comparable. Non-cardiac patient derived-MSCs 
have also been tested in other experimental disease mouse models in which they 
showed therapeutic efficacy (20). The presence of injected MSC in the cardiac tissue 
was confirmed in both studies 2 weeks after MI by histology and human ALU repeats-
PCR. Also, the levels of MSC engraftment were comparable (3.2% in the current study 
vs 4.1% in our previous study (4)).
The operating procedures were performed by different, although thoroughly 
trained and experienced operators. Baseline EF, EDV and ESV 2 days after MI were 
comparable in the two studies, indicating similar myocardial damage and loss of 
cardiac function. In the current study we used a 7-Tesla MRI, while in our previous 
study a 9.4-Tesla MRI was used and measurements were performed by a different, 
although experienced operator. However, studies about inter-operator differences 
report of excellent reproducibility of the cardiovascular MRI measurements of the 










All together, we have encountered unexplained discrepant therapeutic efficacy 
of MSCs in the permanent ligation MI mouse model. The experimental conditions 
were overall the same, suggesting that this discrepancy is related to details that are 
not recognized as potential key parameters. Therefore, questions arise concerning 
the robustness of these intricate animal models to assess the efficacy of cell therapy 
using human cells.
Several other studies, both positive and negative, have been performed investigating 
the therapeutic potential of MSC infusion in cardiac disease models. These studies 
showed therapeutic benefit on cardiac function mostly via echocardiography or MRI 
and whilst the experimental protocols seem similar between studies, large variations 
exist between the reported parameters that were beneficially influenced by MSC 
infusion, which hampers a direct comparison between studies (5, 18, 31-36). 
In contrast, debate exists about the therapeutic efficacy of MSC therapy in various 
experimental cardiac disease models, fuelled by a growing number of negative studies 
on MSC therapy (12, 17, 37-41). In a direct comparison between intramyocardial 
injection of various adult cell types in a mouse model of MI, using bone marrow-derived 
MSCs, bone marrow-derived mononuclear cells, skeletal myoblasts and fibroblasts, 
the MSCs did not show any beneficial effect on the preservation of cardiac function 
while  the bone marrow-derived mononuclear cells did (12). Another study by van 
der Bogt et al confirmed this result in a comparable study of adipose tissue-derived 
MSC and bone marrow-derived MSCs where neither cell type was able to preserve 
cardiac function (37). 
Our current results indicate that the reported therapeutic effects of MSCs may 
be easily obscured by unknown study parameters. This poses a major limitation on 
the use of animal models in further development of cell therapy for cardiac diseases.
Conclusion 
Both uMSC and iMSC therapy have no significant beneficial effect on cardiac function 
or remodelling in a NOD/Scid mouse model of MI, in contrast to our previous studies. 
Animal models for cardiac MSC therapy appear less robust than initially envisioned.
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Supplemental Materials and Methods
Animals. All experiments were approved by the Committee on Animal Welfare 
of the Leiden University Medical Center and conformed to the Guide for the 
Care and Use of Laboratory Animals as stated by the U.S. National Institutes 
of Health. To avoid rejection of transplanted human cells, 8- to 10-weeks-
old male non-obese diabetic/severe combined immunodeficient (NOD/Scid) 
mice (Charles River Laboratories, Maastricht, the Netherlands) were used. 
All animals were housed in filtertop cages and were given standard diet and water 
with antibiotics and antimycotics ad libitum.
Primary cultured human Mesenchymal Stromal Cells   (MSCs). Bone marrow-derived 
MSCs (unstimulated: uMSCs) were obtained from patients undergoing orthopedic surgery. 
The bone marrow mononuclear cells were isolated by Ficoll-Paque density gradient 
centrifugation (density: 1.077 g/cm3) and were plated at 1.3 x 105/cm2 in DMEM-low 
glucose (DMEM-LG; Invitrogen Corp., Paisley, UK) supplemented with 10% fetal calf 
serum (FCS; Greiner Bio-one) and Penicillin/Streptomycin (P/S; Invitrogen Corp., Paisley, 
UK). Cultures were grown in 175 cm2 flasks (Corning Life Sciences B.V., Schiphol-Rijk, 
The Netherlands) in a 37°C humidified incubator containing 5% CO2 and the medium 
was refreshed every 3-4 days. When the spindle shaped MSC monolayer reached >80% 
confluence, cells were detached using trypsin/EDTA (Invitrogen Corp., Paisley, UK) and 
replated at a density of 4,000 cells per cm2. Interferon-gamma (IFN) stimulation of MSCs 
(iMSCs) was performed by adding 500U/ml IFN (Sigma-Aldrich Chemie BV, Zwijndrecht, 
The Netherlands) to the culture medium for 7 days, refreshing the medium within 3 days.
Immunophenotyping of cultured MSC (both uMSCs and iMSCs) was performed 
using the following primary antibodies: CD90, CD73, MHC-I, CD34, CD45, CD31, 
CD80, (BD Biosciences, San Diego, USA), and CD105 (Ancell Corp., Bayport, MN, 
USA). Samples were analyzed using a FACSCalibur flow cytometer (BD Biosciences, 
San Diego, CA, USA) and the data were analyzed with FlowJo software (version 
7.6.3., Tree Star Inc. Ashland, OR, USA). MSCs from passages 4 to 5 were used 
for transplantation experiments after lentiviral transduction with a human vector 
expressing the enhanced green fluorescent protein (eGFP) gene which enabled ex vivo 
cell tracing via immunohistochemistry. The cells transduced with lentivirus for eGFP, 
transmitted the eGFP signal in the FITC channel of the FACSCanto II (BD Biosciences, 
San Diego, CA, USA). All sampling procedures were performed in accordance with the 
Helsinki Declaration and were approved by the ethics committee of Leiden University 
Medical Center (LUMC). All patients provided informed consent.
In Vitro Differentiation. For osteogenic differentiation uMSCs and iMSCs were grown to 
80% confluency in 24-well culture plates and were stimulated for 21 days in osteogenic 
differentiation medium consisting of  α-MEM (Invitrogen Corp., Paisley, UK) with 
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L-glutamin (200nM, Invitrogen Corp., Paisley, UK), P/S and 10% FCS supplemented 
with 107 M dexamethason, 50 μg/ml Vitamin C (both from Sigma-Aldrich Chemie BV, 
Zwijndrecht, The Netherlands), and 5 mM β-glycerophosphate (Sigma-Aldrich Chemie 
BV, Zwijndrecht, The Netherlands) and stained for alkaline phosphatase activity 
with Fast Blue (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) and for 
calcium deposition with Alizarine Red (MP Biomedicals LLC, Illkirch Cedex, France.) 
For adipogenic differentiation, MSCs were stimulated for 21 days in adipogenic 
differentiation medium consisting of α-MEM with L-glutamin (200nM, Invitrogen 
Corp., Paisley, UK), P/S and 10% FCS supplemented with 107 M dexamethason, 
insulin (10 μg/ml), indomethacin (5μM) and 3-isobutyl- 1-methylxanthine (5μM) 
(all from Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). Formation of 
lipid droplets was visualized with Oil-red O staining (Sigma-Aldrich Chemie BV, 
Zwijndrecht, The Netherlands). 
Suppression of human peripheral blood mononuclear cell (PBMC) proliferation by MSCs. 
Cultured human MSCs were plated in graded doses in 96-well f lat-bottom plates 
(Corning, Life Sciences) and allowed to adhere overnight. PBMC isolated from buffy 
coats (1.0 x 105/well) were added to the MSCs and stimulated with human T-activator 
CD3/CD28 dynabeads (Invitrogen Corp., Paisley, UK) in a bead:cell ratio 1:5. After 5 
days of co-culture, cells were pulsed with [3H]-thymidine (0.5 µCi/well) and incubated 
for 16 h at 37°C. The cultures were harvested on a glass fiber filter and thymidine 
incorporation was measured with a liquid scintillation counter (Wallac, Turku, 
Finland). Data were expressed as mean corrected counts per minute of triplicate 
co-cultures stimulated with anti-CD28/ anti-CD3-coated Dynabeads (one bead/5 
cells, Invitrogen) and were seeded in Iscove’s modified Dulbecco’s media (Invitrogen) 
supplemented with 5% human serum (Sanquin, Leiden, The Netherlands), and 5% FBS. 
Myocardial Infarction (MI) induction and Cell injection. Mice received 100µL NaCl, 
containing 2 µg buprenorphine, subcutaneously before surgery and again 12 hours 
after surgery. Animals were anesthetized with 5% isof lurane for induction and kept 
anesthetized with 1.5-2% isof lurane in oxygen for the remainder of the surgical 
procedure. Mice were placed supine on a heating pad (34°C), intubated and ventilated 
using a rodent ventilator (model 845, Harvard Apparatus, Holliston, MA, USA) with 
160 breaths per min and a stroke volume of 220 mL. A left thoracotomy was performed, 
followed by opening of the pericardial sac. The left anterior descending coronary 
artery (LAD) was visualized and ligated 1 mm caudally from the tip of the left auricle 
using a 7-0-prolene suture (Johnson and Johnson, New Brunswick, NJ, USA). 
Ischemia was confirmed by myocardial blanching. One minute after LAD ligation 
animals received an introperitoneal injection of lidocaine (6mg/kg) to prevent cardiac 
arrhythmias (1). Five minutes after LAD ligation animals received either 2×105 uMSCs 










with IFN in 15 μL PBS (iMSC group), or 15 μL PBS containing no cells (PBS group). 
Intramyocardial injections were performed at 3 sites in the infarcted area (5 μL per 
site). The chest was then closed in layers and animals were allowed to recover. 
Sham-operated animals were operated in parallel, but without LAD ligation 
and intramyocardial injection, and were used to determine baseline characteristics 
(Sham group).
All surgical procedures and injections were performed by an investigator blinded 
to treatment.
Cardiac Magnetic Resonance Imaging (MRI). Cardiac parameters were assessed 2 and 
14 days post-MI using a 7-Tesla MRI (Bruker Biospin, Ettlingen, Germany) equipped 
with a combined gradient and shim coil, which is inserted into the magnet bore. 
Mice were pre-anesthetized as described above and kept anesthetized with 1.5-2% 
isof lurane, and placed supine in an animal holder. A respiration detection cushion 
was placed underneath the thorax and connected to a gating module to monitor 
respiratory rate (SA Instruments, Inc., Stony Brook, NY, USA). Image reconstruction 
was performed using Bruker ParaVision 5.1 software.
Left ventricular function. Cardiac function was assessed at day 2 and 14. A high-
resolution 2D cine sequence was used to acquire a set of 9 contiguous 1 mm slices 
in short-axis orientation covering the entire heart. Imaging parameters were: echo 
time of 1.49 ms, repetition time of 5.16 ms, field of view (26 mm)2 and a matrix size 
of 144x192.
Image analysis. All MR image data were analysed with the MASS for Mice software 
package (Leiden, the Netherlands). The endocardial and epicardial borders were 
delineated manually by an investigator blinded to treatment (uMSC group n=12, 
iMSC group n=7, PBS group n=7, Sham group n=10). Subsequently, the end-diastolic 
volume, end-systolic volume and ejection fraction were computed.
Pressure-Volume (PV) measurements. Fifteen days after MI, mice were anesthetized 
again as described above and kept anesthetized with 1-1.5% isof lurane for the 
remainder of the surgical procedure. A 1.2F pressure-conductance catheter (standard; 
Scisense Inc, London, Canada) was introduced via the right carotid artery and 
positioned in the left ventricle (LV). The conductance catheter was connected to 
a PV control unit FV 896B (Scisense Inc, London, Canada) for online display and 
recording of LV pressure and volume signals. Parallel conductance was assessed 
by the hypertonic saline method using intravenous bolus injections of ~5 µL (2). 
The abdomen was opened to enable temporary preload reductions by directly 
compressing the inferior caval vein. All data were acquired using Powerlab 8/30 
Model ML870 (ADInstruments, Spechbach, Germany) and LabChart 7 software 
(ADInstruments, Spechbach, Germany). Data were analyzed off-line by a blinded 
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investigator (uMSC group n=7, iMSC group n=7, PBS group n=5, Sham group n=7). 
LV PV signals were acquired in steady-state to quantify general hemodynamic 
conditions and generate PV loops. 
Histology. At day 15 post-MI, mice were weighed, sacrificed after PV loop measurements 
under 5% isof lurane and their hearts and lungs were removed. Lungs were weighed 
immediately after excision, freeze-dried for 24 hours and then weighed again. The 
wet weight/dry weight ratio was used as a measure of pulmonary congestion. 
Per group 5 hearts were fixed by immersion in buffered 4% paraformaldehyde and 
embedded in paraffin. Serial transverse sections of 5 μm were cut along the entire long 
axis of the LV for (immuno)histological analyses. Sections were deparaffinated and 
dehydrated in xylene and alcohol. Antigen retrieval was accomplished by heating in a 
microwave oven (98°C) in 0.01 M citric buffer of pH 6.0 for 12 minutes for all sections. 
Sections were incubated overnight at room temperature with primary antibodies and 
for 60 minutes with secondary antibodies.
Engraftment rate. MSC engraftment was detected by immunostaining with a rabbit 
anti-GFP antibody (A11122, Invitrogen, Paisley, UK), followed by a biotinylated goat 
anti-rabbit IgG (E0432, Dako, Glostrup, Denmark) and a Qdot 655 streptavidin-
conjugated (Q10121MP, Invitrogen, Paisley, UK) antibody.   Nuclei were visualized 
by Hoechst 33342 (Invitrogen, Paisley, UK).
The number of engrafted MSCs was assessed by counting the GFP-positive cells 
at a 20x magnification in every 10th serial section along the long axis of the heart. 
The number of counted cells was multiplied by 10 to obtain an estimate of the total 
number of engrafted cells in the heart. Subsequently this number was divided by the 
total number of transplanted MSCs (2×105) and the result was multiplied by 100%.
Real-time Polymerase Chain Reaction (PCR). Mice were sacrificed 15 days post-MI to 
quantify the number of transplanted MSCs by real-time PCR (3). Per group 5 hearts were 
harvested, frozen in liquid nitrogen and stored at -80° C. Hearts were minced with fine 
scissors and suspended in lysis buffer (100 mM NaCl, 10 mM Tris-Cl pH 8, 25 mM EDTA 
pH 8, 0.5% SDS, 0.1 mg/ml proteinase K) and incubated at 55° C overnight, followed 
by incubation in 0.025 mg/ml ribonuclease at 37° C for 1 hour. DNA concentrations 
were measured using NanoDrop 1000 (NanoDrop products, Wilmington, DE, USA). 
PCR reactions were performed in a volume of 10 µL, containing 5 µL Universal PCR 
Master Mix (Applied Biosystems, Carlsbad, CA, USA), 900 nM forward and reverse 
primers, 250 nM TaqMan probe and 50 ng of target template. Reactions were incubated 
at 50° C for 2 min and 95° C for 10 min, and then amplified for 40 cycles. Each cycle 
comprised of an incubation step at 95° C for 15 s followed by 60 ° C for 1 min. 
Standard curves were generated by serially diluting human genomic DNA 
(Roche, Basel, Switzerland) in murine genomic DNA. The sequence of the PCR 










as follows: forward PCR primers, 5’-CATGGTGAAACCCCGTCTCTA-3’; reverse 
PCR primer, 5’-GCCTCAGCCTCCCGAGTAG-3’; TaqMan probe, 5’-FAM-
ATTAGCCGGGCGTGGTGGCG-TAMRA-3’.
Flow cytometry. From each treatment group, mice not subjected to functional and 
histological analysis were used for f low cytometric analysis of cardiac inf lammatory 
cell invasion. Mice were sacrificed on days 1, 3, and 7 after MI (n = 3 mice per time 
point). Sham animals were used as controls to determine base line characteristics. 
Infarct tissue and healthy hearts were harvested, minced with fine scissors, and 
placed into a solution of 2% collagenase IA (Sigma-Aldrich, Chemie BV, Zwijndrecht, 
The Netherlands) in PBS and shaken at 37 ° C for 1 h. The cell suspension was then 
triturated through a nylon mesh and centrifuged in PBS at 300 g for 10 min at 4°C. 
Red blood cells in the cell pellet were lysed with lysis buffer (AZL, Leiden, The 
Netherlands), and the cells were washed in PBS and subsequently resuspended in 
medium containing IMDM (Lonza, Verviers, Belgium) supplemented with 2.5% 
fetal calf serum (FCS; Greiner Bio-one) and Penicillin/Streptomycin (P/S; Invitrogen 
Corp., Paisley, UK).   Total cardiac cell numbers were determined with a Sysmex cell 
counter (Sysmex America, Inc. Mundelein, Illinois, USA).  The resulting single-cell 
suspensions were stained for f low cytometry with primary antibodies for 30 minutes 
at 4°C in the dark and the cells were washed with PBS/1% human Albuman (Sanquin, 
Leiden, The Netherlands) before analysis using a FACSCanto II (BD Biosciences, 
San Diego, CA, US). The following antibodies were used: anti–CD90-APC, 53–2.1,–
B220-APC, RA3-6B2, –CD49b-APC, DX5, –NK1.1-APC, PK136, –Ly-6G-APC, 1A8, 
CD11b-eFluor 450, M1/70,–CD11c-FITC, HL3, – I-Ab -FITC, AF6-120.1, –Ly-6C-PE, 
AL-21, –CD11c-PE, HL3 (all above antibodies are from BD Biosciences), –F4/80-FITC, 
C1:A3-1 (ABD Serotec, Kidlington, UK). Monocytes were identified as CD11b high 
(CD90/B220/CD49b/NK1.1/Ly-6G) low (F4/80/I-Ab /CD11c) low Ly-6C high/low as 
previously described (4, 5). Macrophages were identified as CD11b high, F4/80 high. 
Dendritic cells were identified as CD11b, I-Ab and CD11c high. Neutrophils were 
identified as CD11b, Ly-6G high. Monocyte and macrophage/dendritic cell numbers 
were calculated as the total cells multiplied by the percentage of cells within the 
monocyte/macrophage gate. The analysis of the acquired data was done with FlowJo 
software version 7.6.1 (Tree Star Inc. Ashland, OR, USA).
Statistical Analysis. Numerical values were expressed as means ± standard deviation. 
Comparison of MRI parameters and inf lammatory cells between the uMSC, iMSC, 
PBS and Sham groups was performed using two-way repeated-measures analysis 
of variance (ANOVA), with Bonferroni correction. Comparison of the remaining 
parameters was performed using one-way ANOVA, with Bonferroni correction.  
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Introduction: We previously showed that human cardiomyocyte progenitor 
cells (hCMPCs) injected after myocardial infarction (MI) had differentiated into 
cardiomyocytes in vivo 3 months post-MI. Here, we investigated the short-term (2 
weeks) effects of hCMPCs on the infarcted mouse myocardium. 
Methods: MI was induced in immunocompromised (NOD/Scid) mice, immediately 
followed by intramyocardial injection of hCMPCs labeled with enhanced green 
f luorescent protein (hCMPC group) or vehicle only (control group). Sham-operated 
mice served as reference. Cardiac performance was measured 2 and 14 days after 
MI by magnetic resonance imaging at 9.4T. Left ventricular (LV) pressure-volume 
measurements were performed at day 15 followed by extensive immunohistological 
analysis. 
Results: Animals injected with hCMPCs demonstrated a higher LV ejection fraction, 
lower LV end-systolic volume and smaller relaxation time constant than control 
animals 14 days post MI. hCMPCs engrafted in the infarcted myocardium, did not 
differentiate into cardiomyocytes, but increased vascular density and proliferation 
rate in the infarcted and border zone area of the hCMPC group. 
Conclusions: Injected hCMPCs engraft into murine infarcted myocardium where 
they improve LV systolic function and attenuate the ventricular remodeling process 
2 weeks post-MI. Since no cardiac differentiation of hCMPCs was evident after 
2 weeks, the observed beneficial effects were most likely mediated by paracrine 
factors, targeting amongst others vascular homeostasis. These results demonstrate 
that hCMPCs can be applied to repair infarcted myocardium without the need to 











In recent years, it has been demonstrated that cell therapy can improve left ventricular 
(LV) function in animal models for myocardial infarction (MI) and in patients with 
acute MI. Several cell types have been studied to date, with bone marrow (BM)-derived 
mononuclear cells including hematopoietic stem cells (1) and mesenchymal stem 
cells (MSCs) (2) as the most extensively investigated cell populations. However, also 
embryonic stem cells (3), skeletal myoblasts (4) and endothelial progenitor cells (5) 
have shown cardiac regeneration potential in animal MI models.
Although most of the clinical studies applying BM-derived cells revealed no 
significant side effects, stem cell-induced improvements in cardiac function remained 
modest (6), comparable to currently used treatment modalities for post-MI patients 
(7). The improvement of LV function appears to result from neovascularisation (8, 9), 
reduction of apoptosis (10) and improvement of scar compliance (11), probably through 
paracrine effects. Cardiomyogenic differentiation of engrafted BM-derived stem cells 
is uncertain (12), and at best seems to be a very rare event (13). 
The recent identification of populations of cardiac stem or progenitor cells (CPCs) 
that reside in the heart itself, has generated new opportunities for cell-based therapy, 
since these cells are capable of cardiac regeneration (14). We recently isolated human 
cardiomyocyte progenitor cells (hCMPCs) from fetal hearts (15). These cells express the 
stem cell markers stem cell antigen-1 (Sca-1)-like protein and islet-1 (Isl-1), and the early 
cardiac transcription factors GATA-4 and Nkx2.5. hCMPCs are able to differentiate 
into spontaneously beating cells, when stimulated with the DNA methyltransferase 
inhibitor 5-azacytidine. Further maturation is achieved by adding transforming 
growth factor-β (TGF-β) to the culture medium. Differentiated hCMPCs are able to 
form highly conductive gap junctions and generate ventricular cardiomyocyte-like 
action potentials (15). Previously we showed that hCMPCs transplanted into infarcted 
mouse myocardium differentiated into both cardiomyocytes and vascular cells and 
that hCMPC-treated animals displayed less deterioration of cardiac function in the 
long-term (3 months) compared to control mice (16). 
To learn more about the mechanism and the time course of these beneficial effects, 
we now analysed the effects of hCMPC injection into the infarcted mouse heart after 
a short-term (2 weeks).
To this end, we investigated the in vivo behaviour of undifferentiated hCMPCs in 
an immunocompromised mouse model 2 weeks after acute MI and assessed 1) the 
engraftment and differentiation state of the intramyocardially injected hCMPCs and 
2) the effects of intramyocardial hCMPC injection on LV function by small animal 
magnetic resonance imaging (MRI) and pressure-volume (PV) analysis.
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Materials and Methods
Details about the materials and methods are described in the Supplemental Materials 
and Methods at the end of this chapter.
Animals. All experiments were approved by the Committee on Animal Welfare of 
the Leiden University Medical Center, Leiden, the Netherlands. To avoid rejection of 
injected human cells, experiments were performed in 8- to 10-weeks-old male non-obese 
diabetic/severe combined immunodeficient (NOD/Scid) mice (Charles River Laboratories, 
Maastricht, the Netherlands). The animals were housed in filtertop cages and were given 
standard diet and water with antibiotics and antimycotics ad libitum. The experiments 
conformed to the principles of Laboratory Animal Care formulated by the Guide for the 
Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996).
Isolation and expansion of hCMPCs. For human fetal tissue collection, individual 
permission using standard informed consent procedures and prior approval of the Medical 
Ethics Committee of the University Medical Center Utrecht, Utrecht, the Netherlands, 
were obtained. hCMPCs were isolated by magnetic cell sorting (MACS; Miltenyi Biotec, 
Sunnyvale, CA) using Sca-1-conjugated beads, as described previously (15). To facilitate 
their identification in vivo, hCMPCs were transduced with a human adenovirus vector 
encoding the enhanced green fluorescent protein (eGFP) as previously described (17). 
MI model and cell implantation. MI was induced as described previously (18). 
Brief ly, animals were anesthetized and intubated. After left thoracotomy, the left 
anterior descending (LAD) coronary artery was ligated using a 7-0-prolene suture 
(Johnson and Johnson, New Brunswick, NJ). Twenty minutes after MI, animals 
received 20 μL culture medium (M199, Invitrogen) containing 2×105 hCMPCs 
(MI+hCMPC group) or 20 μL culture medium containing no cells (MI+vehicle group) 
by intramyocardial injections at 5 sites in the infarcted area. Sham-operated animals 
were used to determine baseline characteristics (Sham group). In the MI+hCMPC 
group 25 animals were included, 11 animals reached the end-point. In the MI+vehicle 
group 26 animals were included, 12 animals reached the end-point. In the Sham group 
16 animals were include, 10 animals reached the end-point. Only measurements of 
the animals that reached the 15 day end-point were taken into account in the analysis 
of the performed experiments.
Cardiac MRI. LV volumes and function were serially assessed at day 2 and 14 after surgery 
by high-field (9.4T) MRI as described previously (19). All data were analysed by manual 
tracing of endocardial and epicardial borders with the MR Analytical Software System 
(MASS) for Mice (MEDIS, Leiden, the Netherlands). End-diastolic and end-systolic 
phases were identified automatically, after which LV end diastolic-volume (LVEDV), LV 










Pressure-volume (PV) loop analysis to assess LV function. At day 15 a 1.4-F pressure-
conductance catheter (SPR-719; Millar Instruments, Houston, TX) was introduced via the 
right carotid artery, positioned in the left ventricle, and connected to a Sigma-SA signal 
processor (CD Leycom, Zoetermeer, the Netherlands) for online display and recording 
of LV pressure and volume signals. Parallel conductance and LV pressure-volume signals 
were measured as described previously (20-22). All data were acquired using Conduct-NT 
software (CD Leycom) at a sample rate of 2,000 Hz and analyzed off-line with custom-
made software. 
Histological examination. At day 15 after MI, the mice were sacrificed, weighed and 
their hearts and lungs were excised. Lung weight was measured immediately after excision 
and following freeze-drying for 24 h. The wet weight/dry weight ratio was used as a 
measure of pulmonary congestion. The hearts were fixed by immersion in buffered 4% 
paraformaldehyde and embedded in paraffin. Serial transverse sections of 5 μm were cut 
for (immuno)histological analyses.
Assessment of hCMPC engraftment and differentiation. hCMPC engraftment was assessed 
by immunostaining using an anti-GFP antibody. Double immunostainings were 
performed to investigate differentiation of eGFP-labelled hCMPCs. Serial sections 
were immunostained using antibodies against human CD31 (also known as platelet 
endothelial cell adhesion molecule-1 (PECAM-1)), α-smooth muscle actin (ASMA), 
α-sarcomeric actin (αSA), cardiac troponin I (cTnI), cardiac troponin T (cTnT), and 
atrial natriuretic factor (ANF). Primary antibodies were visualized with appropriate 
secondary biotinylated IgG and Qdot-655-streptavidin conjugates. GFP-specific 
labeling was visualized using Alexa Fluor 488-conjugated IgGs.
Morphometric analyses. To determine the angiogenic effects of hCMPC transplantation, 
vascular density was assessed by quantifying the number of murine CD31 positive vessel 
per mm2. The effect of hCMPC transplantation on cell proliferation and reparative nuclear 
DNA synthesis in donor and recipient cells was evaluated by nuclear staining with an 
anti-proliferating cell nuclear antigen (PCNA) antibody. Double immunostainings were 
performed to identify PCNA-positive cell types. Serial sections were immunostained 
using antibodies against CD31, ASMA, and cTnI. The effect of hCMPCs transplantation 
on scar composition was assessed by staining for collagen type III. LV collagen type III 
density was expressed as the ratio of the percentage of collagen type III-positive tissue in 
the left ventricle to that in the right ventricle of the same section. To analyze the extent 
of the total collagen deposition after hCMPC transplantation, sections were stained with 
picro-sirius red. Total collagen deposition was determined by the area stained tissue 
within the left ventricle as a percentage of the whole left ventricle.
The effect of hCMPCs engraftment on LV wall thickness was quantified at 2 
separate border zone areas, at the midpoint of the infarct region and averaged for all 
3 measurements.
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Statistical analysis. Numerical values were expressed as mean ± standard deviation (SD). 
Comparisons of parameters between the Sham, MI+vehicle, and MI+hCMPC groups were 
performed using one-way analysis of variance, with Bonferroni correction. P-values less 
than 0.05 were considered statistically significant.
Results
hCMPCs preserve systolic heart function. Cardiac volumes and ejection fractions 
were evaluated 2 and 14 days after MI by small animal MRI. Representative images 
of systolic and diastolic 3D reconstructions of MRI short axis views for all three 
experimental groups at day 14 are shown in Figure 1A. Already 2 days after MI, both 
the MI+vehicle group and the MI+hCMPC group had undergone cardiac remodelling 
as shown by an increase in LVEDV (61±2 µL and 56±3 µL respectively) and LVESV 
(42±2 µL and 37±3 µL respectively), as well as a considerable decrease in LVEF 
(30±2% and 35±2%; respectively), compared to Sham (LVEDV: 48±2 µL, LVESV: 
24±1 µL and LVEF: 51±1%) (Figure 1B). Two weeks after MI, the MI+vehicle group 
showed substantial ongoing LV remodelling and a further decrease in LVEF. However, 
this decrease in LVEF was significantly less in the MI+hCMPC group than in the 
MI+vehicle group (24±2% versus 15±1%; p<0.05). Likewise, the increase in LVESV in 
the MI+hCMPC group was significantly less than in the MI+vehicle group (89±8 µL 
versus 114±9 µL; p<0.05) (Figure 1B). 
hCMPCs improve mechanical performance. PV loop data confirmed the extensive 
LV remodelling post-MI. This effect was attenuated by injection of hCMPCs, as 
demonstrated by significant differences in LVESV, LVEDV, LVEF and relaxation time 
constant (Tau) between animals that received cells and those that were injected with 
vehicle only (Table 1). In addition, the intercept of the end-systolic PV relationship 
(ESPVR) as well as the slope and intercept of the preload recruitable stroke-work 
relation (PRSW) significantly improved in the MI+hCMPC group compared to the 
MI+vehicle group, indicating improvement of LV systolic function by injected hCMPCs 
(Table 1).
Summarized schematic PV loops (based on mean LVESV, mean LV end-systolic 
pressure (LVESP), mean LVEDV and mean LV end-diastolic pressures (LVEDP), 
mean LV end-systolic PV relationships (slope: Ees) and mean LV end-diastolic PV 
relationships (slope: Eed) are presented in Figure 2.
hCMPCs engrafted in the infarcted murine myocardium do not undergo 
cardiomyogenic differentiation within the first 15 days after transplantation. hCMPCs 
were labeled with GFP to assess engraftment. Fifteen days after cell transplantation, 
injected hCMPCs were predominantly observed in the infarcted anterolateral wall and 










of injected cells was identified in the hearts of animals treated with hCMPCs (Figure 3). 
hCMPCs were absent in the non-infarcted posterior and septal walls. Serial sections 
were examined at day 15 to identify GFP-positive cells co-expressing differentiation 
markers (Figure 4). None of the injected hCMPCs stained positive for the human 
endothelial cell-specific marker CD31. The cardiomyocyte-specific markers cTnI, cTnT 
Figure 1. Assessment of LV function at day 14 after MI by MRI. Representative 3D 
reconstructions of LV end-diastolic volume (EDV) and LV end-systolic volume (ESV) for 
Sham, MI+vehicle and MI+hCMPC (A). Graphs summarizing the results of the anatomical and 
functional analysis of the left ventricle by MRI for all three experimental groups: EDV, ESV 
and ejection fraction (EF) (B). *: p<0.05 versus MI mice that received vehicle only. #: p<0.05 
versus Sham-operated animals.
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and ANF were present in the heart. However, none of the injected hCMPCs expressed 
these markers. The injected cells did express ASMA and αSA, but the staining pattern 
of the latter protein was diffuse, and without cross-striations at this moment in time 
(Figure 4).
hCMPCs alter vascular density. LV functional improvements after hCMPC transplantation 
in the ischemic heart may occur through paracrine effects. Therefore, we studied the effects 
of hCMPCs on neovascularization, cellular proliferation and scar composition in the 
anterolateral wall (infarct zone) and lateral wall (border zone) of the heart (Figures 5-8). 
The presence of MI promoted neovascularization in the border zone, but not in the 
infarcted area (Figure 5A-5D). In hCMPC-transplanted mice, the number of vessels 
was significantly higher in both the infarct and border zone (Figure 5A) than in mice 
treated with vehicle (Figure 5B), which demonstrates a positive effect of hCMPCs on 
neovascularization (Figure 5D). None of the hCMPCs expressed hCD31, indicating all 
vessels were derived from host tissue (Figure 4).  
hCMPCs are capable of self-renewal and increase cellular proliferation of host tissue. 
PCNA was upregulated in both the infarct and border zone of hCMPC-treated mice 
(Figure 6A) when compared to mice treated with vehicle only (Figure 6B), demonstrating 
Figure 2. Pressure-volume loops at day 15 post-MI. PV loops in the Sham, MI+vehicle and 
MI+hCMPC groups of mice at day 15 post-MI (based on mean LV end-diastolic and LV end-
systolic pressures and volumes). The oblique lines represent the end-systolic (Ees) and end-










Figure 3. Histological engraftment of hCMPCs. Immunohistological staining of engrafted 
GFP-labeled cells (brown) 15 days after MI and intramyocardial hCMPC transplantation.
a stimulatory effect of transplanted hCMPCs on cell proliferation (Figure 6D). This 
increase in cell proliferation involved both hCMPCs and host tissue (data not shown). 
The presence of MI altered proliferation rate only in the border zone (Figure 6A-6D). 
PCNA expression was present predominantly in cells that were also positive for 
the smooth muscle cell marker ASMA, with a significant upregulation of PCNA in 
animals with a myocardial infarction. CD31 positive nuclei showed a comparable 
PCNA expression between all groups. cTnI positive nuclei had the lowest expression 
of PCNA, when compared to ASMA and CD31 staining, but were also comparable 
between all groups (Figure 6E).
hCMPCs only suppress collagen type III density but do not decrease total collagen 
deposition after MI. MI was associated with increased total collagen density in the left 
ventricle, which treatment with hCMPCs could not prevent. (Figure 7A-7D). Injection of 
hCMPCs only resulted in a significantly lower collagen type III deposition in the border 
zone and infarct region (Figure 8A), when compared to mice treated with vehicle only 
(Figure 8B-D) (23). Quantification of LV wall thickness showed a significant thinning 
of the infarcted wall, when compared to sham-operated animals. A non-significant 
trend towards an attenuated process of wall thinning was observed in animals treated 
with hCMPCs, when compared to mice treated with vehicle (p=0.056) (Figure 7E). 
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Figure 4. Double immunofluorescent stainings for GFP and cardiac markers to assess the 
differentiation capacity of hCMPCs. The left column shows engrafted hCMPCs in green (Alexa 
488) and nuclei in blue (Hoechst 33342), the middle column shows staining for the indicated 
cardiac marker (Qdot 655) and the right column is a merge of both images. hCMPCs show a diffuse 
staining for α-smooth muscle actin (ASMA) and α-sarcomeric (α-SA) actin 15 days after injection. 
Control immunostainings of human tissue sections for the human endothelial cell-specific 










Figure 5. Photomicrographs of representative sections of the LV wall 15 days after MI showing 
CD31-positive murine (i.e. host) vessels (brown). The vascularity in hearts that received 
hCMPCs (A), was higher than in hearts of vehicle-treated (B) and sham-operated mice (C). 
Quantification of CD31 staining (D). *: p<0.05 versus MI mice that received vehicle only. 
#: p<0.05 versus sham-operated animals.
Assessment of pulmonary congestion. Pulmonary water accumulation (wet weight – dry 
weight ratio) at day 15 was assessed for all experimental groups. In the MI+vehicle group 
there was a significant increase in lung fluid compared to the Sham group (0.19±0.02 g 
versus 0.14±0.01 g; p<0.05). In contrast, in the MI+hCMPC group pulmonary water 








Figure 6. Photomicrographs of representative sections of the LV wall 15 days post MI after 
immunostaining for the cellular proliferation marker PCNA (brown, marked with triangle). 
The number of PCNA-positive nuclei is augmented in hearts treated with hCMPCs (A), when 
compared to those of animals that received vehicle only (B) or were sham-operated (C). 
Quantification of PCNA staining (D). Quantification of double immunostainings for PCNA 











Figure 7. Photomicrographs of representative sections of the heart 15 days post-MI showing 
total collagen (red) by Sirius red staining. MI increased the total collagen deposition in the 
left ventricle in both animals treated with hCMPCs (A) and animals treated with vehicle only 
(B), when compared to sham-operated mice (C). Quantification of Sirius red staining (D). 
Quantification of LV wall thickness 15 days post MI shows a non-significant trend towards an 
attenuated wall thinning in animals treated with hCMPCs, when compared to animals treated 







Figure 8. Photomicrographs of representative sections of the LV wall 15 days post-MI after 
immunostaining for the extracellular matrix component collagen type III. Collagen type III 
was less prominent in animals treated with hCMPCs (A), than in those that received vehicle 
only (B) while the hearts of sham-operated mice contained the lowest amount of collagen 
type III (C). Quantification of collagen type III staining (D). LV Collagen type III intensity is 
expressed as ratio of the percentage of collagen type III-positive tissue in the left ventricle to 
that in the right ventricle of the same section.  *: p<0.05 versus MI mice that received vehicle 
only. #: p<0.05 versus sham-operated animals.
Discussion
The main findings of the present study are that 2 weeks after hCMPC injection in the 
infarcted heart of an immunocompromised mouse model we observe (i) significant 
preservation of LV systolic function, (ii) hCMPCs engraftment in the ischemic 
area, without cardiomyogenic differentiation, and (iii) attenuation of the adverse 
ventricular remodelling process, probably by paracrine factors. The present study 
therefore demonstrates the ability of hCMPCs to alleviate the deleterious effects of 










Since Beltrami et al. proposed that cardiomyocytes may re-enter the cell cycle 
and undergo mitotic division, there has been discussion about the regenerative 
capacities of the heart (24). Recent studies have confirmed this finding (25, 26), but 
it remains controversial whether the number of newly formed cardiomyocytes is 
actually sufficient to contribute to the injured myocardium (27). Hsieh et al. suggested 
that progenitor cells might play a role in this process as they provided evidence that 
these cells may contribute to the process of cardiomyocyte renewal after injury of 
the heart (28). However, the contribution of progenitor cells appears to be limited 
during normal ageing, as main cardiac regeneration then occurs through pre-existing 
cardiomyocytes (28). 
In contrast to the small amount of regeneration that occurs in mammalian hearts, 
zebrafish are able of cardiac regeneration (29). Recent studies showed an indisputable 
role for pre-existing cardiomyocytes as cardiac renewal source, while the contribution 
of progenitor cells was minimal at best (30, 31).
Zuo et al. recently provided evidence for another important role for stem or 
progenitor cells in a rat MI model. Injected MSCs released paracrine factors which 
acted on the native cardiomyocytes and resulted in less vulnerability to apoptosis 
(32). This observed phenomenon of stem cell-mediated cardioprotection, has been 
reported earlier (33, 34).
Beltrami et al. demonstrated that the heart contains a pool of CPCs displaying 
endogenous regenerative potential (35). So far CPC populations residing in postnatal 
hearts have been reported in rats (35), mice (36) dogs (34) and humans (37). These 
populations were identified by expression of several marker proteins, including c-kit 
(34, 36, 37), Isl-1 (38) and Sca-1 (39). 
Few studies have described CPC isolation from human tissue. Messina et al. isolated 
clusters of fibroblast-like cells, termed cardiospheres, from human heart biopsies 
that expressed the endothelial markers kinase insert domain receptor and CD31, as 
well as the stem cell markers CD34, Sca-1 and c-kit (37). In co-culture with adult rat 
cardiomyocytes these cells differentiated into cardiomyocyte-like cells that displayed 
spontaneous beating (37). Furthermore, intramyocardial injection of these cells in NOD/
Scid mice following induction of acute MI resulted in expression of endothelial, smooth 
muscle and cardiomyocyte markers with preservation of cardiac function (37, 40). 
The observed improvement of cardiac function appears to be cell-type specific, as 
recent studies show that fibroblast were not able to improve cardiac function, in 
contrast to CPCs (40, 41).
Earlier and in the current study we were able to isolate hCMPCs from the human 
fetal heart. These cells are able to grow in culture for at least 25 passages (42). We 
have previously reported that when hCMPCs are stimulated with 5-azacytidine and 
TGF-β, spontaneously beating cardiomyocytes can be identified within the culture after 
approximately 3 weeks (15). Both undifferentiated hCMPCs and beating hCMPC-derived 
cardiomyocytes were intramyocardially transplanted in an animal model with long-term 
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follow-up. Both cell types preserved cardiac function and underwent phenotypic changes 
in vivo, including expression of sarcomeric proteins. Twelve weeks after injection, 
intramyocardial human grafts expressed cTnI and myosin light chain 2a (16).  
Having established that intramyocardially injected undifferentiated hCMPCs 
spontaneously differentiated into cardiomyocytes in vivo after twelve weeks and 
prevented deterioration of cardiac function, we now studied the short-term effects of 
the intramyocardial administration of undifferentiated hCMPCs in a mouse MI model. 
LV function of the heart was assessed by MRI and PV measurements (20). hCMPC 
transplantation significantly preserved the systolic function of the LV, as the increase 
in LVESV and the deterioration of LVEF after MI were attenuated in the MI+hCMPC 
group in comparison to the MI+vehicle group. PV relationships showed a significantly 
lower LVEDV in the MI+hCMPC group than in the MI+vehicle group. Injection 
of hCMPCs also resulted in a significant decrease in the relaxation time constant, 
indicating a faster isovolumic relaxation (i.e. improved diastolic function). These 
findings support the concept that transplantation of hCMPCs causes attenuation of 
the pathological remodelling process that normally occurs after MI. The preservation 
of cardiac function that was observed in the present short-term study was previously 
found to be sustained at 4 and 12 weeks post MI (16). 
A significant accumulation of lung f luid, indicative of pulmonary congestion, 
occurred in the MI+vehicle group only, suggesting that symptoms of overt LV failure 
remained absent in the MI+hCMPC group.
Although we hypothesized that hCMPCs may differentiate into functional 
cardiomyocytes in vivo after 2 weeks, we only detected a diffuse staining pattern 
of α-SA and expression of ASMA in injected hCMPCs. As no fully developed 
cardiomyocytes with sarcomeric cross striation were observed, an active contractile 
contribution of the hCMPCs is unlikely. Instead, the observed beneficial effect of 
hCMPCs transplantation on cardiac function and structure are considered to result 
from paracrine pathways.
Nagaya et al. have demonstrated that intramyocardial transplantation of rat 
MSCs improved cardiac function in a rat model of dilated cardiomyopathy, which 
was associated with increased capillary density and secretion of angiogenic factors, 
including vascular endothelial growth factor A (VEGF-A), hepatocyte growth factor 
and adrenomedullin (8). In the present study, we also observed increased vascular 
density in both the infarct and the border area of the hCMPC-injected hearts when 
compared to mice treated with vehicle only (16). Chimenti et al. injected human 
cardiosphere-derived cells intramyocardially after MI and observed an increase in 
vascular density, that was mainly due to paracrine effects as only a small number of 
vessels was derived from human donor tissue (41). 
Since in the present study no hCMPCs were observed in the vascular linings, 










infarcted heart in a paracrine fashion. This coincides with the previous finding that 
undifferentiated hCMPCs excrete VEGF-A, a potent stimulator of angiogenesis (43, 44). 
PCNA acts as a processivity factor for DNA polymerase δ by encircling the template 
DNA and is involved in nuclear DNA synthesis and repair. As the PCNA content of 
cells changes during the cell cycle, reaching a peak at the G1 to S phase transition, 
it can be used as a marker for cell proliferation (45). In the present study PCNA 
upregulation most likely reflects increased cellular proliferation rather than DNA 
repair, since the conditions affecting DNA damage do not differ between treatment 
arms. PCNA was upregulated in cells of donor and recipient origin in the infarct and 
border zone of the heart, indicating increased cellular proliferation in these regions. 
Double immunostainings revealed that PCNA expression was equally present in 
endothelial cells and cardiomyocytes in all groups. However, ASMA expressing cells 
showed a significantly higher PCNA expression in the MI groups, which is in line with 
previous studies (46, 47). After MI scars were shown to undergo rapid changes in their 
content of myofibroblasts, where during the proliferative phase fibroblasts undergo 
phenotypic changes leading to expression of contractile proteins such as ASMA (47). 
Hatzistergos et al. have demonstrated that injection of MSCs in the infarcted heart 
increased the number of mitotic endogenous cardiomyocytes. This significantly higher 
level of host cardiomyocyte turnover reached its maximum at 2 weeks and decreased 
to normal levels by 2 months (48). Following intracoronary administration of CPCs 
in a MI/reperfusion model, Tang et al. also demonstrated increased proliferation of 
especially the transplanted cells. Moreover, the injection of CPCs induced division of 
endogenous CPCs in both infarcted and non-infarcted areas (49).
In the present study, we observed that total collagen deposition in the LV increased 
substantially after MI. Treatment with hCMPCs could not inhibit overall  myocardial 
fibrosis, but attenuated the collagen type III density in the infarcted heart. Collagen 
type III is a constituent of the extracellular matrix and, together with collagen type I, 
an important contributor to the pathological ventricular remodelling process that 
occurs after MI and the consequential loss of cardiac function (23). As both the LVESV 
and LVEDV were better preserved in mice treated with hCMPCs, this may be partly 
explained by this observed phenomenon. 
Berry et al. demonstrated earlier the potential of stem cell therapy in the 
prevention of cardiac remodelling in a MI model. Intramyocardially injected MSCs 
preserved cardiac function after MI by inhibiting fibrosis and LV dilatation, thereby 
conserving myocardial thickness 8 weeks post MI (11). MSCs did not differentiate 
into cardiomyocytes, but attenuated the remodelling process conceivably through 
paracrine effects (11).  
Ever since stem cell therapy has emerged as a putative treatment for ischemic 
heart disease, low engraftment rates of the delivered cells have remained an issue. A 
limitation of this study is the low observed engraftment rate of the cells 15 days after 
injection. Direct intramyocardial injection ensures targeted delivery of the cells into 
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the ventricular wall. However, a significant portion of the injected cells wash away by 
blood flow or are lost by leakage from the injection site (50-52). But when comparing 
the intramyocardial injection method with intracoronary or intravenous delivery 
methods, intramyocardial injection has a preference in case of higher engraftment 
(53, 54), reduction of infarct size (55) and repairing injured myocardium (54). Future 
studies are necessary to further improve acute cell retention and engraftment, thereby 
increasing the beneficial effects of injected cells.
An alternative to the cell injection approach is mobilization of stem cells to the 
site of injury (56). The importance of the presence of injected cells at the site of 
injury is clearly demonstrated by a recent studie from Huber et al. Intraperitoneal 
administration of parathyroid hormone (PTH) increased the mobilization of BM-cells 
and homing of these cells towards the ischemic myocardium, when compared to control 
animals. Altogether this attenuated the cardiac remodelling process and enhanced 
cardiac function in animals which received PTH (57). 
Furthermore, a recent study from Theiss et al. provided evidence that mobilization 
and homing of BM-cells can be improved by granulocyte-colony stimulating factor 
(G-CSF) application and dipeptidylpeptidase IV (DPP-IV) inhibition. Homing cells 
were able to improve myocardial perfusion and attenuated the process of cardiac 
remodelling. The combination of G-CSF treatment and DPP-IV inhibition, a dual stem 
cell based therapy, also increased the pool of resident cardiac stem cells (58), which 
may contribute to the process of cardiomyocyte renewal after injury of the heart (28), 
an important mechanism which may also play a role in the current study. 
So far many small and large animal studies have been performed, generating 
excitement and prompting investigators to translation of these results into the clinic. 
The results from placebo controlled trials show that the use of autologous and allogenic 
BM-derived cells is safe, and overall stem cell therapy positively affects cardiac 
function, suggesting that improvement over existing pharmaceutical therapy can be 
achieved (59). A more recent meta-analysis by Wen et al. already suggests that direct 
injection of BM-derived cells has beneficial effects on cardiac function over regular 
therapy alone (60). Cardiac stem cell therapy with hCMPC transplantation most 
likely requires autologous stem cells, since the immune status of CPCs has not been 
thoroughly investigated yet. Whether injection of hCMPCs has extra beneficial effects 
in comparison to conventional pharmaceutical treatment in patients with ischemic 
heart disease is a question that remains unanswered so far. 
In conclusion, transplantation of hCMPCs into the infarcted heart limits 
deterioration of cardiac function and attenuates the cardiac remodelling process already 
2 weeks after injection. Since the hCMPCs had not differentiated into cardiomyocytes 
at this time point, paracrine stimulation of neoangiogenesis and cell proliferation, 
are considered key factors in preserving short-term cardiac function. These results 
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Supplemental Materials and Methods
Animals. All experiments were approved by the Committee on Animal Welfare of 
the Leiden University Medical Center, Leiden, the Netherlands. To avoid rejection of 
injected human cells, experiments were performed in 8- to 10-weeks-old male non-obese 
diabetic/severe combined immunodeficient (NOD/Scid) mice (Charles River Laboratories, 
Maastricht, the Netherlands). All animals were housed in filtertop cages and were given 
standard diet and water with antibiotics and antimycotics ad libitum. The experiments 
conformed to the principles of Laboratory Animal Care formulated by the Guide for the 
Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996).
Isolation and expansion of human cardiomyocyte progenitor cells (hCMPCs). For 
human fetal tissue collection, individual permission using standard informed consent 
procedures and prior approval of the Medical Ethics Committee of the University Medical 
Center Utrecht, Utrecht, the Netherlands, were obtained. Fetal hearts were collected after 
elective abortion. hCMPCs were isolated by magnetic cell sorting (MACS) using stem cell 
antigen-1 (Sca-1)-conjugated beads, according to the manufacturers’ protocol (Miltenyi 
Biotec, cat. No. 130-091-176, Sunnyvale, CA). Sca-1+ cells were eluted from the column 
by washing with phosphate buffered saline supplemented with 2% fetal bovine serum 
(FBS, Invitrogen, Carlsbad, CA) and cultured in 0.1% gelatin (Type A, Sigma, cat. No. 
G6144, St. Louis, MO) coated dishes in a 3:1 mixture of medium 199 (Invitrogen) and 
endothelial growth medium-2 supplemented with 10% FBS, 10 ng/ml basic fibroblast 
growth factor, 5 ng/ml epithelial growth factor, 5 ng/ml insulin-like growth factor and 
5 ng/ml hepatocyte growth factor. Mice were transplanted with hCMPCs of passage 7.
To facilitate their identification in vivo, hCMPCs were transduced with 100 infectious 
units per cell of a fiber-modified first-generation human adenovirus serotype 5 vector 
(hAd5/F50.CMV.eGFP) encoding the enhanced green fluorescent protein (eGFP) (1) 
in the presence of 5 mmol/L sodium butyrate to enhance transgene expression. 
Myocardial infarction (MI) model and cell implantation. Animals were pre-
anesthetized with 5% isoflurane in a gas mixture of oxygen and nitrogen, followed 
by endotracheal intubation. The animals were subsequently ventilated using a rodent 
ventilator (model 845, Harvard Apparatus, Holliston, MA) with 200 breaths per min 
and a stroke volume of 200  mL, and were kept anesthetized with 0.5-1.5% isoflurane 
for the remainder of the surgical procedure. After a left thoracotomy, the left anterior 
descending (LAD) coronary artery was ligated using a 7-0-prolene suture (Johnson 
and Johnson, New Brunswick, NJ). Twenty minutes after MI, animals were grouped 
to receive 20 μL culture medium (M199, Invitrogen) containing 2×105 hCMPCs or 
20 μL culture medium containing no cells. Intramyocardial injections were performed 
at 5 sites in the infarcted area using a 20-μL syringe with a 33G needle (Hamilton 










to recover. Sham-operated animals were used to determine baseline characteristics. 
In the MI+hCMPC group 25 animals were included, 11 animals reached the end-point. 
In the MI+vehicle group 26 animals were included, 12 animals reached the end-point. 
In the Sham group 16 animals were include, 10 animals reached the end-point. Only 
measurements of the animals that reached the 15 day end-point were taken into 
account in the analysis of the performed experiments.
Cardiac magnetic resonance imaging (MRI). Left ventricular (LV) volumes and 
function were serially assessed at day 2 and 14 after surgery by high-field MRI. Mice 
were anesthetized as described above and maintained at 1-2% isoflurane during the 
procedure. All measurements were performed with a vertical animal MRI (Biospin, 
Bruker, Rheinstetten, Germany).  The MRI setup consisted of a vertical 9.4-T (400 MHz), 
89-mm bore nuclear magnetic resonance spectrometer equipped with a shielded gradient 
set (1 T/m) and a 30-mm birdcage resonator. Biotrig software (Bruker) was used to acquire 
electrocardiographs (ECGs) and to measure respiratory rates, and image reconstructions 
were performed using Bruker ParaVision 3.02 software.
A high-resolution ECG- and respiration-triggered 2D fast-gradient echo (i.e. FLASH) 
sequence was used to acquire a set of contiguous 1-mm slices in short axis orientation 
covering the entire long axis of the heart. Imaging parameters were: echo time of 
1.9 ms, repetition time of 7 ms, field of view (25.6 mm)2, matrix size 256x256 and a 
flip angle of 15°.
All MRI data were analyzed with the MR Analytical Software System (MASS) for 
Mice (MEDIS, Leiden, the Netherlands). Endocardial and epicardial borders were then 
traced manually by two independent investigators who were blinded to the treatment 
groups. End-diastolic and end-systolic phases were identified automatically, after which 
LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV) and LV ejection 
fraction (LVEF) were computed.
Pressure-volume (PV) loop analysis to assess LV function. At day 15 mice were again 
anesthetized as described above and kept anesthetized with 0.5-1.5% isoflurane for the 
remainder of the surgical procedure. A 1.4-F pressure-conductance catheter (SPR-719; 
Millar Instruments, Houston, TX) was introduced via the right carotid artery, positioned in 
the left ventricle, and connected to a Sigma-SA signal processor (CD Leycom, Zoetermeer, 
the Netherlands) for online display and recording of LV pressure and volume signals. 
Parallel conductance was assessed by the hypertonic saline method using intravenous 
bolus injections of ~5 µL(2). The abdomen was opened to enable temporary preload 
reductions by directly compressing the inferior vena cava. All data were acquired using 
Conduct-NT software (CD Leycom) at a sample rate of 2,000 Hz and analyzed offline 
with custom-made software. 
LV PV signals were acquired in steady-state to quantify general hemodynamic 
conditions, including heart rate (HR), stroke volume (SV), cardiac output (CO), LVEDV, 
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LVESV, LVEF, LV end diastolic pressure (LVEDP), LV end systolic pressure (LVESP), 
stroke work (SW), dP/dtmax and dP/dtmin, and the isovolumic relaxation time constant 
(Tau). To quantify systolic function, we used the end-systolic PV relationship (ESPVR), 
the relationship between dP/dtmax and LVEDV, and the preload recruitable stroke-
work relationship (PRSWR; SW versus LVEDV). The slopes of these relationships, 
end-systolic elastance (EES), slope of dP/dtmax-LVEDV relationship and slope of the 
SW-LVEDV relationship (PRSWR), respectively, are sensitive measures of intrinsic 
systolic LV function. For diastolic function, the end-diastolic stiffness (Eed) was 
determined by linear fitting the end-diastolic PV points.
Histological examination. At day 15 after MI, the mice were sacrificed, weighed and 
their hearts and lungs were excised. Lung weight was measured immediately after excision 
and following freeze-drying for 24 h. The wet weight/dry weight ratio was used as a 
measure of pulmonary congestion. The hearts were fixed by immersion in buffered 4% 
paraformaldehyde and embedded in paraffin. Serial transverse sections of 5 μm were cut 
for (immuno)histological analyses.
Assessment of hCMPC engraftment. hCMPC engraftment was assessed by immunostaining 
with a rabbit anti-GFP antibody (A11122, Invitrogen) followed by a biotinylated goat 
anti-rabbit IgG (BA-1000, Vector Labs, Burlingame, CA). The GFP-specific signal was 
amplified with the ABC staining kit (PK-6100, Vector Labs). 3,3’-diaminobenzidine 
tetrahydrochloride hydrate (DAB, D5637, Sigma-Aldrich, St. Louis, MO) was used 
as substrate for horseradish peroxidase. Sections were counterstained with Mayer’s 
hematoxylin.  
The number of engrafted hCMPCs was determined by counting the DAB-positive 
cells at a 20x magnification in every 10th serial section along the long axis of the heart. 
The number of counted cells was multiplied by 10 to obtain an estimate of the total 
number of engrafted cells in the heart. The hCMPC engraftment rate was subsequently 
calculated by dividing this number by the total number of injected hCMPCs (2×105) 
and multiplying the result by 100%.
Assessment of hCMPC differentiation. Double immunostainings were performed to 
investigate differentiation of GFP-labeled hCMPCs towards endothelial cells, smooth 
muscle cells or cardiomyocytes. Serial sections were immunostained using mouse 
monoclonal antibodies against human CD31 (also known as platelet endothelial cell 
adhesion molecule-1 (PECAM-1), M1536, Sanquin, Amsterdam, the Netherlands), 
α-smooth muscle-actin (ASMA; clone 1A4, A2547, Sigma-Aldrich), α-sarcomeric actin 
(αSA, clone 5C5, A2172, Sigma-Aldrich), cardiac troponin I (cTnI, clone 19C7, Hytest) 
cardiac troponin T (cTnT, ab33589, Abcam, Cambridge, UK), and atrial natriuretic factor 
(ANF, CBL66, Chemicon, Nottingham, UK). Primary antibodies were visualized with 
appropriate secondary biotinylated IgG and Qdot 655 streptavidin conjugates (Q10121MP, 










antibody Alexa Fluor 488 conjugated donkey anti-rabbit IgG (H+L) (A21206, Invitrogen). 
Co-localization of GFP and differentiation markers was examined using a fluorescence 
microscope (Eclipse E800, Nikon, Badhoevedorp, the Netherlands) equipped with 
dedicated Qdot-compatible filter sets and a digital camera (DXM 1200, Nikon).
Morphometric analyses. To determine the angiogenic effects of hCMPCs transplantation, 
vascular endothelial cells were stained with a rat anti-CD31 antibody (clone MEC13.3, 
BD Pharmingen, Erembodegem, Belgium), followed by a biotinylated rabbit anti-rat IgG 
(BA-4001, Vector Labs). 3,3’-diaminobenzidine tetrahydrochloride hydrate (DAB, D5637, 
Sigma-Aldrich, St. Louis, MO) was used as substrate for horseradish peroxidase. Sections 
were counterstained with Mayer’s hematoxylin.
Vascular density was assessed by quantifying the number of murine CD31-positive 
vessels per mm2. Morphometric measurements were performed on photomicrographs 
taken at a 20-fold magnification of three standardized areas of interest in the 
anterolateral (infarcted) wall of the LV and on three standardized areas of interest 
in the lateral (border zone) wall of the LV from 4 animals per group. The number 
of CD31 positive vessels was counted in both areas and calculated as vessels per 
square millimeter. All measurements were performed by an observer blinded to the 
experimental status of the samples, using the Image-Pro Plus software package (Media 
Cybernetics, Silverspring, MD).
The effect of hCMPC transplantation on cell proliferation and reparative nuclear 
DNA synthesis in donor and recipient cells was evaluated by nuclear staining with 
an anti-proliferating cell nuclear antigen (PCNA) antibody (P-8825, Sigma-Aldrich). 
3,3’-diaminobenzidine tetrahydrochloride hydrate (DAB, D5637, Sigma-Aldrich, 
St. Louis, MO) was used as substrate for horseradish peroxidase. Sections were 
counterstained with Mayer’s hematoxylin. Proliferation rate was determined by the 
ratio of PCNA-positive stained nuclei to total nuclei. This analysis was performed on 
photomicrographs taken at a 20-fold magnification of three standardized areas of 
interest in the anterolateral (infarcted) wall of the LV and on three standardized areas 
of interest in the lateral (border zone) wall of the LV from 4 animals per group. The 
percentage of PCNA staining was measured by an observer blinded to the experimental 
status of the samples, using the Image-Pro Plus software package.
To evaluate nuclear DNA synthesis in hCMPCs, double immunostaining was 
performed. Serial sections were immunostained for PCNA using the aforementioned 
primary antibody and visualized with biotinylated goat anti-mouse IgG followed by 
Qdot 655 streptavidin conjugates. The GFP-specific immunostaining was carried out 
as described above. Co-localization of GFP and PCNA was examined using a Nikon 
Eclipse E800 fluorescence microscope equipped with dedicated Qdot-compatible 
filter sets.
Double immunostainings were performed to identify PCNA-positive cell types. 
Serial sections were immunostained using antibodies against CD31, ASMA, and cTnI. 
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Primary antibodies were visualized with appropriate secondary biotinylated IgG and 
Alexa 488 streptavidin conjugates (S-11223, Invitrogen). PCNA-specific signal was 
detected as described above. Co-localization of PCNA and the different cell types was 
examined using a Nikon Eclipse E800 fluorescence microscope equipped with dedicated 
Qdot-compatible filter sets. Proliferation rate in specific cell types was determined 
by the ratio of PCNA-positive stained nuclei to total nuclei also stained for the cell 
specific marker. This analysis was performed on photomicrographs taken at a 40-fold 
magnification of three standardized areas of interest in the anterolateral (infarcted) 
wall of the LV from four animals per group. The percentage of PCNA stained nuclei 
was measured by an observer blinded to the experimental status of the samples, using 
the Image-Pro Plus software package.
The effect of hCMPC transplantation on scar composition was assessed by staining 
for collagen type III density using a primary antibody (AB7778, Abcam) together with 
an appropriate secondary IgG antibody. 3,3’-diaminobenzidine tetrahydrochloride 
hydrate (DAB, D5637, Sigma-Aldrich, St. Louis, MO) was used as substrate for 
horseradish peroxidase. Sections were counterstained with Mayer’s hematoxylin. 
The density of this extracellular matrix component in the LV was determined by the 
cumulative area of collagen type III stained tissue per total LV area. The value was 
expressed as the ratio of the percentage of collagen type III-positive tissue in the LV to 
that in the right ventricle (RV) of the same section. Morphometric measurements were 
performed on photomicrographs taken at a 20-fold magnification of three standardized 
areas of interest in the anterolateral (infarcted) wall of the LV and on three standardized 
areas of interest in the lateral (border zone) wall of the LV from 4 animals per group. 
In addition, we analyzed three standardized areas in the lateral wall of the RV from 
4 animals per group. The density of collagen type III staining was measured by an 
observer blinded to the experimental status of the samples using the Image-Pro Plus 
software package.
To evaluate the extent of the total collagen deposition after hCMPC transplantation, 
sections were stained with picro-sirius red (0.5 gram Sirius red in 500 ml saturated 
aqueous solution of picric acid) for one hour. Slides were then washed twice with 
acidified water and afterwards dehydrated. Total collagen deposition was determined 
by the area stained tissue within the LV as a percentage of the whole LV. This analysis 
was performed on photomicrographs taken at a 2-fold magnification of 15 sections of 
the heart from 4 animals per group. The area of Sirius red staining was measured by 
an observer blinded to the experimental status of the samples, using the Image-Pro 
Plus software package.
The effect of hCMPCs engraftment on LV wall thickness was quantified by an 
observer blinded to treatment. This analysis was performed at 15 photomicrographs 
per heart (same sections as described for total collagen deposition measurements). 
Wall thickness was measured at 2 separate border zone areas, at the midpoint of the 
infarct region and averaged for all 3 measurements. Measurements were performed 
perpendicular to the infarcted wall.
Statistical analysis. Numerical values were expressed as means ± SD. Comparisons of 
parameters between the Sham, MI+vehicle, and MI+hCMPC groups were performed 
using one-way analysis of variance, with Bonferroni correction. P-values less than 0.05 
were considered statistically significant.
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Abstract
Objective: Hypercholesterolemia is a major risk factor for ischemic heart disease 
including acute myocardial infarction (MI). However, long-term effects of 
hypercholesterolemia in a rodent ischemia-reperfusion MI model are unknown. We 
therefore investigated the effects of diet-induced hypercholesterolemia in APOE*3-
Leiden mice on cardiac function up to 8 weeks after myocardial ischemia-reperfusion 
(MI-R) injury.
Methods: In normocholesterolemic (NC-MI, n=16) and hypercholesterolemic 
(HC-MI, n=18) mice myocardial ischemia was induced by coronary ligation for 
45 minutes followed by permanent reperfusion. Left ventricular (LV) dimensions 
were serially assessed using parasternal long-axis echocardiography (0, 1, 3, and 
8 weeks after MI-R) followed by LV pressure-volume measurements 8 weeks post-
MI-R. Subsequently, infarct size and the inf lammatory response were analyzed by 
histology and f luorescence-activated cell sorting (FACS) analysis. 
Results: Intrinsic LV function 8 weeks after MI-R was impaired in HC-MI compared 
to NC-MI mice as assessed by end-systolic pressure (73±3mmHg vs. 89±2mmHg, 
P=0.001), dP/dtMAX (6.1±0.4mmHg/ms vs. 8.3±0.4mmHg/ms, P=0.001), and -dP/dtMIN 
(5.3±0.4mmHg/ms vs. 6.8±0.2mmHg/ms, P=0.005). Paradoxically, infarct size was 
decreased in HC-MI compared to NC-MI mice (12.7±2.0% vs. 22.2±2.9%, P=0.017), 
which was accompanied by increased wall thickness (0.81±0.05mm vs. 0.57±0.05mm, 
P=0.007). Hypercholesterolemia caused a pre-ischemic peripheral monocytosis, in 
particular of Ly-6Chigh monocytes whereas accumulation of macrophages in the 
ischemic-reperfused myocardium of HC-MI mice was decreased. 
Conclusion: Diet-induced hypercholesterolemia caused an impaired LV function 
8 weeks after MI-R injury despite of a reduced post-ischemic infarct size. This was 
preceded by a pre-ischemic peripheral monocytosis, while there was a suppressed 












Hypercholesterolemia plays an important role in the occurrence of atherosclerosis 
(1) and is a major risk factor for ischemic heart disease (2). Several clinical studies 
demonstrated an adverse effect of hypercholesterolemia on coronary heart disease 
events and left ventricular (LV) systolic function after suffering a myocardial 
infarction (MI) (3, 4) and reported positive effects of lipid lowering therapies (5, 6).
Experimental MI studies have reported controversial findings regarding the effect of 
diet-induced hypercholesterolemia on cardiac function following myocardial ischemia-
reperfusion (MI-R). Acute cholesterol feeding, up to 3 weeks, is associated with increased 
MI-R injury (7, 8). Also, prolonged exposure to diet-induced hypercholesterolemia, 
during up to 20 weeks, followed by MI-R injury with reperfusion periods up to 24 hours 
showed a reduced hemodynamic performance (9) and a negative inotropic effect 
(10). In addition, myocardial injury was exacerbated by increased cardiomyocyte 
apoptosis (11), upregulation of the myeloperoxidase-related inflammatory response 
(12, 13), reduced myocardial nitric oxide synthesis (14), and increased myocardial 
necrosis (15, 16). Conversely, other studies reported hypercholesterolemia to cause an 
improved mechanical recovery (9, 10), a positive inotropic effect (15), and decreased 
cardiac necrosis (17). However, information on follow-up periods longer than 24 hours 
is lacking.
To study the effects of hypercholesterolemia on cardiovascular outcome after 
MI, animal models should mimic the clinical setting. The apolipoprotein E3-Leiden 
(APOE*3-Leiden) transgenic mouse (18) develops advanced aortic atherosclerotic 
lesions resembling their human counterparts when exposed to cholesterol feeding 
(19, 20). On normal chow diet these mice develop no hypercholesterolemia or 
atherosclerosis. Thus, this hypercholesterolemic mouse model proved to be useful in 
studying the environmental and genetic factors in the occurrence of hyperlipidemia 
(20, 21) and the development of atherosclerosis (20, 22). In addition, APOE*3-Leiden 
mice have been used to study the effects of various lipid lowering therapies (23-25). 
Although APOE*3-Leiden mice differ from the human situation, because of the absence 
of coronary atherosclerosis resulting in coronary plaque formation and the lack of 
rupture followed by thrombus formation, it does provide an excellent model to study 
the effects of hypercholesterolemia on the pathophysiological processes in an animal 
model after surgical interventions (26-29) including induction of MI. Furthermore, 
hypercholesterolemic-induced atherosclerosis itself is considered to be an inflammatory 
disease which contributes to and affects the post-ischemic inflammatory response 
(1, 30). 
Therefore, the aim of the present study was to investigate the long-term effects of 
hypercholesterolemia on MI-R induced injury in APOE*3-Leiden mice with a follow-up 




Animals and diets. Transgenic female APOE*3-Leiden mice (18), backcrossed for 
more than 40 generations on a C57Bl/6J background, aged 8-10 weeks at the start of 
a dietary run-in period (bred in the animal facility of the Leiden University Medical 
Center), were used for this experiment. Mice were randomly assigned to either a 
normal chow (normocholesterolemic, NC) or a semisynthetic Western-type diet 
supplemented with 0.4% cholesterol (hypercholesterolemic, HC) (AB Diets, Woerden, 
The Netherlands). The diet was started 4 weeks prior to surgery and was continued 
until the end of the experiment. Mice were housed under standard conditions in 
conventional cages and received food and water ad libitum. All animal experiments 
were approved by the Institutional Committee for Animal Welfare and conformed 
to the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, 
revised 1996).
Plasma lipid analysis. Plasma total cholesterol (TC) and triglyceride (TG) levels were 
determined prior to diet exposure, before induction of MI, and 4 and 8 weeks after surgery. 
After a 4 hours fasting period, blood was obtained via tail vein bleeding (~50μl) and assayed 
for plasma total cholesterol (TC) and triglyceride (TG) levels using commercially available 
enzymatic kits according to the manufacturer’s protocols (11489232 and 11488872; Roche 
Diagnostics, Mannheim, Germany, respectively) 
Surgical MI-R protocol. Surgical ligation of the left anterior descending (LAD) coronary 
artery followed by permanent reperfusion was performed at day 0 in 12-14 weeks old female 
APOE*3-Leiden mice as described previously (31). Briefly, mice were pre-anesthetized 
with 5% isoflurane in a gas mixture of oxygen and room air and placed in a supine 
position on a heating pad (37°C). After endotracheal intubation and ventilation (rate 160 
breaths/min, stroke volume 190μl; Harvard Apparatus, Holliston, MA, USA), mice were 
kept anesthetized with 2% isoflurane. Subsequently, a left thoracotomy was performed 
in the 4th intercostal space and the LAD coronary artery was ligated using a 7-0 prolene 
suture. A knot was tied on a 1mm section of a plastic tube placed on top of the LAD to 
occlude the coronary artery during 45 minutes. Ischemia was confirmed by myocardial 
blanching and ECG changes. Muscle flaps were folded back, covered with a pre-warmed 
wet surgical mesh, and body temperature was kept constant between 35-37°C during 
this period. After 35 minutes of ischemia mice received an intraperitoneal injection of 
lidocaine (6mg/kg) (32) to prevent cardiac arrhythmias caused by reperfusion. After 45 
minutes of ischemia permanent reperfusion was established. The thorax was closed in 
layers with 5-0 prolene suture and mice were allowed to recover. Analgesia was obtained 
with buprenorfine s.c. (0.1mg/kg) pre-operative and 12h post-operative. The experimental 
protocol consisted of a normal diet MI-R group (NC-MI, n=16) and cholesterol-enriched 










Echocardiography. To evaluate LV function, in vivo transthoracic echocardiography 
was performed in anesthetized (2% isoflurane) mice using a 15-45MHz RMV707B 
probe interfaced with a Vevo 770 imaging system (VisualSonics Inc, Toronto, Canada). 
Two-dimensional echocardiography was achieved in all mice before induction of 
MI (week 0) to assess baseline cardiac function and serve as an internal control. 
Subsequently, LV function was measured at 1, 3, and 8 weeks after MI-R. Mice were 
placed on a heating table in a supine position, with their extremities fixed to four 
electrocardiography leads. The chest was shaved to minimize ultrasound attenuation 
and warmed Aquasonic gel (Parker Laboratories Inc, Fairfield, USA) was applied to 
optimize visibility.
Parasternal long-axis B-Mode, M-Mode, and EKG-gated Kilohertz Visualization 
(EKV) images were obtained with appropriate angulation and acquisition of maximum 
LV length, from apex to aortic valve. Datasets were analyzed in a blinded manner, 
using Visual Sonics software version 3.0.0 (2008). After tracing the end-systolic and 
end-diastolic endocardial LV area of parasternal long-axis EKV images (33) LV end-
diastolic volume (EDV), LV end-systolic volume (ESV), LV ejection fraction (EF), and 
cardiac output (CO) were calculated.
Hemodynamic measurements. After 8 weeks hemodynamics and LV function indices 
were determined by invasive LV pressure-volume (PV) relationships. After induction of 
anesthesia a midline neck incision was performed, and a 1.2F PV catheter (FTS-1212B-
4518; Scisense Inc, Ontario, Canada) connected to an ADV signal processor (Scisense Inc) 
was inserted via the right carotid artery and positioned optimally into the LV to generate 
high-fidelity PV signals. On-line display and acquisition of the signals (2000 samples·s-1) 
was obtained with a PowerLab 8/30 system and LabChart Pro software (AD Instruments 
GmbH, Spechbach, Germany). Parallel conductance was obtained with the hypertonic 
saline method using intravenous bolus injections of ~5μl 10% saline (34) and calibrated 
with corresponding echocardiographic values of CO. All data were analyzed off-line in 
a blinded fashion with custom-made software.
PV signals were obtained in steady state to measure heart rate (HR), CO, ESV, EDV, 
end-systolic and end-diastolic pressure (ESP and EDP), maximal and minimal rates of 
LV pressure change (dP/dtMAX and dP/dtMIN), isovolumetric relaxation time constant 
(Tau), stroke work (SW), effective arterial elastance (EA), end-systolic peak isovolumic 
pressure (ESPiso), end-systolic elastance (EES), end-systolic intercept volume (ESVint), 
end-diastolic stiffness (EED), and end-diastolic intercept volume (EDVint).
After measurements, the heart and lungs were quickly excised. Hearts were 
immersion-fixated in 4% paraformaldehyde for 24 hours and embedded in paraffin. 
The body weight and wet lung weight were measured from all animals and lungs 
were then freeze-dried. The difference between wet and dry lung-weight was used as 
a measure of pulmonary congestion.
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Infarct size, LV wall thickness and vascular density. Paraffin-embedded hearts were cut 
into serial transverse sections of 5μm along the entire long-axis of the LV and subsequently 
mounted on slides (n=8 for each group). To analyze collagen deposition as an indicator of 
the fibrotic area, every 50th section of each heart was stained with Sirius Red resulting in 
approximately 15 stained sections of each heart. Infarct size was determined by planimetric 
measurement of all sections and calculated as fibrotic area divided by the total LV wall 
surface area including the interventricular septum. LV wall thickness was measured in 
five different sections equally distributed through the infarcted area. Per section, wall 
thickness was analyzed in the mid-infarcted area, both border zones, and interventricular 
septum. Measurements were performed perpendicular to the ventricular or septal wall. 
To determine the vascular profile, serial sections were stained for PECAM-1 (CD31, 
clone MEC13.3, 550274; BD Pharmingen, San Diego, CA, USA). Subsequent to incubations 
with an appropriate biotinylated secondary antibody and the signal amplifying ABC 
system (Vectastain; Vector Laboratories, Burlingame, CA, USA), the reaction product was 
visualized with 3,3‘-diaminobenzidine and counterstained with Mayer’s hematoxillin. 
Vascular density was determined by quantifying the number of PECAM-1 positive 
blood vessels per 0.25mm2 per section, differentiating between small (<20μm) and large 
(>20μm) vessels, in the infarcted border zones (4 areas), and infarcted myocardium 
(5 areas). All measurements were performed by an observer blinded to the groups, using 
the Image-Pro Plus software package (Media Cybernetics Inc, Bethesda, MD, USA).
Inflammatory response. To study the in vivo effects of the cholesterol enriched diet 
and MI-R injury, whole blood was analyzed for peripheral monocytosis one week before 
induction of MI (NC-MI, n=11, and HC-MI, n=15) and 3 weeks after MI-R (NC-MI, 
n=6, and HC-MI, n=7). Hematological values obtained were white blood cell counts 
(WBC, x106/ml), red blood cell counts (RBC, x109/ml), and platelets (PLT, x106/ml) 
using a semi-automatic hematology analyzer F-820 (Sysmex; Sysmex Corporation, 
Etten-Leur, The Netherlands). For FACS analysis, 35μl of whole blood was incubated 
for 30 minutes on ice with directly conjugated antibodies directed against Ly-6C-
FITC (AbD Serotec, Dusseldorf, Germany), Ly-6G-PE (BD Pharmingen, San Diego, 
CA, USA), CD11b-APC (BD Pharmingen, San Diego, CA, USA), CD115-PerCP (R&D 
Systems, Minneapolis, MN, USA), and CD45R-APC-Cy7 (eBioscience, San Diego, 
CA, USA). Monocytes were gated based on their expression profile: Ly-6G-negative, 
CD11b-positive, and CD115-positive. Pro-inflammatory monocytes were identified 
based on high Ly-6C expression levels.
For analysis of the local cardiac inflammatory response 8 weeks after MI-R, 
paraffin sections of the mid-infarct region of the heart were stained using antibodies 
against leukocytes (anti-CD45, 550539; BD Pharmingen, San Diego, CA, USA) and 
macrophages (anti-Mac-3, 550292; BD Pharmingen, San Diego, CA, USA). The number 
of leukocytes and macrophages were expressed as a number per 0.25mm2 in the septum 










Statistical analysis. Values were expressed as means±SEM. Comparisons of parameters 
between the NC-MI and HC-MI groups were made using independent samples t-test or 
2-way analysis of variance with repeated measures and Bonferroni correction in case 
of multiple time points. A value of P<0.05 was considered to represent a significant 
difference. All statistical procedures were performed using SPSS 20.0.0 (SPSS Inc – IBM, 
Armonk, NY, USA).
Results
Plasma lipid profiles and animal characteristics. Total cholesterol plasma levels in 
the HC-MI group were increased after exposure to the cholesterol-enriched diet for 
4 weeks compared to the normal chow diet group (18.2±1.1mmol/L vs. 2.0±0.3mmol/L, 
P<0.001) and remained stable during the experimental protocol. Triglycerides levels 
(3.0±0.1mmol/L vs. 2.5±0.3mmol/L) were not significantly different between groups 
(Figure 1).












































Figure 1. Lipid profiles. Plasma (A) total cholesterol and (B) triglycerides levels in the NC-MI 
() and HC-MI () group. Data are means±SEM. ***P<0.001 vs. NC-MI group.
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No difference in body weight (BW) was observed between groups prior to the 
induction of MI-R. However, 8 weeks after MI-R weight gain as expressed by BW 
change was increased in HC-MI as compared to NC-MI mice (12.1±1.1% vs. 7.3±1.3%, 
P=0.009). No difference in the amount of lung fluid was observed between both groups 
(Supplementary material, Table 1). In addition, cumulative survival was comparable 
between both groups (data not shown).
Echocardiography. Serial echocardiography 8 weeks post MI-R revealed an increase in 
LV dimensions in both groups as compared to baseline cardiac function before MI-R. 
In the HC-MI group EDV (49.6±2.1μl vs. 41.4±0.5μl, P<0.001) and ESV (27.4±1.7μl 
vs. 16.6±0.6μl, P<0.001) were increased. In the NC-MI group the EDV (52.0±2.7μl vs. 
39.4±0.9μl, P<0.001) and ESV (30.3±2.7μl vs. 14.5±0.5μl, P<0.001) were increased as well 
(Figure 2A and 2B). This was accompanied by a progressive impairment of LV function 8 
Table 1. Pressure-volume loops-derived LV function indices. 
NC-MI HC-MI
HR (beats min-1) 551 ± 18 531 ± 20
CO (ml min-1) 13.5 ± 2.5 11.4 ± 1.0
ESV (μl) 29 ± 5 28 ± 5
EDV (μl) 53 ± 7 49 ± 6
ESP (mmHg) 89 ± 2 73 ± 3***
EDP (mmHg) 4.4 ± 0.6 5.9 ± 0.8
dP/dtMAX (mmHg ms
-1) 8.3 ± 0.4 6.1 ± 0.4***
-dP/dtMIN (mmHg ms
-1) 6.8 ± 0.2 5.3 ± 0.4**
Tau (ms) 9.8 ± 0.3 11.1 ± 0.8
SW (mmHg.ml) 1.9 ± 0.2 1.6 ± 0.0
EA 4.8 ± 1.1 3.7 ± 0.3
ESPiso 164 ± 5 131 ± 5***
ESPVR
slope: EES (mmHg μl
-1) 3.8 ± 0.6 2.8 ± 0.3
intercept: ESVint (μl) 26.3 ± 4.9 29.9 ± 5.1
EDPVR
slope: EED (mmHg μl
-1) 0.18 ± 0.03 0.26 ± 0.05
intercept: EDVint (μl) 61.1 ± 10.9 46.7 ± 4.0
CO, cardiac output; dP/dtMAX, maximum rate of pressure increase; -dP/dtMIN, maximum rate of pressure 
decrease; EA, effective arterial elastance; EDP, end-diastolic pressure; EDPVR, end-diastolic pressure-volume 
relationship; EDV, end-diastolic volume; EDVint, end-diastolic intercept volume; EED, end-diastolic stiffness; EES, 
end-systolic elastance; ESP, end-systolic pressure; ESPiso, end-systolic peak isovolumic pressure; ESPVR, end-
systolic pressure-volume relationship; ESV, end-systolic volume; ESVint, end-systolic intercept volume; HR, heart 










weeks after MI-R as indicated by a decrease in EF (Figure 2C) in the HC-MI (45.0±2.0% 
vs. 60.1±1.3% before MI-R, P<0.001) and NC-MI group (43.3±2.5% vs. 63.3±0.7% before 
MI-R, P<0.001). There were no differences observed between the HC-MI and NC-MI 
group during the experiment. 
Hemodynamic measurements. The functional PV loop-derived data of the groups 
are presented in Table 1. In accordance with the echocardiographic data, LV volumes 
did not differ between the HC-MI and NC-MI group. However, when compared to the 
NC-MI group, a marked impaired intrinsic LV function was found in the HC-MI group 
as demonstrated by a significantly depressed ESP (73±3mmHg vs. 89±2mmHg, P=0.001), 
dP/dtMAX (6.1±0.4mmHg/ms vs. 8.3±0.4mmHg/ms, P=0.001), -dP/dtMIN (5.3±0.4mmHg/ms 
vs. 6.8±0.2mmHg/ms, P=0.005).
Infarct size, LV wall thickness, and vascular density. Histological evaluation 8 weeks 
after MI-R showed a smaller infarct area in the HC-MI group compared to the NC-MI 
group (12.7±2.0% vs. 22.2±2.9%, P=0.017, Figure 3A). The subendocardial and epicardial 



















































































Figure 2. Serial echocardiography. (A) End-diastolic volume, (B) end-systolic volume, (C) 
ejection fraction, and (D) cardiac output in NC-MI () and HC-MI () groups at baseline, 1, 
3, and 8 weeks after MI-R. Data are means±SEM. *P<0.05, **P<0.01, ***P<0.001 all vs. week 0.
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surviving borders of cardiomyocytes in the HC-MI group (Figure 3D) were larger 
compared with the NC-MI group (Figure 3C). This resulted in an increased LV wall 
thickness in the mid-infarct area in the HC-MI group as compared to the NC-MI group 






























































Figure 3. Infarct size, LV wall thickness, and vascular profile 8 weeks after MI-R. Infarct size was 
significantly smaller in the HC-MI group compared with the NC-MI group (A). Wall thickness 
of the infarct area was significantly larger in the HC-MI group (B). Sirius red staining in the 
HC-MI group showed a more pronounced subendocardial and epicardial border of surviving 
cardiomyocytes in the HC-MI group (D) compared to the NC-MI group (C). Vascular analysis 
showed no differences in number of small capillaries (<20μm) or large vessels (>20μm) in the border 








































Analysis of the vascular profile in HC-MI and NC-MI groups showed no significant 
differences in the number of small capillaries (<20μm) and large vessels (>20μm) 
between the groups (Figure 3E).
Inflammatory response. After a dietary run-in period the HC-MI group revealed a 
pre-ischemic peripheral monocytosis as compared to the NC-MI group as expressed 
by the percentage of monocytes (41.6±2.1% vs. 33.6±1.6% of total leukocytes, P=0.009, 
Figure 4A), which was normalized 3 weeks after MI-R.  Furthermore, the HC-MI group 
showed a higher percentage pro-inflammatory Ly-6Chigh monocytes of the total monocyte 
population in peripheral blood prior to MI-R (40.8±2.7% vs. 30.6±2.2% of total monocytes, 
P=0.01, Figure 4B), which was normalized as well 3 weeks after MI-R. These results suggest 
a loss of total and in particular Ly-6Chigh monocytes from peripheral blood of HC-MI 
mice due to MI-R. In contrast, 8 weeks after MI-R a non-significant decreased number 
of infiltrated CD45+ leukocytes was observed in the infarct area of the HC-MI group as 




































































Figure 4. Inflammatory response as a result of the cholesterol enriched diet and MI-R. 
Quantification of monocytes as a percentage of total leukocytes (A) and activated (Ly-6Chigh) 
monocytes as a percentage of total monocytes (B) in whole blood 1 week before induction of 
MI-R and 3 weeks after MI-R. **P<0.01 vs. time-corresponding NC-MI group. Quantification 
of leukocytes (C) and macrophages (D) 8 weeks after MI-R in the infarct area, border zone and 
septum, expressed as the number per area. Data are means±SEM. *P<0.05.
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compared to the NC-MI group (4.7±0.4 vs. 7.0±2.0 cells per 0.25mm2, P=0.27, Figure 4C) 
whereas the number of macrophages was significantly reduced (7.9±1.8 vs. 20.7±5.4 cells 
per 0.25mm2, P=0.049, Figure 4D).
Discussion
Key findings of the present study are that diet-induced hypercholesterolemia in 
APOE*3-Leiden mice caused 1) a pre-ischemic peripheral monocytosis, in particular of 
the Ly-6Chigh pro-inf lammatory monocytes, and 2) an impaired intrinsic LV function 
8 weeks after acute MI-R, paradoxically accompanied by 3) a reduced infarct size 
and 4) a suppressed accumulation of infiltrated inf lammatory cells in the ischemic-
reperfused myocardium after 8 weeks. This study is the first to extend the follow-up 
after MI-R to 8 weeks.
Impaired cardiac function as a result of hypercholesterolemia. In the present study, 
hypercholesterolemia resulted in an impaired intrinsic LV function 8 weeks after MI-R 
as reflected by a reduced left ventricular ESP, dP/dtMAX, and dP/dtMIN. No differences of 
LV dimensions were observed between the HC-MI and NC-MI groups as assessed by 
cardiac echocardiography and PV loop measurements. These results are in line with 
previous studies reporting that unreperfused MI in HC animals results in depressed 
LV function in rabbits (35) and exacerbated LV diastolic dysfunction in rats (36) at least 
8 weeks after ischemia. In contrast, intrinsic cardiac function in a HC pig model was 
preserved 24 hours after MI-R as compared to NC animals, though follow-up was not 
extended up to 8 weeks (15). Thus, short-term (24 hours) results differ markedly from 
long-term (8 weeks) results.
Hypercholesterolemia itself was suggested to cause cardiomyopathy by formation 
of myocardial cholesterol deposits. Shifting of ATP production from glucose to free 
fatty acids increased free radicals which resulted in myocardial injury (37). A reduced 
hemodynamic performance caused by hypercholesterolemia may lead to decreased 
metabolic demand. This is proposed to confer a cardioprotective state (9, 38) that may 
lead to improved post-ischemic functional recovery in HC versus NC rabbit hearts. 
In this way, HC may increase myocardial tolerance against myocardial ischemia (10).
Reduction of infarct size . In this study, the reduced infarct size accompanied by preserved 
LV wall thickness of the infarcted myocardium in the HC animals may have been caused 
by the aforementioned reduced myocardial metabolic demand and resulting increased 
tolerance against myocardial ischemia. Differences in myocardial perfusion (reserve) 
are not likely, since vascular density was similar in both groups. Another explanation 
could be a different course of the post-ischemic inflammatory response. In accordance 
with the decreased infarct size, our study showed a reduced influx of leukocytes and 










A positive correlation between infiltrated inflammatory cells and infarct size has been 
reported by previous studies in humans and rats (39, 40). 
In contrast to our long-term results 8 weeks after MI-R, previously reported 
short-term (24 hours or less) experimental studies using HC MI-R models reported 
an increased infarct size in rabbits (16) and pigs (15) accompanied by increased 
myeloperoxidase expression in rats (13) and rabbits (12) and increased cardiomyocyte 
apoptosis (11). In contrast, MI-R in HC mice resulted in smaller infarcts 2 hours 
after onset of reperfusion and was concluded to provide cardioprotection in mice 
(17). After permanent ischemia without reperfusion in rabbits (35) or rats (36), 
hypercholesterolemia caused no difference in infarct size 8 weeks after MI. 
Pre-ischemic monocytosis followed by reduced integrated inflammatory cells in 
the ischemic-reperfused myocardium. In parallel with the decreased infarct size, our 
study shows a reduced influx of leukocytes and macrophages in the ischemic-reperfused 
myocardium of HC mice 8 weeks post MI-R. This finding is preceded by a pre-ischemic 
hypercholesterolemia-associated peripheral monocytosis. Hypercholesterolemia has been 
reported to cause a peripheral monocytosis with regard to the Ly-6Chigh subset in HC mice 
(41). In addition, the inflammatory response after MI-R is more complex as compared 
to MI without reperfusion, since reperfusion itself induces a pathophysiological process 
of reperfusion injury (42). The pro-inflammatory state resulting from this monocytosis 
could affect the post-ischemic inflammatory response following MI-R since Ly-6Chigh 
monocytes are involved in the initial inflammatory response against ischemia. Previous 
studies demonstrated that within the first hours after MI, monocytes and their lineage 
descendant macrophages infiltrate the infarcted myocardium resulting in the release of 
cytokines and growth factors, phagocytosis of debris, clearance of apoptotic cells, and 
the release of proteases (43, 44). Especially the pro-inflammatory Ly-6Chigh monocyte 
subset is known to promote digestion of infarcted tissue and clearance of necrotic debris 
(45). After myocardial ischemic injury, a baseline Ly-6Chigh monocytosis could favorably 
affect the subsequent Ly-6Clow-mediated reparative phase, accelerating repair and thereby 
limiting tissue damage on the long-term. Conversely, atherosclerosis-related leukocytosis 
was found to disturb the acute post-ischemic healing process (30). Following permanent 
ischemia, Ly-6Chigh monocytosis has been reported to disturb infarct healing and enhance 
left ventricular remodelling after 3 weeks (46). This underscores that the post-ischemic 
inflammatory response after permanent MI differs from the inflammatory response 
after MI-R (43).
Conclusion
In summary, hypercholesterolemia in an in vivo APOE*3-Leiden mouse model causes 
a pre-ischemic peripheral monocytosis and an impaired systolic and diastolic cardiac 
function 8 weeks after myocardial ischemia-reperfusion injury. This is accompanied 
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however with a decreased myocardial infarct size and a reduced accumulation of 
inf lammatory cells in the ischemic-reperfused myocardium. 
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Table 1. Animal characteristics. Body weight (BW), heart weight (HW). Values are means±SEM. 
**P<0.01 vs. NC-MI.
    Normal Cholesterol 
  T (wk) NC-MI HC-MI
N 16 18
age (days) 0 86±3 88±2
BW (g) 0 20.9±0.3 20.5±0.4
  8 22.4±0.4 22.9±0.4
BW change (%) 7.3±1.3 12.1±1.1**
 
HW (mg) 8 191±16 176±5
HW/BW ratio (mg/g) 8.2±0.6 7.5±0.2



















The aim of the current thesis was to investigate the potential of cell-based therapy to 
improve cardiac function and attenuate the cardiac remodelling process in ischemic 
heart disease, with emphasis on the role of the inf lammatory response occurring 
after myocardial infarction (MI). 
Chapter 1 provides a general introduction to this thesis and describes the current 
concepts of cardiovascular disease and the underlying risk factors with emphasis 
on hypercholesterolemia. The underlying causes of ischemic heart disease and the 
inflammatory events that occur during the development of atherosclerosis and after 
ischemia has occurred are discussed, as are current treatment options and more 
specific cell-based therapy. 
Part I: Cardiac inflammation after MI and the potential of mesenchymal stromal cells 
(MSCs) for cell-based therapy. 
Chapter 2 discusses the current knowledge about the specific myocardial inflammatory 
events that occur following MI, which are important for the process of infarct healing. 
The role of cell-based therapy to inf luence this process of cardiac inf lammation is 
reviewed, with a focus on the potential of the (MSC). This multipotent cell type is 
easily accessible, shows limited risks of tumorigenicity, allows allogeneic use and 
produces paracrine factors able to attenuate the damaging effects of the inflammatory 
response post-MI, thereby making it a promising candidate in the field of cell-based 
therapy for ischemic heart diseases.
Chapter 3 provides a comparative analysis of two different rodent MI models for 
stem cell therapy research. The usefulness of the clinically relevant model using transient 
ligation of the left anterior descending coronary artery (LAD) (ischemia-reperfusion) 
was determined and compared to the commonly used model using permanent coronary 
artery ligation (permanent ischemia). MI was induced in immunodeficient mice 
in which human cells can be studied without the use of pharmacological immune 
suppression. Both models were analyzed for left ventricular (LV) cardiac function, 
infarct size, total collagen deposition and inflammatory response. Transiently ligating 
the LAD resulted in a modest decline of cardiac function and less pronounced cardiac 
remodeling, comparable to levels in Sham animals 2 weeks after MI. In contrast, 
permanent ligation resulted in a significant infarct size, decline in cardiac function 
and enhanced cardiac remodelling when compared to both transient ligation and 
Sham animals. The inflammatory response was also less dynamic in the transient 
ligation model as compared to the permanent ligation model, indicating this clinically 
relevant experimental model seems not ideal for investigating stem cell therapy due 
to the limited inflicted myocardial damage, hampering identification of potential 
positive effects of cell therapy. Although MI was induced in immunodeficient mice, 
the inflammatory state did significantly alter in these animals. 
154
In Chapter 4 previous research regarding the beneficial effect of unstimulated 
MSC (uMSC) therapy after MI by permanent ligation was extended by studying the 
additive effect of pre-stimulating MSCs (iMSCs) with the pro-inflammatory cytokine 
interferon-gamma (IFN). Recent studies in different disease models reported additional 
beneficial effects of iMSCs when compared to uMSCs. Two weeks after MI, cardiac 
function did not improve when compared to control animals in neither the uMSC nor 
the iMSC group, despite comparable myocardial engraftment rates between groups 
and to earlier research for our group. In addition myocardial inflammatory cell 
percentages were not significantly altered compared to controls. The absent beneficial 
effect of uMSC therapy in the current study was in discordance with previous studies 
performed in our laboratory, for which no cause could be identified. While (subtle) 
differences in execution between studies are inevitable, this finding suggest the presence 
of unrecognized variables in experimental design that determine outcome. Thus, rodent 
animal models of MI seem less robust than initially envisioned, hampering drawing 
thorough conclusions about the potential of MSC therapy.
Part II: Cardiomyocyte progenitor cells for cell-based therapy in the infarcted heart. 
Chapter 5 studies the potential of human cardiomyocyte progenitor cells (hCMPCs) 
to restore ischemic myocardium and improve LV function in a MI model in mice 
2 weeks after MI. hCMPCs were isolated from human fetal heart tissue, cultured and 
injected intramyocardially immediately after MI. Assessment of LV function showed 
that hCMPCs were able to improve LV ejection fraction, LV end-systolic volume and 
relaxation time constant when compared to controls. This improvement in cardiac 
function was accompanied by an increased vascular density and proliferation rate in 
the infarcted and border zone areas of hearts injected with hCMPCs. Despite their ability 
to undergo cardiomyogenic differentiation in vitro after approximately three weeks, 
hCMPCs did not differentiate into cardiomyocytes in vivo at the 2 week time point, 
suggesting that the observed beneficial effects were mediated by paracrine factors rather 
than neomyocardiogenesis. 
Part III: Effects of hypercholesterolemia after myocardial ischemia-reperfusion injury. 
In Chapter 6 the effect of diet-induced hypercholesterolemia on cardiovascular 
outcome after MI by ischemia-reperfusion injury in APOE*3-Leiden mice was studied 
with a follow-up of 8 weeks. Assessment of cardiac function showed a significant 
deterioration of intrinsic LV function in hypercholesterolemic mice after MI when 
compared to normocholesterolemic controls. Paradoxically, this deterioration in 
LV function was accompanied by a smaller infarct size, which may be caused by a 
reduced myocardial metabolic demand by hypercholesterolemia, resulting in increased 
tolerance against myocardial ischemia. In addition, hypercholesterolemia leads to a 












•	 The rodent ischemia-reperfusion myocardial infarction which mimics the clinical 
situation of myocardial ischemia followed by reperfusion as a result of primary 
percutaneous intervention either leads to limited myocardial damage or excessive 
mortality, hampering its use in cell therapy research.
•	 Myocardial infarction induces an inflammatory response also in immunodeficient 
mice indicating this mouse strain is a valuable tool in cell therapy research.
•	 Rodent animal myocardial infarction models for cell therapy research seem 
less robust than initially envisioned, hampering drawing thorough conclusions 
about the potential of mesenchymal stromal cell therapy due to the presence of 
unrecognized variables in experimental design that determine outcome.
•	 Human cardiomyocyte progenitor cells are able to alleviate the deleterious effects 
of myocardial infarction before their cardiomyogenic differentiation, probably 
by paracrine factors.
•	 Hypercholesterolemia in an in vivo APOE*3-Leiden mouse model causes a pre-
ischemic peripheral monocytosis and an impaired intrinsic cardiac function 
8 weeks after myocardial ischemia-reperfusion injury. This is accompanied by a 
decreased myocardial infarct size and a reduced accumulation of inf lammatory 
cells in the ischemic-reperfused myocardium.
Future perspectives
Although cell-based therapy shows promising results for the treatment of MI as 
demonstrated by the beneficial effects of hCMPC therapy on cardiac function, 
this thesis clearly demonstrates that the beneficial effects of cell-based therapy in 
rodent MI models are variable and not as robust as initially envisioned. While both 
experimental animal studies and clinical trials showed that cell-based therapy for MI 
is feasible and safe, the therapeutic effects are variable, indicating several challenges 
still need to be addressed. 
While the heart itself has inherent regenerative capacities, the rate of cardiomyocyte 
proliferation is limited and likely insufficient in completely repairing injured 
myocardium. Augmentation of cardiac repair after ischemic injury may be accomplished 
by supplementing the regenerative pool by injection of progenitor cells of exogenous 
origin. Also, application of chemotactic factors may recruit endogenous reparative cells 
to the site of injury. With different cell populations showing therapeutic potential for 
ischemic heart diseases, determination of the optimal cell type(s) is pivotal. Ideally, 
transplanted cells are able to differentiate towards cardiomyocytes, endothelial cells and 
smooth muscle cells. In addition, these cells would need to couple electromechanically 
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to host tissue cardiomyocytes to ensure a rapid and equal spread of electrical impulses 
so the heart can contract in unison.
When this ideal cell type is transplanted in the ischemic myocardium, it is essential 
that these cells engraft and survive. Although the observed engraftment rate in this 
thesis is comparable to other studies in literature, it’s still low, indicating benefit 
could be gained when improving the retention of these cells after transplantation. 
In light of the inflammatory events that occur after MI, a (too) strong inflammatory 
response by the local influx of inflammatory cells may hamper the engraftment and 
survival of transplanted cells and thereby their cell-mediated repair mechanisms. 
Dampening these inflammatory processes might prevent transplanted cells from 
undergoing phagocytosis and apoptosis, improving cell survival. However, regulation 
of the inflammatory response should be done with care, since its indispensable in the 
formation of a stable scar. Therefore, further knowledge on inflammatory cellular 
processes is needed to prevent degradation of transplanted cells as far as possible.
Another potential way to increase the engraftment and survival rate is by 
improvement of the delivery method. The emerging field of tissue engineering where 
cells are seeded on scaffolds before local cardiac application or grafts of cells are 
transplanted holds great potential as therapy for ischemic heart diseases. In combination 
with the developments in nanotechnology, local support of transplanted cells may 
further improve cell-based therapy in ischemic heart diseases.
Concluding, further research is needed to explore the most competent cell type(s) 
for cardiac repair, optimize cell preparation and delivery methods, and enhance cell 
survival, integration and therapeutic action in situ. Special care should be directed 
towards the role of the immune response in the ischemic cardiac environment in order 











In dit proefschrift wordt de potentie van celtherapie onderzocht als behandeling voor 
ischemische hartziekten om de pompfunctie van het hart te verbeteren en het risico op 
het ontwikkelen van hartfalen te verminderen. Tevens wordt gekeken naar de invloed 
die celtherapie heeft op de ontstekingsreactie die optreedt na het doormaken van 
een myocardinfarct (MI). De algemene inleiding van dit proefschrift (Hoofdstuk 1) 
beschrijft de huidige status van hart- en vaatziekten en de onderliggende risicofactoren 
voor het ontwikkelen van deze ziekten, zoals hypercholesterolemie. De onderliggende 
oorzaken van ischemische hartziekten en de ontstekingsreactie die optreedt na 
ischemie worden besproken, net als de huidige behandelingsopties, waarbij de nadruk 
ligt op celtherapie.
Hoofdstuk 2 geeft een uitgebreid overzicht van de ontstekingsreactie die optreedt 
na een MI en die belangrijk is voor het genezingsproces van het myocardweefsel. De 
potentie van celtherapie om dit proces van lokale ontsteking in het hart positief te 
beïnvloeden wordt besproken, waarbij de nadruk ligt op de mesenchymale stromale 
cel (MSC). Dit multipotente celtype is gemakkelijk te verkrijgen vanuit het weefsel, 
toont beperkte risico’s van tumorgeniciteit, is in staat tot het produceren van paracriene 
factoren en heeft unieke immunomodulerende capaciteiten, die allogeen gebruik 
mogelijk maken. Alles samengenomen maakt dit de MSC een veelbelovende kandidaat 
op het gebied van celtherapie voor ischemische hartziekten.
In Hoofdstuk 3 wordt de vergelijking besproken van twee verschillende MI-modellen 
om het effect van celtherapie te onderzoeken. Het in de literatuur meest voorkomende 
MI-model, dat gebruikmaakt van permanente ligatie van de ramus desecendens 
anterior coronairarterie (RDA), wordt vergeleken met een klinisch relevant MI-model, 
waarbij de RDA tijdelijk wordt geligeerd en vervolgens permanent geperfundeerd - 
iets wat beter vergelijkbaar is met de klinische situatie van een percutane coronaire 
interventie (“dotteren”). MI werd geïnduceerd in immuundeficiente muizen, waarbij 
humane celtherapie kon worden getest zonder dat deze cellen worden afgestoten of 
immunosuppressieve therapie nodig zou zijn. Beide modellen werden geanalyseerd 
voor de linkerventrikel (LV) -functie, de infarctgrootte, de totale hoeveelheid 
collageen en de ontstekingsreactie in zowel het serum als het hart zelf. Het tijdelijk 
ligeren van de RDA leidde tot een minimale afname van de pompfunctie en minder 
uitgesproken remodelering (verandering van de oorspronkelijke grootte, vorm en 
dikte) van het hart, met waarden die vergelijkbaar zijn met de sham-geopereerde 
groep. Daarentegen leidde het permanent ligeren van de RDA tot een significante 
afname van de pompfunctie en uitgesproken remodelering. Daarnaast was ook 
de ontstekingsreactie minder dynamisch in de tijdelijke-ligatie-groep dan in de 
permanente-ligatie-groep. Kortom, hoewel tijdelijk ligeren klinisch relevanter is, is 
dit MI-model inferieur voor celtherapieonderzoek, aangezien de geïnduceerde schade 
te klein is om positieve effecten van celtherapie te kunnen meten. Hoewel MI werd 
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geïnduceerd in immuundeficiente muizen was er wel sprake van een significante 
verandering in de ontstekingsreactie na MI, wat suggereert dat deze muizenstam 
relevant is voor het bestuderen van humane celtherapie.
Hoofdstuk 4 beschrijft een uitbreiding van een eerder uitgevoerd experiment 
in ons laboratorium aangaande de positieve effecten van niet-gestimuleerde MSC-
therapie (uMSC) na MI via permanente ligatie. Dit experiment werd uitgebreid met 
het bestuderen van de effecten van MSCs die in vitro werden gestimuleerd (iMSC) met 
het ontstekingsbevorderende cytokine interferon-gamma (IFN-γ), vóór injectie in het 
myocardweefsel. Recente studies in proefdieren met verschillende ziektebeelden lieten 
een toegevoegd positief effect zien van iMSCs vergeleken met uMSC-therapie. Twee 
weken na MI toonden zowel de MRI als de druk-volume metingen geen significante 
verbetering van de hartfunctie door uMSC- of iMSC-therapie vergeleken met de 
controlegroepen, ondanks dat er een vergelijkbaar aantal cellen als in het eerder 
uitgevoerde experiment in ons laboratorium, was ingenesteld in het myocard. 
Daarnaast had de aanwezigheid van uMSCs of iMSCs geen invloed op het percentage 
ontstekingscellen in het hart. Het ontbrekende positieve effect van uMSC-therapie 
kwam niet overeen met eerdere experimenten die in ons laboratorium waren verricht. 
Hoewel verschil in uitvoering tussen experimenten onoverkomelijk is, leidde dit 
tot de vraag of het eerder geobserveerde positieve effect wel gedegen genoeg is om 
consequente resultaten te verkrijgen, of dat er variabelen zijn in het studieontwerp die 
we nu niet herkennen als belangrijke parameters. Samenvattend lijkt MSC-therapie in 
MI-diermodellen minder robuust dan in eerste instantie werd aangenomen, en lijkt 
dit model ontoereikend om gedegen conclusies te trekken aangaande de potentie van 
MSC-therapie.
Hoofdstuk 5 bestudeert de potentie van zogenoemde myocardvoorlopercellen 
(cardiomyocyt progenitorcellen of CMPC) als celtherapie voor ischemische hartziekten 
in een MI-model via permanente ligatie. CMPCs werden geïsoleerd uit menselijk 
hartweefsel, gekweekt en intramyocardiaal geïnjecteerd onmiddellijk na MI. Twee 
weken na MI werd de LV-functie geanalyseerd. Hieruit bleek dat CMPC-therapie 
de LV-ejectiefractie, het LV-eind-systolische volume en de relaxatietijdconstante 
kon verbeteren. Deze verbetering in hartfunctie na CMPC-injectie ging gepaard 
met een toename van het aantal bloedvaten en de proliferatiesnelheid van onder 
andere endotheelcellen en gladde spiercellen in zowel het infarctgebied als de gebieden 
direct daaromheen. Ondanks het vermogen van CMPCs om te differentiëren naar 
een cardiomyocyt in vitro, gebeurde dit niet in vivo in deze studie. Dit maakt het 
zeer waarschijnlijk dat de waargenomen gunstige effecten werden veroorzaakt door 
paracriene factoren.
In Hoofdstuk 6 wordt het effect van dieet-geïnduceerde hypercholesterolemie 
bestudeerd in APOE*3-Leiden-muizen onderworpen aan een MI-model dat 
gebruikmaakte van tijdelijke ligatie, waarna deze gedurende acht weken werden gevolgd. 










functie zien in de hypercholesterolemische muizen, vergeleken met controledieren 
die een normaal cholesterolniveau hadden. Deze achteruitgang van de hartfunctie 
ging echter gepaard met een kleinere infarctgrootte, mogelijk veroorzaakt door een 
verminderde myocardiale metabole vraag door hypercholesterolemie en als gevolg 
daarvan mogelijk een verhoogde tolerantie tegen myocardiale ischemie. Daarnaast 
leidde hypercholesterolemie tot een stijging van het aantal ontstekingscellen in het 
serum vóór MI en een verminderde instroom van ontstekingscellen in het myocard 
ná MI. 
Conclusies
•	 Het induceren van een myocardinfarct in een muismodel via tijdelijke ligatie van 
de ramus descendens coronairarterie is klinisch relevanter, maar inferieur voor 
celtherapieonderzoek, aangezien de geïnduceerde schade te klein is om positieve 
effecten van celtherapie te kunnen meten.
•	 Het induceren van een myocardinfarct leidt ook tot een significante verandering 
in de ontstekingsreactie van immuundeficiente muizen, wat suggereert dat deze 
muizenstam relevant is voor het bestuderen van humane celtherapie.
•	 Myocardinfarct-diermodellen lijken minder robuust dan gedacht en ontoereikend 
om gedegen conclusies te trekken aangaande de potentie van mesenchymale 
stromale cellen als celtherapie, door variabelen in het studieontwerp die we nu 
niet herkennen als belangrijke parameters.
•	 Cardiomyocyt progenitorcellen kunnen de hartfunctie verbeteren na het 
induceren van een myocardinfarct in een muismodel, zonder dat deze cellen 
differentieren naar een cardiomyocyt, wat het zeer waarschijnlijk maakt dat de 
waargenomen gunstige effecten worden veroorzaakt door paracriene factoren.
•	 Het induceren van een myocardinfarct in APOE*3-Leiden-muizen met een te hoog 
cholesterolgehalte leidt tot een verminderde pompfunctie en een stijging van het 
aantal ontstekingscellen in het serum vóór het induceren van een myocardinfarct 
en een verminderde instroom van ontstekingscellen in het myocard hierna.
Toekomstperspectieven
Celtherapie lijkt een goede kandidaat voor de behandeling van een myocardinfarct 
(MI) gezien de hoopvolle resultaten. Eerder experimenteel onderzoek heeft aangetoond 
dat celtherapie uitvoerbaar en veilig is, maar dat de positieve effecten op de hartfunctie 
nog bescheiden zijn. Ondanks deze potentie laat dit proefschrift duidelijk zien dat de 
geobserveerde effecten van celtherapie nog variabel zijn en niet zo robuust als verwacht, 
en dus meer onderzoek en verbetering van het huidige protocol wenselijk zijn.
Hoewel het hart mogelijkheden heeft tot het zelf regenereren van weefsel, is dit 
zeer beperkt en onvoldoende om beschadigd myocard in het geheel te herstellen. 
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Celtherapie zou hierin een aanvulling kunnen zijn. Met vele verschillende celpopulaties 
als potentiële kandidaat voor de behandeling van ischemische hartziekten, is het 
bepalen van het optimale celtype het belangrijkst. Idealiter dienen de gekozen cellen te 
differentiëren tot cardiomyocyten, endotheelcellen en gladde spiercellen. Ook zouden 
ze in staat moeten zijn om elektromechanisch te koppelen aan de reeds in het hart 
aanwezige cardiomyocyten, om zo te zorgen voor een gelijkmatige samentrekking.
Wanneer dit ideale celtype ingespoten wordt in het ischemische myocardium, is het 
essentieel dat de cellen overleven en integreren in het hartweefsel. Hoewel het aantal 
geïntegreerde cellen in het myocardweefsel in dit proefschrift vergelijkbaar is met 
andere studies, is het nog steeds erg laag. Kortom, het optimaliseren van de overleving 
van deze cellen na transplantatie, zou kunnen leiden tot een verdere verbetering van 
het effect van stamceltherapie. Op basis van de in dit proefschrift verkregen kennis 
over de ontstekingsreactie na een MI, kan men stellen dat door de lokale instroom van 
ontstekingscellen, de integratie en overleving van getransplanteerde cellen belemmerd 
worden, en daarmee ook de cel-gemedieerde herstelmechanismen. Het remmen van 
deze ontstekingsprocessen zou deze belemmering kunnen tegengaan. Het beïnvloeden 
van de ontstekingsreactie na een MI dient echter met grote zorgvuldigheid te worden 
gedaan, aangezien dit proces onmisbaar is bij de vorming van stabiel littekenweefsel. 
Daarom is het van belang onze kennis op het gebied van inflammatoire cellulaire 
processen te blijven verbeteren om zo de juiste balans te bepalen in het reguleren van 
de ontstekingsreactie en daarmee de afbraak van getransplanteerde cellen zo veel 
mogelijk te voorkomen.
Een andere manier om de integratie en overleving van getransplanteerde cellen 
te verbeteren, is het gebruik van een geperfectioneerde transplantatiemethode. Het 
veld van de cel- en weefseltechnologie (tissue engineering), waarbij cellen worden 
gezaaid op scaffolds voor lokale toepassing in het hart, of cellen als graft worden 
getransplanteerd, staat momenteel nog in de kinderschoenen. In combinatie met 
het zich nog ontwikkelende gebied van de nanotechnologie, die gericht is op lokale 
ondersteuning van de getransplanteerde cellen, biedt dit vele mogelijkheden voor de 
toekomst van celtherapie als behandeling voor ischemische hartziekten. De studies 
in dit proefschrift focussen op celtherapie via injectie direct in het myocard. Echter, 
in het gehele onderzoeksveld van celtherapie voor ischemische hartziekten worden 
ook andere strategieën gebruikt, zoals het injecteren van cellen in het serum, de 
kransslagaders of het toedienen van bepaalde factoren om lichaamseigen cellen te 
rekruteren naar het beschadigde myocard. Welke manier van celtoediening het meest 
effectief en succesvol is, kan pas worden bepaald na verder onderzoek.
Samenvattend is er verder onderzoek nodig om zo het meest competente celtype 
voor transplantatie te verkrijgen en de gunstige effecten van celtherapie te optimaliseren 
door een goede in-vitrovoorbereiding en verbeterde lokale applicatie en overleving. 
Voorts moet de rol van de ontstekingsreactie in het ischemische cardiale milieu worden 
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wat jaren, weet dat onze vriendschap erg belangrijk is voor mij. Mijn lieve vriendinnen 
Charlotte, Eva en Sophie, bedankt dat jullie altijd voor mij klaarstaan. Lieve Sop, jouw 
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ook bij jullie gezin mag horen. Renske, ik ben blij dat ik er een zusje bij heb. Annika 
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mama, zonder jullie onvoorwaardelijke steun was ik nooit zo ver gekomen. Ik ben 
trots dat jullie mijn ouders zijn. 
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